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SUMMARY 
This thesis reports on the development of novel methodologies for the solid-phase 
synthesis of 1,3,5-triazine derivatives and biological evalution of the synthesized 1,3,5-
triazine derivatives as nNOS inhibitors.   
In the first project, a small library consisting of trisubstituted 1,3,5-triazine-2,4(1H,3H)-
diones were synthesized using solid phase synthetic methodology that is amenable to KBr 
FTIR monitoring to afford the compounds. Key steps of the reaction are (i) S-alkylation of 
substituted ethyl carbomothioylcarbamate onto a bromomethyl resin, (ii) cyclization using 
various isocyanates, (iii) oxidation using dimethyl dioxirane, and (iv) nucleophilic 
substitution using various primary amines, ammonium hydroxide or hydroxylamine. In 
addition microwave assisted cleavage was used to cleave the substrate whenever possible.  
The second project works on developing a new synthetic strategy for the analogs of 1,3,5-
traizines. In this new synthetic route, S-alkylation of bromomethyl resin generates the solid 
supported thiouronium salt as the primary precursor for cyclization reactions to yield the 
corresponding solid supported triazine derivatives. Afterwhich the triazine compounds were 
released from the solid support via either oxidative activation and cleavage or microwave 
assisted cleavage. In addition, we developed a general Liebeskind-Srogl coupling condition 
for the cleavage for three sets of triazine substrates. 
The third project reports on the nNOS inhibition studies on 45 triazine derivatives. The 
preliminary results show that triazinetriones are potential candidates for futher development 
as inhibitors of nNOS enzyme. 
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Chapter 1: Introduction 
 
1.1.1 Solid-Phase Synthesis  
The first solid-phase organic synthesis was reported in 1963 by the late R. B. Merrifield.1 
In that seminal publication, Merrifield used chloromethylated copolymer of styrene and 
divinylbenzene as the solid support for the synthesis of a tetrapeptide. At that time, 
Merrifield’s strategy was considered a remarkable breakthrough because it circumvented the 
complicated purification and isolation problems commonly associated with peptide coupling 
reactions. Shortly after his first publication, Merrifield demonstrated the applicability of his 
approach with a series of reports on peptide syntheses.2-7 In the following years, solid-phase 
methodology was rapidly adopted by other groups for the synthesis of oligonucleotides8 and 
carbohydrates,9 desymmetrization reactions,10,11 natural product synthesis12 and asymmetric 
natural product synthesis.13 Over the past four decades, use of solid support synthetic 
methodology has expanded to all facets of synthetic organic chemistry. Use of solid supports 
paved the way for the development of multiple parallel synthesis of peptides by Geysen14 
(multipin) and Houghten15 (tea-bag) in the 1980s and laid the foundation for the emergence 
of the field of combinatorial chemistry during the late 1990s to early 2000s. Development of 
solid-phase techniques allowed the rapid generation of chemical libraries through automation 
of standard organic transformations. All these developments in turn revolutionized the life 
sciences and accelerated drug discovery processes. As recognition of his immense 
contribution to the field of organic synthesis, the Nobel Prize in Chemistry in 1984 was 




  A typical solid-phase synthesis reaction generally consists of a solid support, linker and 







Figure 1.1. Three key elements of solid-phase synthesis 
 
The advantages of solid-phase synthesis are as follow: 
i. Rapid post reaction isolation through filtration. 
ii. Large excess of reagent can be used to push the reaction to completion without 
complicated purification. 
iii. Automation of reaction sequences. 
iv. Ease of handling unstable or toxic intermediates that are tethered to the solid support. 
The limitations of solid-phase synthesis: 
i. Quantities are more limited than solution phase synthesis. 
ii. Monitoring reactions and characterization of intermediate can be difficult. 
iii. Only applicable to reactions with very high yields. Reactions with moderate or low 
yield may result in difficult post cleavage purification. 
 
1.1.2 Solid Supports 
The primary role of the solid support is to provide an insoluble platform on which the 
tethered substrate or reagent can be easily separated from the reaction mixture during 
workup. A typical solid support is made of inert material that is thermally and chemically 
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stable to the reactions conditions. The term “solid phase synthesis” is a misnomer; during the 
reaction solvent molecules will engage in non-covalent interaction with the solid support 
material. This interaction is termed swelling and it involves transformation of solid support 
into a gel-like matrix. The process of swelling is very important because the reagents or 
reactants can only penetrate sufficiently into the polymeric matrix and reach the substrate 
when the solid support material is swollen. Swelling of solid support is highly dependent on 
the type of solid support material and the solvent used for the reaction. Listed below are the 
commonly used solid supports used in solid-phase reactions. 
i)  Divinylbenzene cross-linked polystyrene resins. These are the most commonly used 
solid support material attributable to the ease of manufacture and handling. Due to the 
non-polar and hydrophobic nature of the polystyrene backbone, polystyrene resin can 
only swell well in aprotic solvents like THF, DCM, DMF or toluene.  When use of protic 
solvents like water or methanol is required, it is necessary to perform the reactions in a 
mixture of protic to aprotic good swelling solvent. 
ii)  Polystyrene-PEG graft resin. Divinylbenzene cross-linked polystyrene resin containing 
poly(ethylene) graft polymers were first prepared by Bayer16 and Rapp. These are 
commercially known as Tentagel™, Argogels17 and Novagel18. Due to the 
conformational flexibility of the PEG chains, PEG-grafted polystyrene supports are more 
hydrophilic than pure polystyrene and swell in a wide variety of solvents.19 However, 
PEG-grafted polystyrene resin suffers several drawbacks. First, PEG-PS resins are 
usually of lower loadings. Second, PEG-PS resins are unstable to treatment with TFA. 
Third, due to the hydrophilicity of the PEG unit, PEG-PS based solid supports are 
adherent and difficult to dry.20 
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iii) Polyacrylamides resins.  Polyacrylamide solid supports are developed as solid support 
material more hydrophilic than polystyrene. Polyacrylamides swell strongly in both 
aprotic (DMF, pyridine, DCM) and protic (methanol, water) solvents.21 Polyacrylamides 

























Figure 1.2. Structure of various solid supports23 
1.1.3 Linkers 
The primary role of a linker is to tether the substrate to the solid support.  In general, 
linkers in solid-phase synthesis are akin to protecting groups immobilized onto solid support 
material.24,25 There are three main considerations for the selection of linker. First, the reaction 
that tethers the substrate to the linker should be relatively simple and proceed in high yield. 
Second, the linker should be inert to the subsequent reactions performed on the substrate. 
Third, reaction that decouples the substrate from the solid support should be linker specific 
and not affect the substrate.  
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A large number of linkers are designed by modeling the analogous solution phase 
protecting group chemistry; the types of linkers can be generalized as one of the following: 
acid-labile, base-labile, traceless and safety catch linker. 
 
1.1.3.1 Acid Labile Linkers 
Acid-labile linkers account for a majority of the linkers developed for solid-phase 
synthesis. The main reason for this preference is because solid-phase methodology was 
originally developed for peptide synthesis. Since a large proportion of protecting groups used 
in peptide synthesis are acid-labile, development of acid-labile linkers will allow concurrent 
cleavage and global deprotection of the associated functional groups to yield the final 
product in one step. Futhermore, acidic cleavage usually employs the use of volatile acids 























1,2- and 1,3- 
Diols 


















5% TFA in DCM31 
 Table 1.1. Representative examples of functional group and acid labile linkers 
combinations. 
 
  Generally, acid-labile linkers follow the chemistry of their solution phase protecting 
group chemistry closely. The functional group used to tether the substrate on solid phase is 
usually recovered after the cleavage step. 
Cleavage of acid labile linkers follows the SN1-type mechanism involving the cleavage of 
the carbon heteratom bond. The ease of acid promoted cleavage is highly dependent on the 
stability of the leaving group which can be easily modified using various electron-donating 
substituents on the ortho or para positions.  
 
1.1.3.2 Base Labile Linkers 
Base labile linkers can be generally classified as either nucleophile-labile linkers or base-
labile linkers. Linkers belonging to the former classification are generally ester bonds where 





Figure 1.3. General representation of nucleophile-labile ester linker cleavage26 
 
As shown in Figure 1.3, the cleavage of nucleophile-labile linkers involves nucleophilic 
addition and elimination reaction on the carbonyl group attached to the linker. Functional 
group attached to the cleaved product is highly dependent on the type of nucleophile 
employed during the cleavage process.  
Besides using an intermolecular nucleophile for the cleavage step, intramolecular 



















Figure 1.4. Synthesis of indolyl diketopiperazine alkaloids32 
Base labile linkers generally release the substrate under basic conditions via E1cb 













Figure 1.5. Generic representative of base labile cleavage process26 
An example of base-labile cleavage strategy was reported by Kroll and coworkers35 
(Figure 1.6). In their synthesis, base-promoted cleavage releases the trialkyl-ammonium 
bromide in 5-60% overall yields and as a result of the elimination reaction, a vinyl sulfone 






















 DMF, 20 oC, 16 h
5-10 equiv. allyl bromide
 DMF, 20 oC, 16 h
5 equiv. DiEA, 
DCM, 20 oC, 16 h
 
Figure 1.6. Kroll’s solid-phase synthesis of trialkyl-ammonium salt via base promoted 
cleavage. 
 
 1.1.3.3 Traceless Linkers 
Traceless linkers refer to linkers that do not leave remnants of the tether on the cleaved 
substrate. Acid-labile and base-labile linkers often release products with a functional group 
through which it is attached to the solid support prior to the cleavage. These remnants of 
linker are usually polar functional groups which may be detrimental to the bioavailability of 
9 
 
the cleaved products. The efforts to find linkers that do not leave any unwanted appendages 







































Figure 1.8. Ellman’s traceless synthesis of benzodiazepine via germanium linker36 
 
The initial concept of traceless linkers was confined to linker groups which insert a C-H or 
C-C bond at the point of cleavage.26,37 Pioneering work by Ellman et al described the use of 
silicon38 and germanium36 linkers for the traceless synthesis of benzodiazepine derivatives. 
Despite the elegance of the Ellman’s traceless strategies, silicon and germanium based 
traceless linkers are not widely used because both linkers require a laborious preparation 
process.39 In addition to linkers which cleave and insert an C-H or C-C bond, the term 
10 
 
traceless synthesis was expanded to describe synthetic strategies which yield products that do 
not carry any discernible point of linkage to the solid support.39-42 One example of such 
synthesis was reported by Houghten and associates, their traceless synthesis of 
triazinedione43 used nucleophile-labile p-nitrophenol carbonate linkers but the Houghten’s 
synthesis was considered to be traceless because the final product do not carry any remnants 

































Figure 1.9. Houghten and associates’ traceless synthesis of triazinedione43 
 
1.1.3.4 Safety Catch Linkers 
Safety catch linkers are defined as linkers that require an activation step before cleavage. 
This is in contrast to other linkers which require only one step for cleavage. The two step 
























Besides the use of sulphonamide, sulfide linkers are also been widely used in solid phase 
synthesis as a safety catch linker for peptide45,46 and heterocyclic synthesis.47-52 The 
propensity of sulfide oxidation to sulfone is exploited in designing sulfur based safety catch 
linkers. Stability of sulfide linkers to both acidic and basic conditions allows the attached 
substrate to undergo a wide variety of reactions in both acidic and basic conditions. Facile 
oxidation of the sulfide to sulfones and subsequent SNAr type substitution reactions cleaved 




































Figure 1.11. Villalgordo’s safety catch synthesis of 4-alkoxy-substituted pyrimidines49 
1.2.1   1,3,5-Triazine Derivatives 
  
1,3,5-Triazine (or s-triazines) are 6-membered heterocyclic compounds containing 3 
nitrogen atoms at the 1,3,5 position (Figure 1.12).  The parent structure 1.1 is relatively 
stable to temperature of up to 600 oC. Above which, 1.1 decomposes into hydrogen 
cyanide.53 The most well known derivative of 1,3,5-triazine is 2,4,6-triamino-1,3,5-triazine, 
commonly known as melamine. Melamine is a used extensively as a starting material for 
12 
 
inexpensive household plastic cookware. More recently, melamine was used illegally as the 
















Figure 1.12. General structure of 1,3,5-triazine 
The toxicity of melamine does not arise from of the compound itself but the propensity of 
melamine to form insoluble melamine-cyanuric acid co-crystals in the kidney leading to renal 
tubules which in turn results in progressive tubular blockage and degeneration.55 The ability 
to form aggregates was due to the extensive highly ordered hydrogen bonding (Figure 1.13) 
and was utilized for the preparation of supramolecular materials.56,57 
 




Besides applications in supramolecular chemistry, 1,3,5-triazine derivatives are used  in a 
wide variety of biologically active compounds in the agricultural59-63 (Figure 1.14) and 





















R = Cl (Chorsulfuron)
R = CO2Me (Methsulfuron methyl)




































X = NHR, NRR', OPh

























Figure 1.15. Structures of pharmaceutically active 1,3,5-triazines 
1-2b, Atrazine, is a well-known broad-leaved herbicide that is widely used the United 
States68 (Figure 1.14). The activity of atrazine within the plants is not well understood; it is 
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thought that atrazine molecules enter the chlorophyll of the plant and disrupt the 
photosynthesis in broadleaf weeds.69 Bicyclic triazinedione 1-3 is a 5-HT2A-receptor 
antagonist which exhibits potential therapeutic activity for treatment of hypertension64 
(Figure 1.15). Analogs with the general structure of 1-4 are a class of patented triazinedione 
which exhibits analgesic effects.65 1-5 are potential inhibitors of tumor associated carbonic 
anhydrase.70 6-amino-1,3,5-triazinan-2,4-diones 1-6 are potential lead compounds as non-
peptidic prokineticin receptor antagonists.67,71,72 1-7 is modified from another triazine 
derivative, Almitrine, and is capable of moderately sensitizing the highly resistant cell line 
DC-3F/AD to actinomycin.73 
 
1.2.2. Synthesis of 1,3,5-Triazine Derivatives 
Due to the multitude of synthetic strategies available for the synthesis of 1,3,5-triazine,74-
76 this section will concentrate on the recent solution-phase and solid-phase syntheses of the 
1,3,5-triazine derivatives. 
 




















X, Y, Z = N, O, S, C
R1....R6 = Alkyl,
                Alkenyl,
                Aryl  
Scheme 1.1. Synthesis of 2,4,6-trisubstituted-1,3,5-triazine using cyanuric chloride77 
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The low cost78 and ease of handling cyanuric chloride makes reaction of cyanuric chloride 
with various nucleophilic reactions the most common strategy for the synthesis of 2,4,6-
trisubstituted-1,3,5-triazine. For example, the sequential addition of nucleophile onto various 
positions of the triazine ring can be accomplished in one pot in over 72-80% yield and 
sequential addition of selected nucleophiles led to the synthesis of trisubstituted-triazine 
dimers with different substituents and yields of 68%.77  
Besides using cyclic starting materials for the synthesis of 1,3,5-triazine, derivatives of 
1,3,5-triazine can be assembled from acyclic fragments. Examples of this strategy were 
described by Eschenmoser et al in the synthesis of purinoid79 1-8 (Scheme 1.2) and Katritzky 



























1) MeOH, rt, 2 h
2) 45oC, 3 h
1) POCl3, 75 oC, 2 h
2) 110 oC, 3 h
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Scheme 1.2.  Preparation and derivatization of purinoid 1-879 
 
 
In the synthesis highlighted in Scheme 1.2, two different routes were used to assemble 
purinoid 1-11. The first route involved the condensation reaction between biguanide 1-9 and 
N-formylglycine ethyl ester 1-8 to yield a triazine intermediate 1-11 which was subsequently 
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cyclised to purinoid 1-11. Another route treated 4-aminoimidiazole 1-12 with sodium 
dicyanamide 1-13 under acidic conditions to yield 1-11 in one step.  
In another synthesis, Katritzky and coworkers  treated 1-9 with various  mono substituted 
ureas and thioureas under basic conditions to yield a library of  4(6)-amino-1,6(4)-
disubstituted-1,3,5-triazin-2-ones and 4(6)-amino-1,6(4)-disubstituted-1,3,5-triazin-2-

















R3 = H, Alk
t-BuOK, THF, rt































































1.2.2.2 Solid-Phase Synthesis of 1,3,5-Triazine Derivatives 
Majority of the reported strategies for the solid-phase synthesis of trisubstituted-1,3,5-
triazine uses cyanuric chloride as the starting material.81-84 These solid-phase syntheses 
consist of sequential SNAr reactions of various functionalized amino groups on cyanuric 
chloride on polymer support followed by cleavage to yield the trisubstituted-1,3,5-triazine 
products (Scheme 1.4). 
 
Scheme 1.4. Combinatorial synthesis of 2,4,6-trisubstituted-1,3,5-triazine libraries using 
cyanuric chloride.81 
 
There are only three reported solid-phase syntheses of the 6-amino-1,3-disubstituted-1H-
[1,3,5]triazine-2,4-diones containing aromatic substituents. In the first publication, 
Gopalsamy and co-workers reported a solid-phase route used for the synthesis of 6-amino-
2,4-dioxo-3,4-dihydro-1,3,5-triazine derivatives (Scheme 1.5).85  
Gopalsamy’s strategy used Wang resin as the solid support and after the cleavage, an acid 





































































 Reagents and conditions: (a) HOBT, DIC, DMAP, DMF, rt, 18 h; (b) 20% piperidine/DMF, rt, 2 x 10 min; (c) DCM, rt, 20 min; (d) 20% 
piperidine/DMF, 1 x 10 min, 1 x 30 min; (e) MeI, DMF, rt, 18 h; (f) DMSO, 80 oC, 24 h; (g) ClCONCO, THF, room temperature, 2 h; (h) 
50% TFA/DCM, room temperature, 1 h. 
 
Scheme 1.5. Gopalsamy and co-workers’ synthesis of triazinedione  
 
In two other reported solid-phase syntheses, Houghten and associates described the 
synthesis of  1,3,5-trisubstituted 1,3,5-triazine-2,4,6-triones86 (Scheme 1.6) and a traceless 





















































Scheme 1.6. Houghten and co-workers’ syntheses of triazinetrione86 
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For the synthesis of triazinetriones (Scheme 1.6), the key steps involve the cyclization 
between a chiral disubstituted urea with chlorocarbonyl isocyanate and finally the acidic 
cleavage to release the triazine trione amide. 
 
Reagents and conditions: (i) S-methylisothiouronium sulfate (6 equiv., 0.1 M), Cs2CO3 (12 equiv., 0.2 M) in DMF, rt, 48 h. (ii) R1NCO (6 
equiv., 0.1 M) in DCM, rt, overnight. (iii) R2NH2 (6 equiv., 0.1 M) in THF, 50 C, overnight. (iv) KOEt (3 equiv, 0.1 M) in EtOH, 60 C, 
overnight. (v) TFA/DCM (1:1), 1 h. 
 
Scheme 1.7. Houghten and associates’ traceless synthesis of triazinedione43 
 
In Houghten’s synthesis of triazinediones, p-nitrophenyl carbonate resin was treated with 
S-methyl isothiouronium sulfate to provide the solid supported S-methylisothiourea which 
then underwent reaction with isocyanates followed by base promoted intramolecular 
cyclization with concomitant cleavage of the desired product (Scheme 1.7). To date, this is 
the only reported solid supported traceless synthesis of 3-substituted-6-amino-1,3,5-triazine-
2,4-diones.  
 
1.3 Purpose of the Research Work in this Thesis 
Section 1.2 highlights the broad spectrum of bioactivities and the syntheses of 1,3,5-
triazine derivatives. Careful examination of the syntheses of 1,3,5-triazine derivatives 
presented in section 1.2 showed that use of solid-phase strategies for the synthesis of 6-
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amino-1,3-disubstituted-1H-[1,3,5]triazine-2,4-diones are not fully explored. A majority of 
the synthesis requires the used of toxic and moisture sensitive isocyanates for the synthesis of 
the triazine analogues. In addition, majority of the syntheses reported syntheses are only 
capable of providing access to a single class of triazine compounds. Since solid-phase 
synthesis is recognized as a powerful synthetic methodology for the rapid synthesis of 
pharmaceutically useful compounds, it would be synthetically useful to formulate traceless 
solid-phase strategies for the generation of 1,3,5-triazine libraries. In addition, the 
synthesized compounds will be subjected to enzyme inhibition studies to evaluate their 




Traceless Solid-Phase Synthesis of 6-Amino- and 6-Hydroxyimino-1,3,5-
triazine-2,4-diones and 1,3,5-Triazine-2,4,6-triones 
 
2.1 Introduction 
6-Amino-1,3,5-triazine-2,4-diones 2-1 is a template found in a wide variety of 
biologically active compounds that are of pharmaceutical64-66,87 and agricultural interests59,62. 
Recent works have also shown the potential use of 2-1 as non-peptidic prokineticin receptor 
antagonists.67,71,72,88 This multifaceted profile bodes well for the interaction of such 
heterocycles with a variety of biological targets, which has consequently led to the 
development of a number of synthetic strategies leading to disubstituted and trisubstituted 6-
amino-1,3,5-triazine-2,4-diones.43,66,67,85,89,90 Generally, these syntheses involve multistep 
reactions which would limit the synthesis of large number of compounds if performed using 
solution-phase methodology. Solid-phase approach to the synthesis of small organic 
molecule libraries39 would offer a good pathway to a large number of these analogues. To our 
knowledge, there is only one earlier report by Houghten and co-workers on the traceless 
solid-phase synthesis (SPS) of 2-1 with two points of diversification.43 In that synthesis, p-
nitrophenyl carbonate resin was treated with S-methyl isothiouronium sulphate to provide the 
solid supported S-methylisothiourea which then underwent reaction with isocyanates 
followed by base-promoted intramolecular cyclization and concomitant cleavage of 2-1 
(Scheme 1.7). As part of a continuing effort towards the development of SPS protocols for 
generation of small molecules, we were interested in developing a traceless approach for the 
SPS of fully-substituted 2-1. Since 2-1 is structurally similar to 1,3,5-triazine-2,4,6-triones 2-
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2, a biologically interesting compound which is known to be a human gonadotropin-releasing 
hormone receptor antagonist91 and cytosolic phospholipase A2 inhibitor92, we were 
interested in designing a synthetic strategy which could be applied in parallel for the traceless 
SPS of both 2-1 and 2-2. We reckoned that a sulfide linker would be an attractive solid 
support for this synthesis as the linker is relatively stable in basic and acidic reaction 
conditions but is readily oxidized to a labile sulfone functionality which could then be 
cleaved by primary amines via a safety-catch approach.40,52,82,83,93 Thus we herein describe a 
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Scheme 2.1. Overall synthetic strategies for the synthesis of 2-1 and 2-2 
 
2.2 Results and Discussion 
2.2.1 Solution-Phase Synthesis.  
Prior to the SPS, preliminary solution-phase studies were carried out to survey the 
requisite reaction conditions and establish the modifications for the solid-phase synthesis. To 
begin our investigation, ethyl methylcarbamothioylcarbamate 2-5 (R1= CH3, Scheme 2.2) 
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was prepared in quantitative yield by treating ethoxycarbonyl isothiocyanate 2-4 with 
methylamine in dichloromethane using a procedure modified from Tam and coworkers.94 
Subsequent base-promoted S-alkylation with benzyl bromide mimicked the attachment of 2-5 
onto the solid support. For this reaction various bases like triethylamine, DBU, DiEA and 
NaH were used and only reactions that involving NaH with an excess of 2-5 provided 2-6. 
Since compounds 2-6 and 2-5 had similar polarities, the presence of the latter in the reaction 
mixture made purification difficult and the yield of 2-6 obtained after column 
chromatography was only 68%. However, we reasoned that this problem should not arise on 
















































Scheme 2.2. Solution-phase Synthesis 
 
We next proceeded to cyclize 2-6 with various isocyanates using a procedure reported by 
Sanemitsu and co-workers.95 The reaction was found to proceed well with phenyl isocyanate 
(Table 2.1, entry 4) but was less satisfactory with alkyl, m-tolyl and benzyl isocyanates 
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(Table 2.1, entries 1, 7 and 11). Hence we investigated different reaction conditions and 
found that for alkyl isocynates, the reaction gave the best yield (Table 2.1, entry 2) when the 
cyclization reaction was performed at 60 oC in the presence of catalytic amounts of 
tetramethylguanidine (TMG) and with DMF as the solvent, whilst for benzyl and m-tolyl 
isocynates, the reaction surprisingly afforded a better yield when acetonitrile was used as the 
solvent (Table 2.1, entries 9 and 12). To explore if the relatively inert sulfide linkage could 
provide a direct nucleophilic displacement of the thiolate ion, compound 2-7 (R2= benzyl) 
obtained was treated with methylamine under microwave irradiation at 180 oC for 20 min. 
This gave 2-1a1 in 66% yield. 
 
Entry R2 solvent TMGa temp (oC) Yield (%)b 
1c phenylethyl DMF 0.1 eq rt 0 
2 phenylethyl DMF 0.1 eq 60 72 
3 phenylethyl CH3CN 0.1 eq 60 30 
4c phenyl DMF - rt 67 
5 phenyl DMF 0.1 eq 60 60d 
6 phenyl CH3CN 0.2 eq 60 20d 
7 benzyl DMF 0.1 eq rt 20 
8 benzyl DMF 0.1 eq 60 40 
9 benzyl CH3CN 0.2 eq rt 60 
10 benzyl THF 0.2 eq rt 0 
11 m-tolyl DMF 0.1 eq rt 30 
12 m-tolyl CH3CN 0.2 eq rt 52 
a TMG = tetramethylguanidine;  b yield after 24 h; 
c Reaction conditions used in ref 10; d side products were observed; 




To explore other means of cleaving the sulfide linkage, we investigated the safety-catch 
approach by first oxidizing the thioether on 2-7 to a sulfone. When m-CPBA, potassium 
peroxymonosulfate, Oxone® and magnesium monoperoxyphthalate hexahydrate (MMPP) 
were used as oxidants, the sulfone intermediate 2-8 was not isolated. Instead the hydrolyzed 
product, 1,3,5-triazine-2,4,6-trione 2-2 was obtained in 80% yield. This could be attributed to 
the presence of water in the peroxy acid oxidation which readily hydrolyzed 2-8 to 2-2. Since 
water is less nucleophilic than amines, this result was encouraging in the sense that it 
indicated that in the absence of water, it would be possible for the sulfone to be displaced by 
an amine.  
Suckling et al had earlier reported96 obtaining a hydrolyzed product when Oxone® was 
used in the oxidation of pteridine sulfide analogs. This problem was eventually circumvented 
by replacing Oxone® with anhydrous dimethyldioxirane (DMDO). Encouraged by this 
finding, we decided to adopt Suckling’s procedure for the synthesis of the sulfone. Since the 
sulfone linkage was highly labile and 2-8 could not be isolated, solution-phase validation of 
the reaction was therefore not performed and the oxidation and subsequent nucleophilic 
displacement reaction would be carried out directly on the solid-phase format.   
 
2.2.2 Solid-Phase Synthesis.  
With the solution-phase pathway evaluated, we proceeded to synthesize 2-1 and 2-2 via 
SPS. Treatment of bromomethyl resin 2-3 in THF with carbamoyl thiourea 2-5 and sodium 
hydride gave resin 2-9 which was amenable to KBr FTIR monitoring for the appearance of a 
strong  C=N stretch at 1637 cm-1. Resin 2-9 was then reacted with the respective isocyanates 
using the optimized solution-phase reaction conditions (Table 2.1) to afford resin 2-10 which 
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according to FTIR analysis showed a strong C=O stretch at 1735 cm-1 and a blue shift of the 
iminium stretch to 1655-1685 cm-1. Cleavage of resin 2-10 (R1= methyl) with the primary 
amines and DiEA in DMF under microwave irradiation at 180 oC and 5 bars for 20 min 
provided 2-1a in generally >90% purity (by 1H NMR and HPLC) and 39-70% overall yields, 






















































































































































































































2-1a4 (17%) 2-1a5 (48%)2-1a1 (70%)
2-1a7 (42%)2-1a6 (46%)
2-1a2 (53%) 2-1a3 (39%)
2-2a (39%) 2-2b (52%)
2-2g (55%)
























2-2j (20%) 2-2k (23%)2-2i (21%)  
 a Overall yield was calculated based on the loading of resin 2-3 
Figure 2.1. Library of 2-1 and 2-2 obtained from the direct substitution and peroxy acid 
oxidation of resin 2-10.a 
 
The only exception was compound 2-1a4 where the overall yield was much lower when a 
secondary isocyanate was used in the synthesis of resin 2-10. When a similar cleavage 
reaction was applied to resin 2-10 (R1= benzyl), interestingly it behaved differently to afford 
1-benzyl-6-thioxo-1,3,5-triazine-2,4-dione 2-1a’ as the major product (28% yield). The 
formation of the thione side product is probably the result of sterically bulky R1 substituents 
hindering the nucleophilic attack on the adjacent imine bond and as a result the benzyl 
sulfide bond is cleaved leading to the elimination of the thione product. This cleavage 
reaction thus appears to be dependent on the R1 substituent which therefore limits its 
applicability in our library synthesis. We next investigated the peroxy acid oxidation of resin 
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2-10. As expected, reaction of resin 2-10 with mCPBA in CH2Cl2 at room temperature for 3 
h  gave 2-2 in 35-55% overall yields (Figure 2.1). 
To demonstrate the thioether oxidation on resin 2-10, DMDO in anhydrous acetone was 
prepared and its concentration was determined prior to usage.97,98 Attempts to apply 
Suckling’s procedure96 where the oxidation was carried out twice, each time with two to 
three equivalence of DMDO in anhydrous acetone, resulted in a sluggish reaction due to the 
poor swelling of resin 2-10 in acetone. Hence CH2Cl2 was added as a co-solvent and the resin 
mixture was shaken at room temperature for different periods of time (30, 15, 10, 5 and 4 
min). Since it was apparent that the sulfone is highly reactive, the resin was carefully filtered 
at the end of the reaction and the filtrate was concentrated and checked by TLC for the 
presence of hydrolyzed product 2-2. We found that the oxidative rate was dependent on the 
size of the R1 substituent but nevertheless the oxidation generally occurred rapidly. This is 
probably because the triazine moiety is sufficiently planar to allow the DMDO to access the 
thioether linkage easily. When R1 was a methyl group, the oxidation was completed within 4 
min but for larger R1 substituents, the reaction required 10 min. Formation of compound 2-2 
was not observed during these reaction times however prolong reaction gave increasing 
amounts of 2-2 which could probably be attributed to traces of water in the resin mixture 
even despite our best efforts to ensure an anhydrous reaction condition. The formation of 
resin 2-11 was monitored by KBr FTIR which showed a blue shift of the iminium stretch to 
1675-1692 cm-1. 
With resin 2-11 in hand, we reacted it with various amino compounds as cleavage 
reagents. Treatment of resin 2-11 with ammonium hydroxide solution and the respective 
primary amines proceeded smoothly to give 2-1b and 2-1c respectively. Reaction of resin 2-
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11 with hydroxylamine provided the oxime tautomer 2-1d as the stable product, as confirmed 
by the X-ray crystal structure of compound 2-1d3. Unlike the direct substitution of the 
thioether with an amine, the safety-catch approach was applicable to resin 2-11 containing 
different R1 substituents. To demonstrate the versatility of this solid-phase methodology, a 
representative set of 33 members of 6-amino- and 6-hydroxyimino- 1,3,5-triazine-2,4-diones 

















































































































































































































2-1b9 (44%) 2-1b10 (47%)
2-1b1 (56%) 2-1b2 (30%)








2-1c4 (53%) 2-1c5 (29%)
2-1c8 (62%)
2-1c6 (63%) 2-1c7 (59%)
2-1c9 (54%) 2-1d1 (51%)
2-1d2 (26%) 2-1d3 (42%) 2-1d4 (27%) 2-1d5 (24%) 2-1d6 (33%)
2-1d7 (25%) 2-1d8 (31%) 2-1d9 (30%) 2-1d10 (29%)
2-1c11 (28%)2-1c10 (35%)
 
a Overall yield was calculated based on the loading of resin 2-3 
Figure 2.2. Library of 2-1 obtained by the oxidative activation followed by the nucleophilic 




In conclusion, we have described the first example of a traceless SPS route to fully-
substituted 6-amino-1,3,5-triazine-2,4-diones 2-1 and 1,3,5-triazine-2,4,6-triones 2-2. In the 
process, we have also demonstrated an expedient thioether oxidation using anhydrous 
DMDO in acetone-CH2Cl2 mixture to provide an activated sulfone linkage which is 
cleavable by nucleophilic substitution. 
 
2.4 Experimental Section 
General Procedures.  Bromomethyl resin was purchased from Tianjin Nankai Hecheng 
Science and Technology Co. (100-200 mesh, 1.5 mmol/g, 1% divinylbenzene cross-linking). 
All other chemical reagents were purchased from Aldrich, Merck, Lancaster or Fluka and 
were used without further purification. Moisture-sensitive experiments were carried out 
under nitrogen in atmosbag with commercially obtained anhydrous solvents.  The solid-
phase, room temperature reactions were agitated on a flask shaker SF1 (Stuart Scientific). 
Microwave reactions were carried out using the Biotage Initiator microwave synthesizer. 
Analytical TLC was carried out on pre-coated plates (Merck silica gel 60, F254) and 
visualized with UV light or stained with iodine or Dragendorff-Munier. Flash column 
chromatography was performed with silica (Merck, 70-230 mesh).  
All the compounds were fully characterized using 1H, 13C and high resolution mass 
spectrometry. 1H NMR and 13C NMR spectra were measured at 298 K on a Bruker DPX 300 
or DPX 500 Fourier Transform spectrometer. Chemical shifts were reported in  (ppm), 
relative to the residual undeuterated solvent which was used an internal reference. The 
signals observed were described as: s (singlet), d (doublet), t (triplet), m (multiplet). The 
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number of protons (n) for a given resonance was indicated as nH. All Infra-red (IR) spectra 
were recorded on a Bio-Rad FTS 165 spectrometer. Mass spectra were performed on 
Finnigan MAT 95/XL-T spectrometer under electron impact (EI), electrospray ionization 
(ESI) or fast atom bombardment (FAB) techniques.  
 
Procedure for the Synthesis of Ethyl methylcarbamothioylcarbamate 2-5 
Methylamine (100 mmol) was added to ethoxy isothiocyanate 2-4 (5.91 mL, 50 mmol) in 
anhydrous dichloromethane and stirred for 4 hours. The reaction mixture was washed twice 
with 10% HCl to remove any non-volatile amines followed by additional washing with brine. 
The solution was then concentrated and purified by column chromatography (EtOAc:hexane 
= 1:3) to obtain 2-5 as a white solid in quantitative yield (99%). 1H NMR (CDCl3, 300 MHz): 
 9.61 (s, NH, 1H), 8.91 (s, NH, 1H), 4.10 (q, J = 7.1 Hz, CH2CH3, 2H), 3.06 (d, J = 4.5, 
NHCH3, 3H), 1.18 (t, J = 7.1 Hz, CH2CH3, 3H,); 13C NMR (CDCl3, 75 MHz):  179.8, 
152.6, 62.2, 31.6, 13.7; HRMS (ESI, C5H10N2O2S -H) calcd: 161.0385, found: 161.0387. 
 
Procedure for the Synthesis of Ethyl(benzylthio)(methylamino)methylene carbamate  
2-6.  
Sodium hydride (60% dispersion in mineral oil) (0.2508 g, 6.6 mmol) was added to 2-5 
(R1= CH3, 0.3888 g, 2.4 mmol) in anhydrous THF (10 mL). Effervescence was observed. 
Thereafter benzyl bromide (0.2378 mL, 2.0 mmol) was added and the reaction mixture was 
stirred for 12 h and then quenched with deionised water at 0 oC. The reaction mixture was 
concentrated in vacuo and the residue obtained was washed with brine (20 mL) and extracted 
with EtOAc (3x20 mL). The combined organic layer was dried with MgSO4, filtered, 
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concentrated and purified by column chromatography (EtOAc:hexane = 1:3) to give 2-6 
(0.3774 g, 68% yield) as a pale yellowish white solid. 1H NMR (CDCl3, 300 MHz):  9.78 (s, 
NH, 1H), 7.37-7.24 (m, 5H, ArH), 4.37 (s, ArCH2S, 2H), 4.17 (q, J = 7.1 Hz, CO2CH2CH3, 
2H), 2.95 (s, NHCH3, 3H), 1.32 (t, J = 7.1 Hz, CH2CH3, 3H,); 13C NMR (CDCl3, 75 MHz):  
173.9, 162.2, 135.9, 128.9, 128.3, 127.2, 61.0, 35.0, 29.7, 14.2; HRMS (ESI, C12H16N2O2S 
+Na) calcd: 275.0825, found: 275.0835. 
 
Procedure for the Synthesis of 6-(Benzylthio)-1,3,5-triazine-2,4-(1H,3H)-dione 2-7.  
The respective isocyanate (6 equiv.) was added to 6 according to the reaction conditions 
listed in Table 2.1. The resultant reaction mixture was stirred overnight, concentrated in 
vacuo and purified by column chromatography (EtOAc:hexane = 1:3) to give 2-7 as a white 
solid. 
3-Benzyl-6-(benzylthio)-1-methyl-1,3,5-triazine-2,4-(1H,3H)-dione 2-7a. Yield: 60%. 
1H NMR (CDCl3, 300 MHz):  7.39-7.11 (m, ArH, 10H), 4.92 (s, NCH2Ar, 2H), 4.31 (s, 
SCH2Ar, 2H), 3.20 (s, NCH3, 3H); 13C NMR (CDCl3, 75 MHz):  169.2, 152.1, 149.9, 135.9, 
134.4, 129.2, 129.1, 128.9, 128.8 (2 carbons), 128.6 45.5, 36.8, 30.9; HRMS (ESI, 
C18H17N3O2S +Na) calcd: 362.0934, found: 362.0933.  
6-(Benzylthio)-1-methyl-3-m-tolyl-1,3,5-triazine-2,4-(1H,3H)-dione 2-7b. Yield: 52%. 
1H NMR (CDCl3, 300 MHz):  7.44-7.05 (m, ArH, 9H), 4.53 (s, SCH2Ar, 2H), 3.46 (s, 
NCH3, 3H), 2.39 (s, ArCH3, 3H); 13C NMR (CDCl3, 75 MHz):  170.0, 152.1, 150.2, 139.4, 
134.4, 134.3, 129.8, 129.3, 129.2, 128.8, 128.3, 128.0, 124.7, 36.9, 31.2, 21.2; HRMS (ESI, 
C18H17N3O2S +Na) calcd: 362.0934, found: 362.0933. 
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6-(Benzylthio)-1-methyl-3-phenylethyl-1,3,5-triazine-2,4-(1H,3H)-dione 2-7c. Yield: 
72%. 1H NMR (CDCl3, 300 MHz):  7.35-7.15 (m, ArH, 10H), 4.40 (s, SCH2Ar, 2H), 4.07-
4.02 (m, NCH2CH2Ar, 2H), 3.33 (s, NCH3, 3H), 2.91-2.85 (m, NCH2CH2Ar, 2H); 13C NMR 
(CDCl3, 75 MHz):  169.3, 152.1, 150.1, 138.0, 134.6, 129.4, 128.9, 128.8, 128.4, 128.1, 
126.5, 43.7, 36.8, 33.7, 31.1; 13C DEPT135 NMR (CDCl3, 75 MHz):  129.4, 128.9, 123.8, 
128.5, 128.1, 126.5, 43.8, 36.9, 33.4, 31.1; HRMS (ESI, C19H19N3O2S +Na) calcd: 376.1090, 
found: 376.1096. 
6-(Benzylthio)-1-methyl-3-phenyl-1,3,5-triazine-2,4-(1H,3H)-dione 2-7d. Yield: 67%. 
1H NMR (CDCl3, 500 MHz):  7.36-7.13 (m, ArH, 10H), 4.40 (s, SCH2Ar, 2H), 3.29 (s, 
NCH3, 3H); 13C NMR (CDCl3, 125 MHz):  169.8, 151.6, 149.9, 134.4, 134.4, 129.2, 129.1, 
128.6 (2 carbons), 127.9, 127.7, 36.8, 31.0; 13C DEPT135 NMR (CDCl3, 75 MHz):  129.2, 
129.1, 128.6, 127.8, 127.7, 36.7, 31.0; HRMS (ESI, C17H15N3O2S +Na) calcd: 348.0777, 
found: 348.0794. 
 
Procedure for the Synthesis of 3-Benzyl-1-methyl-6-(methylamino)-1,3,5-triazine-
2,4(1H,3H)-dione 2-1a1.  
DMF (15 mL), methylamine (2M in THF, 2.5 mL, 5 mmol) and DiEA (0.870 mL, 2.50 
mmol) were added to 2-7 (R2 = benzyl, 1 mmol) in a 20 mL microwave vessel. The resultant 
mixture was a clear pale yellow solution. The reaction mixture was then microwave 
irradiated at 180 oC for 20 min at a pressure of 5 bars. After which the reaction was 
concentrated in vacuo to yield a pale yellow solid which was washed with diethyl ether and 
EtOAc to give 2-1a1 as a white solid (0.1723 g, 70% yield). 1H NMR (DMSO-d6, 300 MHz): 
 7.72 (d, J = 3.63, NHCH3, 1H), 7.27- 7.21 (m, ArH, 5H), 4.88 (s, ArCH2, 2H), 3.22 (s, 
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NCH3, 3H), 2.80 (d, J = 3.93 Hz, NHCH3, 3H,); 13C NMR (DMSO-d6, 75 MHz):  155.9, 
154.7, 152.1, 138.6, 129.2, 128.5, 128.0, 45.3, 30.1, 29.3; HRMS (ESI, C12H14N4O2 +Na) 
calcd: 269.1009, found: 269.1009. Mp: 226.2-228.4 oC. 
 
General Procedure for the Preparation of Resin 2-9.  
Bromomethyl resin 2-3 (10 mmol, 1.55 mmol/g) was swollen in anhydrous THF (100 mL) 
for 10 min. Thereafter compound 2-5 (20 mmol) and sodium hydride (60% dispersion in 
mineral oil, 1.2 g, 30 mmol) were added and the reaction mixture was stirred overnight at 
room temperature. After which, the resin was filtered and washed thoroughly with DMF (20 
mL x 3), ethanol (20 mL x 3), acetone (20 mL x 3), ethyl acetate (20 mL x 3) and THF (20 
mL x 3) respectively and dried overnight in a vacuum oven at 40 °C. FTIR:  (C=N stretch) 
1637 cm-1. 
 
General Procedure for the Preparation of Resin 2-10.  
Resin 2-10 was prepared according to the reaction conditions listed in Table 2.1. Resin 2-
9 (3 mmol) was swollen in the reaction solvent (30 mL) for 10 min. Thereafter the respective 
isocyanate (15 mmol) and tetramethylguanidine (0.2 equiv., when R2= aliphatic or benzyl) 
were added and the reaction mixture was stirred overnight after which, the resin was filtered 
and washed thoroughly with DMF (20 mL x 3), ethanol (20 mL x 3), acetone (20 mL x 3), 
ethyl acetate (20 mL x 3) and THF (20 mL x 3) respectively and dried overnight in a vacuum 





Procedure for the Synthesis of 1,3-dibenzyl-6-thioxo-1,3,5-triazinane-2,4-dione 2-1a’.  
DMF (15 mL), methylamine (2M in THF, 2.5 mL, 5 mmol) and DiEA (0.870 mL, 5 
mmol) were added to 2-10 (R1= R2 = benzyl, 1 mmol) in a 20 mL microwave vessel. The 
resultant mixture was a clear pale yellow solution. The reaction mixture was then microwave 
irradiated at 180 oC for 20 min at a pressure of 5 bars. After which the reaction was 
concentrated in vacuo to yield a pale yellow solid which was purified using column 
chromatography with EA:hexane (1:3) as eluent. This afforded 2-1a’ as a white solid (0.078 
g, 24% yield). 1H NMR (MeOD-d4, 300 MHz):  7.37- 7.24 (m, ArH, 10H), 5.50 (s, 
ArCH2N, 2H), 4.85 (s, ArCH2N, 2H); 13C NMR (MeOD-d4, 75 MHz):  178.6, 150.1 (2 
carbons), 147.9, 137.3, 137.2, 129.5, 129.3, 129.3, 128.8, 128.5, 51.2, 46.3; HRMS (ESI, 
C17H15N3O2S1 -H) calcd: 324.0812, found: 324.0810. 
 
General Procedure for the Synthesis of 2-1a from Resin 2-10.  
Resin 2-10 (1 mmol) and anhydrous DMF (15 mL) were placed in a 20 mL microwave 
vessel and the resin was allowed to swell in DMF for 10 min. Methylamine (2M in THF, 2.5 
mL, 5 mmol) and DiEA (0.870 mL, 5 mmol) were added and the reaction mixture was 
microwave irradiated at 180 oC for 20 min at a pressure of 5 bars. After which the reaction 
mixture was filtered through a frit and washed with DMF (2 x 10 mL). The filtrate was then 
concentrated in vacuo to yield a pale yellow solid which was then washed with diethyl ether 
and EtOAc to yield a white solid. 
1-Methyl-6-(methylamino)-3-m-tolyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1a2. Overall 
yield: 53%. 1H NMR (DMSO-d6, 500 MHz):  7.77 (s, NH, 1H), 7.31-6.97 (m, ArH, 4H), 
3.24 (s, NCH3, 3H), 2.85 (s, NHCH3, 3H), 2.31(s, ArCH3); 13C NMR (DMSO-d6, 75 MHz):  
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155.0, 153.4, 150.9, 137.9, 136.3, 129.1, 128.3, 128.3, 125.7, 28.9, 28.3, 20.6; HRMS (ESI, 
C12H13N4O2 –H) calcd: 245.1044, found: 245.1036.  Mp: 329.2-331.9 oC. 
1-Methyl-6-(methylamino)-3-phenylethyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1a3. 
Overall yield: 39%. 1H NMR (DMSO-d6, 300 MHz):  7.66 (s, NH, 1H), 7.29-7.19 (m, ArH, 
5H), 3.91-3.86 (m, , NCH2CH2Ar, 2H), 3.21(s, NCH3, 3H), 2.80-2.75 (m, NCH2CH2Ar, 2H), 
2.8-2.75 (m, NHCH3, 3H);  13C NMR (DMSO-d6, 75 MHz):  154.7, 153.4, 150.8, 138.6, 
128.5, 128.3, 126.2, 42.4, 33.3, 28.9, 28.2; HRMS (ESI, C13H16N4O2 +Na): calcd: 283.1165, 
found: 283.1160.  Mp: 212.2-217.8 oC. 
3-Isopropyl-1-methyl-6-(methylamino)-1,3,5-triazine-2,4(1H,3H)-dione 2-1a4. Overall 
yield: 17%. 1H NMR (CDCl3, 500 MHz):  6.62 (s, NH, 1H), 5.02 (m, J = 6.95 Hz, 
CH(CH3)2, 1H), 3.41 (s, NCH3, 3H), 3.02 (s, NHCH3, 3H), 1.43-1.42 (d, J = 6.95 Hz, 
CH(CH3)2, 6H); 13C NMR (CDCl3, 125 MHz):  154.6, 154.3, 150.2, 47.0, 29.0, 29.0, 19.3; 
HRMS (ESI, C8H14N4O2 –H): calcd: 197.1044, found: 197.1042. Mp: 216.4 -218.5 oC.  
3-Allyl-1-methyl-6-(methylamino)-1,3,5-triazine-2,4(1H,3H)-dione 2-1a5. Overall 
yield: 48%. 1H NMR (CDCl3, 500 MHz):  7.12 (s, NH, 1H), 5.86 (m, CH2CHCH2, 1H), 
5.20 (d, J = 17.65 Hz, 10.05 Hz, CH2CHCH2, 1H,), 5.15 (d, J = 10.05 Hz, CH2CHCH2, 1H,), 
4.46 (d, J = 5.7 Hz, CH2CHCH2, 2H), 3.43 (s, NCH3, 3H), 2.98 (s, NHCH3, 3H); 13C NMR 
(CDCl3, 125 MHz):  155.2, 155.1, 150.8, 131.8, 117.5, 44.3, 29.0, 28.9; 13C DEPT135 
NMR (CDCl3, 125 MHz):  131.8, 117.5, 44.3, 29.0, 28.9; HRMS (ESI, C8H12N4O2 –H) 
calcd: 195.0887, found: 195.0881. Mp: 209.5-213.7 oC.  
1-Methyl-6-(methylamino)-3-phenyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1a6. Overall 
yield: 46%. 1H NMR (MeOD-d4, 500 MHz):  7.81 (s, NH, 1H), 7.43-7.18 (m, ArH, 5H), 
3.25 (s, NCH3, 3H), 2.84 (s, NHCH3, 3H); 13C NMR (MeOD-d4, 125 MHz):  155.0, 153.4, 
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150.9, 136.5, 128.7, 128.5 127.6, 29.0, 29.4; HRMS (EI, C11H12N4O2+) calcd: 232.0960, 
found: 232.0961. Mp: 286.4 -291.5 oC. 
1-Methyl-6-(methylamino)-3-o-tolyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1a7. Overall 
yield: 42%. 1H NMR (DMSO-d6, 500 MHz):  7.81 (s, NH, 1H), 7.30-7.09 (m, ArH, 4H), 
3.26 (s, NCH3, 3H), 2.86 (s, NHCH3, 3H) 2.03 (s, ArCH3, 3H); 13C NMR (DMSO-d6, 125 
MHz):  155.2, 153.0, 150.5, 135.7, 135.5, 130.2, 128.8, 128.0, 126.3, 29.0, 28.4, 16.9; 13C 
DEPT135 NMR (DMSO-d6, 125 MHz):  130.2, 128.8, 128.0, 126.3, 29.0, 28.4, 16.9; 
HRMS (ESI, C12H14N4O2 –H) calcd: 245.1044, found: 245.1028. Mp: 276.2-280.9 oC. 
6-(butylamino)-1-methyl-3-phenyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1a8. Column 
chromatography with acetone:EtOAc (1:1) as eluent afforded 2-1a8 as a white solid. Overall 
yield 46%. 1H NMR (MeOD-d4, 500 MHz):  7.47-7.23 (m, ArH, 4H), 3.49 (t, 
NCH2CH2CH2CH3, 3H), 3.37 (s, NHCH3, 3H), 1.65 (m, NCH2CH2CH2CH3, 2H), 1.65 (m, 
NCH2CH2CH2CH3, 2H), 1.39 (m, NCH2CH2CH2CH3, 2H), 0.98 (m, NCH2CH2CH2CH3, 3H) 
. 13C NMR (MeOD-d4, 125 MHz):  157.4, 156.8, 152.8, 137.2, 130.0, 129.7, 129.4, 42.8, 
32.2, 29.6, 21.0, 14.1; HRMS (ESI) [M+H]+ Calcd for C14H19N4O2-: 275.1503; found: 
275.1504.  
 
General Procedure for the Synthesis of 2-2 from Resin 2-10.  
Resin 2-10 (0.5 mmol) was swollen in CH2Cl2 (20 mL) for 10 min. Thereafter mCPBA (3 
equiv.) was added and the reaction mixture was shaken at room temperature for 3 h. The 
resin was then filtered using a frit and washed with CH2Cl2 (2 x 10 mL). The combined 
filtrate and washings was then extracted with deionized H2O at pH 8 (50 mL, pH of the water 
was adjusted using saturated NaHCO3). The combined organic extracts was dried over 
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MgSO4, filtered and concentrated in vacuo to yield a colourless syrup which was purified by 
column chromatography. The isolated compounds were not UV active and were visualized 
on TLC using I2 vapour. 
1-Benzyl-3-methyl-1,3,5-triazinane-2,4,6-trione 2-2a. Column chromatography with 
acetone:hexane (1:2) as eluent afforded 2-2a as a white solid. Overall yield:  39%. 1H NMR: 
(CDCl3, 300 MHz)  9.62 (s, NH, 1H), 7.39-7.36 (m, 2ArH, 2H), 7.22-7.20 (m, 3ArH, 3H), 
4.92 (s, NCH2Ar, 2H), 3.21 (s, NCH3, 3H); 13C NMR: (CDCl3, 75 MHz)  149.8, 148.7, 
148.6, 135.4, 129.1, 128.5, 128.2, 45.5, 28.7; HRMS (EI, C11H11N3O3) calcd: 233.0800, 
found: 233.0799. 
1-Benzyl-3-phenyl-1,3,5-triazinane-2,4,6-trione 2-2b. Column chromatography with 
EtOAc:hexane (1:1) as eluent afforded 2-2b as a white solid. Overall yield: 52%. 1H NMR: 
(CDCl3, 300 MHz)  7.50-7.19 (m, 10H, 10ArH), 5.04 (s, 2H); 13C NMR: (CDCl3, 75 MHz) 
 149.6, 148.3, 147.9, 135.4, 133.0, 129.5, 129.5, 128.6, 128.3 (3 carbons), 45.83; HRMS 
(EI, C16H13N3O3+) calcd: 295.0957, found: 295.0957. 
1-Benzyl-3-butyl-1,3,5-triazinane-2,4,6-trione 2-2c. Column chromatography with 
EA:hexane (1:2) as eluent afforded 2c as a white solid. Overall yield: 43%. 1H NMR: 
(CDCl3, 300 MHz)  7.46-7.44 (m, ArH, 2H), 7.23-7.25 (m, ArH, 3H), 4.99 (s, CH2Ar, 2H), 
3.82 (t, J = 7.32 Hz, CH2CH2CH2CH3, 2H), 1.60 (m, CH2CH2CH2CH3, 2H), 1.33 (m, 
CH2CH2CH2CH3, 2H), 0.92 (t, J = 7.29 Hz, CH2CH2CH2CH3, 3H);  13C NMR: (CDCl3, 75 
MHz)  149.6, 148.7, 148.5, 135.6, 128.9, 128.4, 128.0, 45.3, 42.3, 29.6, 19.7, 13.5;  HRMS 
(EI, C14H17N3O3+) calcd: 275.1270, found: 275.1264. 
1-Hexyl-3-phenyl-1,3,5-triazinane-2,4,6-trione 2-2d. Column chromatography with 
EtOAc:hexane (1:2) as eluent afforded 2-2d as a white solid. Overall yield:  35%. 1H NMR: 
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(CDCl3, 300 MHz)  9.26 (s, br, NH, 1H), 7.53-7.42 (m, 3ArH, 3H), 7.27-7.24 (m, ArH, 
2H), 3.89 (t, J = 7.32 Hz, CH2CH2CH2CH3, 2H), 1.65  (m,  CH2CH2CH2CH2CH2CH3, 2H), 
1.29 (m, CH2CH2CH2CH2CH2CH3, 6H), 0.88 (t, J = 6.6 Hz, CH2CH2CH2CH2CH2CH3, 3H); 
13C NMR: (CDCl3, 75 MHz)  149.4, 148.3, 148.1, 133.0, 129.3, 129.3, 128.3, 42.8, 31.2, 
27.6, 22.4, 13.9; HRMS (EI, C15H19N3O3+) calcd: 289.1426, found: 289.1430. 
1-Allyl-3-phenyl-1,3,5-triazinane-2,4,6-trione 2-2e. Column chromatography with 
EtOAc:hexane (1:1) as eluent afforded 2-2e as a white solid. Overall yield: 53%. 1H NMR: 
(CDCl3, 300 MHz)  7.48 – 7.41 (m, ArH, 3H), 7.23 – 7.21 (m, ArH, 2H), 5.91 to 5.80 (m, 
CH2CHCH2, 1H), 5.32 (d, J = 17.07 Hz, CH2CHCH2, 1H), 5.23 (d, J =10.2 Hz, 
CH2CHCH2, 1H), 4.45 (d, J = 5.94 Hz, CH2CHCH2, 2H); 13C NMR: (CDCl3, 75 MHz)  
149.1, 148.1 (2 carbons), 132.9, 130.4, 129.2, 129.2, 128.2, 119.4, 44.4; HRMS (EI, 
C12H11N3O3+) calcd: 245.0800, found: 245.0799. 
1-Allyl-3-benzyl-1,3,5-triazinane-2,4,6-trione 2-2f. Column chromatography with 
EtOAc:hexane (1:2) as eluent afforded 2-2f as a white solid. Overall yield: 37%. 1H NMR: 
(CDCl3, 300 MHz)  7.46 – 7.43 (m, ArH, 2H), 7.34–7.25 (m, ArH, 3H), 5.90-5.77 (m, 
CH2CHCH2, 1H), 5.31 (dd, J = 17.25 Hz, J = 1.14 Hz, CH2CHCH2, 1H), 5.26 (dd, J = 10.2 
Hz, J = 0.99 Hz, CH2CHCH2, 1H), 5.00 (s, CH2Ar, 2H), 4.43 (d, J = 5.91 Hz, CH2CHCH2, 
2H); 13C NMR: (CDCl3, 75 MHz)  149.3, 148.6, 148.2, 135.4, 130.5, 129.0, 128.5, 128.1, 
119.1 , 45.4, 44.3; HRMS (EI, C13H13N3O3+) calcd: 259.0957, found: 259.0962. 
1-Allyl-3-butyl-1,3,5-triazinane-2,4,6-trione 2-2g. Column chromatography with 
EtOAc:hexane (3:1) as eluent afforded 2-2g as a white solid. Overall yield: 55%. 1H NMR: 
(CDCl3, 300 MHz)  5.91- 5.78 (m, CH2CHCH2, 1H), 5.29 (d,  J = 17.4 Hz, NCH2CHCH2, 
1H), 5.22 (d,  J = 10.44 Hz, NCH2CHCH2, 1H), 4.45 (d, J = 5.58 Hz, NCH2CHCH2, 2H), 
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3.85 (t, J = 7.32 Hz, CH2CH2CH2CH3, 2H,), 1.62 (q, J = 6.99 Hz, CH2CH2CH2CH3, 2H,), 
1.35 (m, CH2CH2CH2CH3, 2H), 0.92 (t,  J = 7.29 Hz, CH2CH2CH2CH3, 3H,); 13C NMR: 
(CDCl3, 75 MHz)  149.3, 148.5, 148.3, 130.6, 119.0, 44.2, 42.3, 29.7, 19.8, 13.5; HRMS 
(EI, C10H15N3O3+) calcd: 225.1113, found: 225.1113. 
1-Hexyl-3-methyl-1,3,5-triazinane-2,4,6-trione 2-2h. Column chromatography with 
acetone:hexane (1:1) as eluent afforded 2-2h as a white solid. Overall yield: 42%. 1H NMR: 
(CDCl3, 300 MHz)  9.59 (s, NH, 1H), 3.84 (t, J = 7.56 Hz, CH2CH2CH2CH2CH2CH3, 2H), 
3.31 (s, NCH3, 3H), 1.62 (m, CH2CH2CH2CH2CH2CH3, 2H), 1.30 (m, 
CH2CH2CH2CH2CH2CH3, 6H), 0.87 (t, J = 6.72 Hz, CH2CH2CH2CH2CH2CH3, 3H); 13C 
NMR: (CDCl3, 75 MHz)  149.7, 148.8, 148.4, 42.5, 31.3, 28.7, 27.6,  26.2, 22.4, 13.9;  
HRMS (EI, C10H17N3O3+) calcd: 227.127, found: 227.1273. 
1-Allyl-3-methyl-1,3,5-triazinane-2,4,6-trione 2-2i. Column chromatography with 
acetone:hexane (1:2) as eluent afforded 2-2i as a white solid. Overall yield: 21%. 1H NMR: 
(CDCl3, 300 MHz)  5.86 (m, NCH2CHCH2, 1H), 5.20 (m, J = 7.56 Hz, NCH2CHCH2, 2H), 
4.40 (m, NCH2CHCH2, 2H), 3.24 (s, NCH3, 3H); 13C NMR: (CDCl3, 75 MHz)  151.6, 
150.6, 150.2, 132.9, 118.1, 44.9, 28.7; HRMS (EI, C7H9N3O3+) calcd: 183.0644, found: 
183.0643. 
1,3-Diphenyl-1,3,5-triazinane-2,4,6-trione 2-2j. Column chromatography with 
acetone:hexane (1:1) as eluent afforded 2-2j as a white solid. Overall yield: 20%. 1H NMR: 
(DMSO-d6, 300 MHz)  12.00 (s, NH, 1H), 7.47-7.37 (m, ArH, 10H); 13C NMR: (DMSO-d6, 
75 MHz)  149.8, 148.8, 134.5, 129.0, 128.8, 128.5; HRMS (EI, C15H11N3O3+) calcd: 
281.0800, found: 281.0800. 
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1-Methyl-3-phenyl-1,3,5-triazinane-2,4,6-trione 2-2k. Column chromatography with 
acetone:hexane (1:1) as eluent afforded 2-2k as a white solid. Overall yield: 23%. 1H NMR: 
(CDCl3, 300 MHz)  10.44 (s, NH, 1H), 7.44-7.31 (m, ArH, 5H), 3.31 (s, NCH3, 3H); 13C 
NMR: (CDCl3, 75 MHz)  151.5, 150.22, 149.6, 136.2, 130.3, 130.9, 29.1;  HRMS (EI, 
C10H9N3O3+) calcd: 219.0644, found: 219.0644. 
General Procedure for the Preparation of Resin 2-11.  
Resin 2-10 (0.5 mmol) was swollen in dichloromethane (3 mL) for 10 min. Thereafter 
DMDO (2.5 equiv.) was added and the reaction mixture was shaken at room temperature for 
10 min (except when R1 = CH3 where the reaction mixture was shaken at room temperature 
for 4 min).  The resin was then filtered, washed with acetone and THF and dried overnight in 
a vacuum oven at 40 °C. 
 
General Procedure for the Synthesis of 2-1b.  
Resin 2-11 (0.5 mmol) was swollen in DMF (20 mL) for 10 min. Thereafter 33% 
ammonium hydroxide (5 mL) was added and the reaction mixture was stirred at 70 oC for 6 
h. After which, the reaction mixture was filtered through a reaction frit and the resin was 
washed with DMF (2 x 10 mL). 
6-Amino-3-benzyl-1-methyl-1,3,5-trazine-2,4(1H,3H)-dione 2-1b1. The filtrate and 
washings were combined and concentrated to yield a white solid as product without further 
purification. Overall yield: 56%. 1H NMR (DMSO-d6, 300 MHz):  7.28-7.24 (m, ArH, 5H), 
4.86 (s, NCH2Ar, 2H), 3.22 (s, NHCH3, 3H); 13C NMR (DMSO-d6, 75 MHz):  156.7, 153.9, 
151.2, 137.6, 128.2, 127.5, 126.9, 44.3, 29.7; 13C DEPT135 NMR (DMSO-d6, 75 MHz):  
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128.2, 127.5, 126.9, 44.3, 29.7; HRMS (ESI, C11H12N4O2 -H) calcd:  231.0887, found: 
231.0882. 
6-Amino-3-benzyl-1-methyl-1,3,5-trazine-2,4(1H,3H)-dione 2-1b2. The filtrate and 
washings were combined and concentrated to yield a white solid as product without further 
purification. Overall yield: 30%. 1H NMR (DMSO-d6, 300 MHz):  7.32-7.18 (m, ArH, 5H), 
3.87 (t, J = 8.01 Hz, NCH2CH2Ar, 2H), 3.21 (s, NCH3, 3H), 2.77 (t, J = 8.37, NCH2CH2Ar, 
2H). 13C NMR (DMSO-d6, 75 MHz):  156.6, 153.7, 150.9, 138.7, 128.5, 128.4, 126.2, 42.5, 
33.4, 29.5; 13C DEPT135 NMR (DMSO-d6, 75 MHz):  128.5, 126.2, 42.5, 33.4, 29.5; 
HRMS (ESI, C12H14N4O2 -H) calcd: 245.1044, found: 245.1028. 
6-Amino-1,3-diphenyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1b3. Column chromatography 
with acetone:EtOAc:hexane (1:1:1) as eluent afforded 2-1b3 as a white solid. Overall yield: 
39%. 1H NMR: (DMSO-d6, 500 MHz)  8.00, (s, 1H, N-H), 7.99 to 7.26, (m, 10H, 10ArH), 
6.35, (s, 1H, N-H); 13C NMR: (DMSO-d6, 125 MHz)  156.2, 153.9, 150.6, 136.2, 133.9, 
129.7, 129.5, 129.0, 128.8, 128.4, 127.6; HRMS (ESI,  C15H12N4O2 +H) calcd: 281.1033, 
found: 281.1039. 
6-Amino-1,3-dibenzyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1b4. Column chromatography 
with acetone:EtOAc:hexane (1:1:1) as eluent afforded 2-1b4 as a white solid. Overall yield: 
26%. 1H NMR: (DMSO-d6, 500 MHz)  7.36-7.23 (m, ArH, 10H), 5.06 (s, NCH2Ar, 2H), 
4.91 (s, NCH2Ar, 2H); 13C NMR: (DMSO-d6, 125 MHz) δ 156.0, 153.7, 151.3, 137.5, 135.6, 
128.5, 128.2 (2 carbons), 127.3, 127.0, 126.4, 45.1, 44.4; DEPT 135: (DMSO-d6, 125 MHz) 
 128.5, 128.2, 127.3, 127.0, 126.4, 45.1, 44.4; 13C DEPT135 NMR (DMSO-d6, 125 MHz)  




6-Amino-1-butyl-3-phenyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1b5. Column 
chromatography with acetone:EtOAc:hexane (1:1:3) as eluent afforded 2-1b5 as a white 
solid.  Overall yield: 51%.  1H NMR: (DMSO-d6, 300 MHz)  7.41-7.37 (m, ArH, 3H), 7.21- 
7.19 (d, J = 6.99 Hz, ArH, 2H), 3.77, (t, J = 7.32 Hz, NCH2CH2CH2CH3, 2H), 1.55 (m, 
NCH2CH2CH2CH3, 2H), 1.32 (m, NCH2CH2CH2CH3, 2H), 0.89 (t, J = 7.32 Hz, 
NCH2CH2CH2CH3, 3H); 13C NMR: (DMSO-d6, 75 MHz)  156.1, 153.4, 150.9, 136.3, 
128.7, 128.4, 127.5, 42.0, 29.2, 19.1, 13.5; 13C DEPT135 NMR (DMSO-d6, 125 MHz)  
128.7, 128.4, 127.5, 42.0, 29.1, 19.1, 13.5; HRMS (ESI, C13H16N4NaO2+Na) calcd: 
283.1165, found: 283.1178. 
6-Amino-1-methyl-3-phenyl-1,3,5-trazine-2,4(1H,3H)-dione 2-1b6. The filtrate and 
washings were combined and concentrated to yield a white solid as product without further 
purification. Overall yield: 60%. 1H NMR (DMSO-d6, 300 MHz):  7.44-7.18 (m, ArH, 5H), 
3.25 (s, NCH3, 3H); 13C NMR (DMSO-d6, 75 MHz):  156.9, 153.7, 151.1, 136.5, 128.8, 
128.6, 127.6, 29.6; 13C DEPT135 NMR (DMSO-d6, 125 MHz):  128.8, 128.6, 127.6, 29.6; 
HRMS (ESI, C10H10N4O2 -H) calcd: 217.0731; found: 217.0726. 
6-Amino-1-benzyl-3-phenyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1b7. Column 
chromatography with acetone:EtOAc:hexane (1:1:1) as eluent afforded 2-1b7 as a white 
solid. Overall yield: 35%. 1H NMR (DMSO-d6, 500 MHz):  7.43 to 7.25 (m, ArH, 10H), 
5.09 (s, NCH2Ar, 2H); 13C NMR (DMSO-d6, 125 MHz):  156.2, 153.4, 151.2, 136.3, 135.5, 
128.8, 128.5, 128.4, 127.7, 127.3, 126.5, 45.0; 13C DEPT135 NMR (DMSO-d6, 125 MHz):  
128.8, 128.5, 128.4, 127.7, 127.3, 126.5, 45.0; HRMS (ESI, C16H14N4O2 +H) calcd: 
295.1190, found 295.1190. 
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3-Allyl-6-amino-1-methyl-1,3,5-trazine-2,4(1H,3H)-dione 2-1b8. The filtrate and 
washings were combined and concentrated to yield a white solid as product without further 
purification. Overall yield:  35%. 1H NMR (DMSO-d6, 300 MHz):  7.73 (br, NH, 1H), 5.84-
5.71 (m, CH2CHCH2, 1H), 5.08-5.04 (ddd, J = 2.07 Hz, 2.46 Hz, 13.74 Hz, NCH2CHCH2, 
2H), 4.27 (d, J = 5.22 Hz, NCH2CHCH2, 2H,), 3.21 (s, NCH3, 3H); 13C NMR (DMSO-d6, 75 
MHz):  156.7, 153.6, 150.9, 133.0, 116.1, 43.2, 29.6; 13C DEPT 135 NMR (DMSO-d6, 75 
MHz):  133.8, 116.9, 44.0, 30.4; HRMS (ESI, C7H10N4O2 -H) calcd: 181.0731, found: 
181.0720. 
6-Amino-3-hexyl-1-phenyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1b9. Column 
chromatography with acetone:EtOAc:hexane (1:1:2) as eluent afforded 2-1b9  as a white 
solid. Overall yield: 44%. 1H NMR (DMSO-d6, 500 MHz):  7.82, (s, 1H, N-H), 7.53-7.51, 
(m, ArH, 3H), 7.40-7.38, (m, ArH, 2H), 6.18, (s, 1H, N-H), 3.68 (t, J = 7.55 Hz, 
NCH2CH2CH2CH2CH2CH3, 2H), 1.52 (m, NCH2CH2CH2CH2CH2CH3,2H), 1.26 (m, 
NCH2CH2CH2CH2CH2CH3, 6H), 0.86 (t, J = 6.35 Hz, NCH2CH2CH2CH2CH2CH3, 3H); 13C 
NMR (DMSO-d6, 125 MHz):  155.8, 154.0, 150.7, 134.0, 129.7, 129.4, 128.9, 41.0, 30.8, 
27.2, 25.8, 21.9, 13.8; 13C DEPT 135 NMR (DMSO-d6, 125 MHz):  129.7, 129.5, 129.9, 
41.0, 30.9, 27.2, 25.9, 21.9, 13.8; HRMS (ESI, C15H20N4O2 –H) calcd: 287.1513, found: 
287.1504. 
6-Amino-3-benzyl-1-butyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1b10. Column 
chromatography with acetone:EtOAc:hexane (1:1:3) as eluent afforded 2-1b10 as a white 
solid. Overall yield: 47%. 1H NMR: (DMSO-d6, 500 MHz)  7.30-7.21 (m, ArH, 5H), 4.87 
(s, NCH2Ar, 2H), 3.76 (t, J = 7.55 Hz, NCH2CH2CH2CH3, 2H), 1.48 (m, NCH2CH2CH2CH3, 
2H), 1.26 (m, NCH2CH2CH2CH3, 2H), 0.87 (t, J = 7.55 Hz, NCH2CH2CH2CH3, 3H) 13C 
45 
 
NMR: (DMSO-d6, 125 MHz)  155.9, 153.7, 151.0, 137.6, 128.1, 127.3, 126.9, 44.2, 42.0, 
29.1, 19.1, 13.5; 13C DEPT 135 NMR (DMSO-d6, 125 MHz)  128.1, 127.3, 126.9, 44.2, 
42.0, 29.1, 19.1, 13.5; HRMS (ESI, C14H18N4O2 +H) calcd: 275.1503; found: 275.1512. 
6-Amino-1-benzyl-3-hexyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1b11. Column 
chromatography with acetone:EtOAc:hexane (1:1:2) as eluent afforded 2-1b11 as a white 
solid. Overall yield: 22%. 1H NMR: (DMSO-d6, 300 MHz)  7.68 (s, NH, 1H), 7.37 to 7.20 
(m, ArH, 5H), 5.03 (s, NCH2Ar, 2H), 3.69 (t, J = 7.32 Hz, NCH2CH2CH2CH2CH2CH3, 2H), 
1.49 (m, NCH2CH2CH2CH2CH2CH3, 2H), 1.23 (m, NCH2CH2CH2CH2CH2CH3, 6H), 0.83 (t, 
J = 5.91 Hz, NCH2CH2CH2CH2CH2CH3, 3H); 13C NMR: (DMSO-d6, 75 MHz)  155.9, 
153.7, 151.2, 135.7, 128.5, 127.4, 126.4, 44.9, 41.2, 30.9, 27.2, 25.9, 21.9, 13.8; 13C DEPT 
135 NMR (DMSO-d6, 75 MHz)  128.5, 127.4, 126.4, 44.9, 41.2, 30.9, 27.2, 25.9, 22.0, 
13.8; HRMS (ESI, C16H22N4O2 +Na) calcd: 325.1635, found 325.1627. 
6-Amino-1-butyl-3-hexyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1b12. Column 
chromatography with acetone:EtOAc:hexane (1:1:3) as eluent afforded 2-1b12 as a white 
solid. Overall yield: 27%. 1H NMR: (DMSO-d6, 500 MHz)  7.61 (s, 2H, NH), 3.75 (t, J = 
6.95 Hz, NCH2CH2CH2CH3, 2H), 3.65, (t, J = 6.95 Hz, NCH2CH2CH2CH3, 2H,), 1.46 (m, 
2CH2, 4H), 1.24 (m, 4CH2, 8H), 0.88 (m, 2CH3, 6H); 13C NMR: (DMSO-d6, 75 MHz)  
155.8, 153.8, 150.9, 41.9, 41.0, 30.9, 29.2, 27.2, 25.8, 21.9, 19.1, 13.8, 13.6; HRMS (ESI, 
C13H24N4O2 +Na) calcd: 291.1791, found 291.1783. 
 
General Procedure for the Synthesis of 2-1c.  
Resin 2-11 (0.5 mmol) was swollen in DMF (10 mL) for 10 min. Thereafter the respective 
primary amine (5 equiv.) was added and the reaction mixture was stirred at 70 oC for 6 h. 
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After which, the reaction mixture was filtered through a reaction frit and the resin was 
washed with DMF (2 x 10 mL). The combined filtrate and washings was then concentrated 
in vacuo and purified using column chromatography to afford 2-1c as a white solid. 
1,3-Dibenzyl-6-(methylamino)-1,3,5-triazine-2,4(1H,3H)-dione 2-1c1. Column 
chromatography with acetone:EtOAc:hexane (1:1:2) as eluent afforded 2-1c1 in 52% overall 
yield.  1H NMR: (DMSO-d6, 500 MHz)  7.79 (s, NH, 1H), 7.36 to 7.20 (m, ArH, 10H), 5.07 
(s, NCH2Ar, 2H), 4.93 (s, NCH2Ar, 2H), 2.77 (s, NCH3, 3H); 13C NMR: (DMSO-d6, 125 
MHz)  154.1, 153.5, 151.2, 137.5, 135.5, 128.6, 128.2, 127.3 (2 carbons) 127.0, 126.2, 44.5, 
44.4, 28.5; 13C DEPT 135 NMR (DMSO-d6, 125 MHz)  128.6, 128.2, 127.3, 127.0, 126.2, 
44.5, 44.4, 28.5; HRMS (ESI, C18H18N4O2 –H) calcd: 321.1357, found 321.1353. 
1-Benzyl-3-hexyl-6-(methylamino)-1,3,5-triazine-2,4(1H,3H)-dione 2-1c2. Column 
chromatography with acetone:EtOAc:hexane (1:1:4) as eluent afforded 2-1c2 in 52% overall 
yield. 1H NMR: (DMSO-d6, 500 MHz)  7.68 (d, J = 4.4 Hz, NH, 1H), 7.36 to 7.33 (m,  
ArH, 2H), 7.29 to 7.26 (m, ArH, 1H), 7.20 to 7.19 (m, ArH, 2H), 5.05 (s, , NCH2Ar, 2H), 
3.71 (t, J = 7.55 Hz, CH2CH2CH2CH2CH2CH3, 2H), 2.75 (d , J = 3.75 Hz, NHCH3, 3H), 
1.50 (m, CH2CH2CH2CH2CH2CH3, 2H), 1.24 (s, CH2CH2CH2CH2CH2CH3, 6H), 0.84 (t, J = 
6.30 Hz, CH2CH2CH2CH2CH2CH3, 3H,); 13C NMR: (DMSO-d6, 125 MHz)  154.0, 153.4, 
151.0, 135.5, 128.5, 127.2, 126.1, 44.3, 41.1, 30.8, 28.4, 27.2, 25.8, 21.9, 13.8;   13C DEPT 
135 NMR (DMSO-d6, 125 MHz)  134.5, 133.2, 132.1, 50.3, 47.1, 36.8, 34.4, 33.1, 31.8, 
27.9, 19.8; HRMS (ESI, C17H24N4O2 –H) calcd: 315.1826, found 315.1819. 
1-Benzyl-6-(methylamino)-3-phenyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1c3. Column 
chromatography with acetone:EtOAc:hexane (1:1:2) as eluent afforded 2-1c3 in 53% overall 
yield.  1H NMR: (DMSO-d6, 300 MHz)  7.84 (s, NH, 1H), 7.46 to 7.25 (m, ArH, 10H), 5.10 
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(s, NCH2Ar, 2H), 2.82 (s, NHCH3, 3H); 13C NMR: (DMSO-d6, 75 MHz)  154.3, 153.3, 
151.1, 136.3, 135.4, 128.8, 128.6, 128.5, 127.8, 127.3, 126.3, 44.5, 28.6; 13C DEPT 135 
NMR (DMSO-d6, 75 MHz)  128.8, 128.6, 128.5, 127.8, 127.3, 126.3, 44.5, 28.6; HRMS 
(ESI, C17H16N4O2 –H) calcd: 307.1200, found 307.1202. 
3-Benzyl-6-(methylamino)-1-phenyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1c4. Column 
chromatography with acetone:EtOAc:hexane (1:1:2) as eluent afforded 2-1c4 in 53% overall 
yield. 1H NMR: (MeOD-d4, 300 MHz)  7.55 (m, ArH, 3H,), 7.41 to 7.24 (m, ArH, 7H), 5.03 
(s, NCH2AR, 2H), 2.82 (s, NHCH3, 3H); 13C NMR: (MeOD-d4, 75 MHz)  154.7, 154.3, 
151.2, 137.9, 133.8, 130.3, 130.1, 129.7, 128.5, 127.9, 127.3, 44.6, 28.9; 13C DEPT 135 
NMR (MeOD-d4, 75 MHz)  130.43, 130.22, 129.88, 128.68, 128.05, 127.47, 44.77, 29.03; 
HRMS (ESI, C17H16N4O2 –H) calcd: 307.1200, found: 307.1198. 
6-(Methylamino)-1,3-diphenyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1c5. Column 
chromatography with acetone:EtOAc:hexane (1:1:1) as eluent afforded 2-1c5 in 29% overall 
yield.  1H NMR: (DMSO-d6, 500 MHz)  7.57 - 7.26 (m, ArH, 10H), 6.66 (d, J = 4.4 Hz, 
NH, 1H), 2.75 (d, J = 4.4 Hz, NHCH3, 3H); 13C NMR: (DMSO-d6, 125 MHz)  154.6, 153.7, 
150.5, 136.1, 133.3, 129.9, 129.7, 129.3, 128.8, 128.5, 127.6, 28.6; 13C DEPT 135 NMR 
(DMSO-d6, 125 MHz)  129.91, 129.71, 129.37, 128.84, 128.52, 127.67, 28.61; HRMS (ESI, 
C16H14N4O2 +H) calcd: 295.1190, found 295.1192. 
3-Benzyl-1-butyl-6-(methylamino)-1,3,5-triazine-2,4(1H,3H)-dione 2-1c6. Column 
chromatography with acetone:EtOAc:hexane (1:1:3) as eluent afforded 2-1c6 in 63% overall 
yield. 1H NMR: (DMSO-d6, 500 MHz)  7.69 (d, J = 3.75 Hz, NH, 1H), 7.69-7.21 (m, ArH, 
5H), 4.88 (s, NCH2Ar ,2H), 3.76 (t, J = 7.55 Hz, NCH2CH2CH2CH3, 2H), 2.81 (d, J = 3.15 
Hz, NHCH3, 3H), 1.49 (m, NCH2CH2CH2CH3, 2H), 1.28 (m, NCH2CH2CH2CH3, 2H), 0.88 
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(t, J = 7.55 Hz, NCH2CH2CH2CH3, 3H,); 13C NMR: (DMSO-d6, 125 MHz)  153.9, 153.5, 
150.9, 137.6, 128.1, 127.3, 126.9, 44.2, 41.4, 29.1, 28.4, 19.1, 13.5; 13C DEPT 135 NMR 
(DMSO-d6, 125 MHz)  128.1, 127.3, 126.9, 44.2, 41.4, 29.1, 28.4, 19.1, 13.5; HRMS (ESI, 
C15H20N4O2 –H) calcd: 287.1513, found 287.1515. 
1-Butyl-6-(methylamino)-3-phenyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1c7. Column 
chromatography with acetone:EtOAc:hexane (1:1:3) as eluent afforded 2-1c7 in 59% overall 
yield. 1H NMR: (DMSO-d6, 300 MHz)  7.77 (s,  NH, 1H), 7.44-7.18 (m, ArH, 5H), 3.78 (t, 
J = 7.29 Hz, NCH2CH2CH2CH3, 2H) 2.85 (s, NHCH3, 3H), 1.52 (m, CH2CH2CH2CH3, 2H), 
1.30 (m, CH2CH2CH2CH3, 2H), 0.89 (t,  J = 6.96 Hz, CH2CH2CH2CH3, 3H,); 13C NMR: 
(DMSO-d6, 75 MHz)  154.1, 153.2, 150.8, 136.3, 128.7, 128.4, 127.5, 41.3, 29.1, 28.4, 
19.1, 13.5; HRMS (ESI, C14H18N4O2+Na) calcd: 297.1322, found: 297.1323.  
3-Hexyl-6-(methylamino)-1-phenyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1c8. Column 
chromatography with acetone:EtOAc:hexane (1:1:4) as eluent afforded 2-1c8 in 62% overall 
yield. 1H NMR: (DMSO-d6, 300 MHz)  7.56 - 7.52 (m, ArH, 3H), 7.40 - 7.38, (m, ArH, 
2H), 6.50 (d, J = 4.26 Hz, NH, 1H), 2.68 (t,  J = 7.41 Hz, CH2CH2CH2CH2CH2CH3, 2H), 
2.67 (d, J = 4.29 Hz, NHCH3, 3H), 1.51 (m, CH2CH2CH2CH2CH2CH3, 2H), 1.25 (m, 
CH2CH2CH2CH2CH2CH3, 6H), 0.85 (t,  J = 6.57 Hz, CH2CH2CH2CH2CH2CH3, 3H); 13C 
NMR: (DMSO-d6, 125 MHz)  154.2, 153.8, 150.5, 133.5, 129.8, 129.6, 129.3, 41.0, 30.9, 
28.4, 27.2, 25.9, 21.9, 13.8; 13C DEPT 135 NMR (DMSO-d6, 75 MHz)  129.8, 129.6, 129.3, 
41.0, 30.9, 28.4, 27.2, 25.9, 21.9, 13.8; HRMS (ESI, C16H22N4O2+Na) calcd: 325.1635; 
found 325.1648. 
1,3-Dibenzyl-6-(butylamino)-1,3,5-triazine-2,4(1H,3H)-dione 2-1c9. Column 
chromatography with acetone:hexane (1:1) as eluent afforded 2-1c9 in 54% overall yield. 1H 
49 
 
NMR: (DMSO-d6, 500 MHz)  7.78 (t, J = 5.05 Hz, NH, 1H), 7.78 to 7.21 (m, ArH, 10H), 
5.13 (s, NCH2Ar, 2H), 4.92 (s, NCH2Ar, 2H), 3.27 (m, NCH2CH2CH2CH3, 2H), 1.42 (m, 
NCH2CH2CH2CH3, 2H), 1.12 (m, NCH2CH2CH2CH3, 2H), 0.79 (t, J = 6.95 Hz, 
NCH2CH2CH2CH3, 3H); 13C NMR: (DMSO-d6, 125 MHz)  153.5(2 carbons), 151.2, 137.5, 
135.5, 128.4, 128.1, 127.3, 127.3, 126.9, 126.2, 44.4, 44.3, 40.8, 30.3, 19.1, 13.5 HRMS (EI, 
C21H24N4O2 +) calcd: 364.1899, found 364.1902.  
1-Benzyl-6-(benzylamino)-3-hexyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1c10. The filtrate 
and combined washings were concentrated in vacuo to yield a yellowish syrup which was 
then dissolved in 30 ml EtOAc and extracted with 20 ml 1 M CuSO4 to remove the residual 
benzylamine. The organic phase was dried over MgSO4  and concentrated to yield a clear 
syrup as crude product which was then purified using column chromatography with 
acetone:hexane (1:3) as eluent afforded 2-1c10 in 35% overall yield. 1H NMR: (CDCl3, 300 
MHz)  7.32- 6.90 (m, ArH, 10H), 5.12 (s, NCH2Ar, 2H), 4.46 (d, J = 5.25 Hz, NHCH2Ar, 
2H), 3.84 (t, J = 7.32 Hz, NCH2CH2CH2CH2CH2CH3, 2H), 1.62 (m, 
NCH2CH2CH2CH2CH2CH3, 2H), 1.29 (m, NCH2CH2CH2CH2CH2CH3, 6H), 0.87 (t, J = 6.42 
Hz, NCH2CH2CH2CH3, 3H); 13C NMR: (CDCl3, 75 MHz)  154.7, 153.9, 151.4, 136.6, 
134.1, 129.2, 128.5, 128.4, 127.5, 127.2, 126.5, 45.5, 45.3, 42.6, 31.4, 27.6, 22.5, 13.9; 13C 
DEPT 135 NMR (CDCl3, 75 MHz)  129.2, 128.5, 128.4, 127.5, 127.2, 126.5, 45.5, 45.3, 
42.6, 31.4, 27.6, 22.5, 13.9; HRMS (ESI, C23H20N4O2 +Na) calcd: 407.1478, found 407.1491.  
1-Benzyl-6-(benzylamino)-3-phenyl-1,3,5-triazine-2,4(1H,3H)-dione 2-1c11. The 
filtrate and combined washings were concentrated in vacuo to yield a yellowish syrup which 
was then dissolved in 30 ml EtOAC and extracted with 20 ml 1 M CuSO4 to remove the 
residual benzylamine. The organic phase was dried over MgSO4  and concentrate to yield a 
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clear syrup as crude product which was then purified using column chromatography with 
acetone:hexane (1:2) as eluent to afford 2-1c11 in 28% overall yield. 1H NMR: (CDCl3, 300 
MHz)  8.47 (s, NH, 1H), 7.46- 7.13 (m, ArH, 15H), 5.23 (s, NCH2Ar, 2H), 4.57 (s, J = 5.25 
Hz, NHCH2Ar, 2H; 13C NMR: (CDCl3, 75 MHz)  154.1, 153.3, 151.2, 138.3, 136.3, 135.4, 
128.8, 128.6, 128.5, 128.1, 127.8, 127.3 (2 carbons), 126.8, 126.5, 44.4, 44.1;13C DEPT 135 
NMR (CDCl3, 75 MHz)  128.8, 128.6, 128.5, 128.1, 127.8, 127.3, 126.8, 126.5, 44.4, 44.1; 
HRMS (ESI, C23H28N4O2 +Na) calcd: 15.2104, found 415.2100. 
 
General Procedure for the Synthesis of 2-1d.  
Resin 2-11 (0.5 mmol) was swollen in DMF (5 mL) for 10 min and thereafter, 
hydroxylamine hydrochloride (0.1739g, 2.5 mmol) and TEA (5 equiv.) were added and the 
reaction mixture was stirred at 70 oC for 6 h. After which, the reaction mixture was filtered 
through a reaction frit and the resin was washed with DMF (2 x 10 mL). The combined 
filtrate and washings were then concentrated in vacuo and purified using column 
chromatography. 
3-Benzyl-6-(hydroxyimino)-1-methyl-1,3,5-triazine-2,4-dione 2-1d1. Column 
chromatography with acetone:EtOAc:hexane (1:1:4) to provide 2-1d1 as an off white solid in 
51% overall yield. 1H NMR (DMSO-d6, 300 MHz):  10.70 (s, OH, 1H), 9.82 (s, NH, 1H), 
7.30-7.24 (m, ArH, 5H), 4.84 (s, NCH2Ar, 2H), 3.08 (s, NCH3, 3H). 13C NMR (DMSO-d6, 
75 MHz):  149.2, 147.7, 140.9, 137.3, 128.3, 127.2, 127.1, 43.9, 28.7; 13C DEPT 135 NMR 
(DMSO-d6, 75 MHz):  128.3, 127.3, 43.9, 28.7. HRMS (EI, C11H12N4O3+) calcd: 248.0909, 
found: 248.0914.  
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6-(Hydroxyimino)-1-methyl-3-phenylethyl-1,3,5-triazine-2,4-dione 2-1d2. Column 
chromatography with acetone:EtOAc:hexane (1:1:4) to yield 2-1d2 as an off white solid in 
26% overall yield. 1H NMR (DMSO-d6, 300 MHz):  10.65 (s, br, NH), 9.78 (s, OH, 1H), 
7.29-7.18 (m, ArH, 5H), 3.85 (m, NCH2CH2Ar, 2H), 3.07 (s, NCH3, 3H), 2.79 (m, 
NCH2CH2Ar, 2H); 13C NMR (DMSO- d6, 75 MHz):  149.0, 147.4, 141.0, 138.4, 128.6, 
128.4, 126.3, 42.1, 33.6, 28.5; 13C DEPT 135 NMR (DMSO- d6, 75 MHz):  128.6, 128.4, 
126.3, 42.1, 33.6, 28.5; HRMS (EI, C12H14N4O3+) calcd: 262.1066, found: 262.1064. 
6-(Hydroxyimino)-1-methyl-3-phenyl-1,3,5-triazine-2,4-dione 2-1d3. Column 
chromatography with acetone:EtOAc:hexane (1:1:4) to yield 2-1d3 as an off white solid in 
42% overall yield. 1H NMR (acetone- d6, 300 MHz):  9.37 (s, NOH, 1H), 9.20 (s, NH, 1H), 
7.44-7.33 (m, ArH, 5H), 3.17 (s, NCH3, 3H). 13C NMR (acetone- d6, 75 MHz):  150.8, 
148.8, 143.5, 136.9, 130.8, 130.1, 129.7, 29.5; 13C DEPT 135 NMR (acetone- d6, 75 MHz):  
130.8, 130.1, 129.7, 29.6. HRMS (EI, C10H10N4O3+) calcd: 234.0753, found: 234.0753. 
1,3-Dibenzyl-6-(hydroxyimino)-1,3,5-triazine-2,4-dione 2-1d4. Column 
chromatography with acetone:EtOAc:hexane (1:1:6) as eluent afforded 2-1d4 as a white 
solid in 27% overall yield. 1H NMR (DMSO-d6, 300 MHz):  10.74 (s, NH, 1H), 9.84 (s, 
OH, 1H), 7.32 - 7.26 (m, ArH, 10H), 4.90 (s, NCH2Ar, 2H), 4.89 (s, NCH2Ar, 2H); 13C NMR 
(DMSO-d6, 75 MHz):  149.4, 147.6, 140.2, 137.2, 136.6, 128.3, 128.2, 128.1, 127.3, 127.2, 
127.1, 127.0, 126.8, 44.8, 44.1; HRMS (ESI, C17H16N4O3 –H) calcd: 323.1150, found 
323.1133. 
1-Benzyl-6-(hydroxyimino)-3-phenyl-1,3,5-triazine-2,4-dione 2-1d5. Column 
chromatography with acetone:EtOAc:hexane (1:1:6) as eluent afforded 2-1d5 as a white 
solid in 24% overall yield. 1H NMR (DMSO-d6, 500 MHz):  10.73 (s, NOH, 1H), 9.86 (s, 
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NH 1H), 7.44 - 7.25 (m, 10H, 10ArH), 4.92 (s, NCH2Ar, 2H); 13C NMR (DMSO-d6, 125 
MHz):  149.4, 147.5, 140.5, 136.6, 135.0, 129.4, 128.6 (2 carbons), 128.2 (2 carbons), 
126.9, 44.8; HRMS (ESI, C16H14N4O3 –H) calcd: 309.0993, found 309.0986. 
1-Benzyl-3-hexyl-6-(hydroxyimino)-1,3,5-triazine-2,4-dione 2-1d6. Column 
chromatography with acetone:EtOAc:hexane (1:1:8) as eluent afforded 2-1d6 as a white 
solid in 33% overall yield. 1H NMR (DMSO-d6, 300 MHz):  10.56 (s, NH, 1H), 9.78 (s, 
NOH, 1H), 7.30-7.25 (m, ArH, 5H), 4.89 (s, NCH2Ar, 2H), 3.70 (t, J = 6.96 Hz, 
NCH2CH2CH2CH2CH2CH3, 2H), 1.52 (m, NCH2CH2CH2CH2CH2CH3, 2H), 1.25 (m, 
NCH2CH2CH2CH2CH2CH3, 6H), 0.85 (t,  J = 6.27 Hz, NCH2CH2CH2CH2CH2CH3, 3H); 13C 
NMR (DMSO-d6, 75 MHz):  149.3, 147.5, 140.3, 136.7, 128.2, 127.0, 126.8, 44.6, 41.0, 
30.9, 27.5, 25.8, 22.0, 13.8; 13C DEPT 135 NMR (DMSO-d6, 75 MHz): 128.2, 127.0, 126.8, 
44.6, 41.0, 30.9, 27.5, 25.8, 22.0, 13.8; HRMS (EI, C16H22N4O3+) calcd: 318.1692; found 
318.1702. 
6-(Hydroxyimino)-1,3-diphenyl-1,3,5-triazine-2,4-dione 2-1d7. Column 
chromatography with acetone:EtOAc:hexane (1:1:5) as eluent afforded 2-1d7 as a white 
solid in 25% overall yield. 1H NMR (DMSO-d6, 300 MHz):  10.82 (s, NOH, 1H), 9.77 (s, 
NH, 1H), 7.44-7.35 (m, 10ArH, 10H); 13C NMR (DMSO-d6, 75 MHz):  148.9, 147.8, 142.2, 
138.4, 135.0, 129.3(2 carbon), 129.3, 128.8, 128.5, 128.1; HRMS (ESI, C15H12N4O3 –H) 
calcd: 295.0837, found 295.0826. 
3-Hexyl-6-(hydroxyimino)-1-phenyl-1,3,5-triazine-2,4-dione 2-1d8. Column 
chromatography with acetone:EtOAc:hexane (1:1:8) as eluent afforded 2-1d8 as a white 
solid in 31% overall yield. 1H NMR (DMSO-d6, 300 MHz):  10.69 (s, NOH 1H,), 9.70 (s, 
NH, 1H), 7.43-7.30 (m, ArH, 5H), 3.68 (t, J = 7.32 Hz, NCH2CH2CH2CH2CH2CH3, 2H), 
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1.53 (m, NCH2CH2CH2CH2CH2CH3, 2H), 1.26 (m, NCH2CH2CH2CH2CH2CH3, 6H), 0.86 (t, 
J = 6.27 Hz, NCH2CH2CH2CH2CH2CH3, 3H); 13C NMR (DMSO-d6, 75 MHz):  148.8, 
147.8, 142.0, 135.4, 129.3 128.8, 128.2, 40.9, 30.9, 27.5, 25.8, 21.9, 13.8; 13C DEPT 135 
NMR (DMSO-d6, 75 MHz):  129.3, 128.8, 128.2, 40.4, 30.9, 27.5, 25.8, 21.9, 13.8 HRMS 
(ESI, C15H20N4O3 –H) calcd: 303.1463; found 303.1445. 
3-Benzyl-1-butyl-6-(hydroxyimino)-1,3,5-triazine-2,4-dione 2-1d9. Column 
chromatography with acetone:EtOAc:hexane (1:1:8) as eluent afforded 2-1d9 as a white 
solid in 30% overall yield. 1H NMR (DMSO-d6, 300 MHz):  10.64 (s, NOH, 1H), 9.82 (s, 
NH, 1H), 7.33 to 7.24 (m, ArH, 5H), 4.84 (s, NCH2Ar, 2H), 3.68 (t, J =7.38 Hz, 
NCH2CH2CH2CH2CH3, 2H), 1.54, (m, NCH2CH2CH2CH2CH2CH3, 2H), 1.27 (m, 
NCH2CH2CH2CH2CH2CH3, 6H), 0.87 (t, J = 7.08 Hz, NCH2CH2CH2CH2CH2CH3, 3H); 13C 
NMR (DMSO-d6, 75 MHz):  149.0, 147.6, 140.1, 137.3, 128.3, 127.2 (2 carbons), 43.9, 
41.6, 28.5, 19.4, 13.6; 13C DEPT 135 NMR (DMSO-d6, 75 MHz):  128.3, 127.2, 43.9, 41.6, 
28.5, 19.4, 13.6; HRMS (ESI, C14H18N4O3 –H) calcd: 289.1306, found 289.1290. 
1-Butyl-6-(hydroxyimino)-3-phenyl-1,3,5-triazinane-2,4-dione 2-1d10. Column 
chromatography with acetone:EtOAc:hexane (1:1:8) as eluent afforded 2-1d10  as a white 
solid in 29% overall yield. 1H NMR (DMSO-d6, 300 MHz):  10.57 (s, NOH, 1H), 9.84 (s, 
NH, 1H), 7.43-7.28 (m, ArH, 5H), 3.70 (t, J = 7.23 Hz, NCH2CH2CH2CH3, 2H), 1.58 (m, 
NCH2CH2CH2CH3, 2H), 1.29 (m, NCH2CH2CH2CH3, 2H), 0.89 (t, J = 7.23 Hz, 
NCH2CH2CH2CH3, 3H); 13C NMR (DMSO-d6, 75 MHz):  148.9, 147.4, 140.4, 135.0, 129.3, 
128.5, 128.1, 41.6, 28.6, 19.5, 13.6; 13C DEPT 135 NMR DMSO-d6, 75 MHz):  129.3, 





Development of a Novel Solid-Phase Traceless Synthetic Strategy for the 
Syntheses of Diverse Libraries with  1,3,5-Triazine Template 
 
3.1 Introduction 
3.1.1 Synthesis of 1,3,5-triazine Heterocycles 
Analogs of 1,3,5-triazine are versatile substrates with wide range of applications as 
potential antimicrobial agents99,100 antitumor agents101-103, polymeric materials104, drug 
delivery105, dyes106 and DNA cleavage reagent107. A thorough search through the scientific 
literature reveals a lack of a unified synthetic approach for the synthesis of analogs of 1,3,5-
triazine. The general strategy for the syntheses of substituted 1,3,5-triazine are usually based 





































Scheme 3.1. Orthogonal Synthesis of a Triazine Library.82 
Among the various reported syntheses which uses cyanuric chloride as a starting material 
for the synthesis of 2,4,6-trisubstituted-1,3,5-triazine, the more noteworthy synthesis was the 
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approach described by Chang and co-workers82 which integrates the safety catch 
methodology with the use of an analog of cyanuric chloride for the synthesis of his triazines 
(Scheme 3.1). Although Chang’s synthesis allows for sequential manipulation at the 2,4,6 
positions using various amines, his approach cannot be modified to change substituents on 
other positions. In summary, use of cyanuric chloride or its analogs limits the substituents on 
the 2,4,6 positions and this limitation prompted us to approach the synthesis via an acyclic 
precursor. 
Masquelin and co-workers first reported an alternative approach that uses thiuronium salt 





















Scheme 3.2. Masquelin’s solution-phase combinatorial library of 2,6-disubstituted 
triazines.109 
 
 In the synthesis highlighted in Scheme 3.2, Masquelin et al reported the use of 
thiuronium salt as a bis-nucleophilic reagent for the synthesis of 2,6-disubstituted triazine. 
Masquelin and associates demonstrated the versatility of this thiouronium approach by 



























Scheme 3.3. Masquelin’s solid-phase synthesis of 2,4-diaminothiazoles via thiouronium 
intermediate.110 
 
By modifying the strategy described by Masquelin and associates, we envisioned the use 
of solid supported thiuronium hydrobromide salt as the primary precursor leading to diverse 
libraries bearing the 1,3,5-triazine template. Our stepwise assembly of the 1,3,5-triazine 
substrate using the thiouronium precursor can accomodate more diversity on various 
positions on triazine substrate and allows us rapid access to a broad range of monocyclic or 
bicyclic compounds with the 1,3,5-triazine template. 
 













Scheme 3.4. Solid-phase preparation of thiuronium hydrobromide salt as primary 
intermediate. 
 
In the syntheses, solid supported thiuronium hydrobromide salt 3-10 was treated with 
various electrophilic reagents to yield bis-nucleophilic intermediates which were cyclised to 
yield a diverse range of 1,3,5-triazine substrates. In order to demonstrate the versatility of our 
approach,  3-10 was used as the starting material towards the synthesis of a small library of 
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4-phenylimino-4,5-dihydro-1,3,5-triazine-2-amine 3-7 which bears structural similarities to a 
series of compounds patented as therapeutic cardiovascular reagents.111 In addition, these 
compounds may also act as novel ligands for transition metal centres.112 
As depicted in Scheme 3.5, the triazine 3-7 will be released from the solid support via the 
























3-10 3-7  
 
Scheme 3.5. Proposed solid-phase synthesis of 2,5,6-trisubstituted-4-phenylimino-4,5-
dihydro-1,3,5-triazine-2-amine 
 
3.3 Results and Discussion for the Synthesis of 2,5,6-trisubstituted-4-phenylimino-4,5-
dihydro-1,3,5-triazine-2-amine 
  
3.3.1 Synthesis of 2-benzylisothiourea 3-1 and 3-2 
The first two steps of the synthetic route adopted Masquelin’s synthesis involving 




Scheme 3.6. Solution-phase route to the synthesis of 2,5,6-trisubstituted-4-phenylimino-4,5-
dihydro-1,3,5-triazine-2-amine 3-7. 
 
3.3.2 Synthesis of (E)-2-benzyl-1-(N'-alkyl-N-phenylcarbamimidoyl)isothiourea 3-4 
Mukaiyama and associates reported the use of 2-chloro-1-methylpyridinium iodide114 
(Mukaiyama’s reagent) for the desulfurization of N,N’-disubstituted  thiourea leading to the 
formation of  carbodiimides (Scheme 3.7).   
 
R = Aryl, alkyl 




Despite numerous reported guanylation reactions involving the Mukaiyama’s reagent 
mediated desulfurization of thioureas,41,115,116 attempts to desulfurize 3-2 with Mukaiyama’s 
reagent or EDC117failed to yield the corresponding carbodiimide 3-3 (Scheme 3.6). 
Desulfurization reactions using SOCl2118 is highly acidic and HgCl2117 generates insoluble 
mercury salts and these reaction conditions are not compatible with 3-2.  
Since the challenge of direct desulfurization of 3-2 proved to be insurmountable, recourse 
was made to our synthesis strategy of 3-4 through the reaction of 3-1 with disubstituted N-
alkyl-N’-aryl carbodiimide, 3-9 to yield 3-4. The revised approach uses N-alkyl-N’-aryl 
carbodiimide 3-9 which was easily regenerated via reaction between Mukaiyama’s reagent 
and N-alkyl-N’-aryl thiourea 3-8 (Scheme 3.8). 
 
Scheme 3.8. Solution-phase reactions leading to N, N’-alkylaryl carbodiimide 3-12114 
 
The initial success of the desulfurization reactions to synthesize N,N’-disubstituted 
carbodiimide 3-9 was short-lived as the Mukaiyama reagent mediated desulfurization is 
limited to N-alkyl-N’-aryl thioureas. Various attempts to apply the desulfurization reactions 
to N,N’-dialkyl disubstituted thioureas failed to yield any significant amounts of the 
corresponding carbodiimide.   
 




Using the desulfurization procedure on thiourea 3-8 generated 3-9 (Scheme 3.8) which 
was subsequently treated with thiouronium hydrobromide salt 3-1 in one pot to give 3-4 in 
77% yield. Isolation of 3-4 was not trivial; the column chromatography involved the removal 
of stoichiometric byproduct from the Mukaiyama’s reagent mediated desulfurization. This 
was followed by the elution of the highly polar and pungent 3-4 using 2-propanol:hexane 
(2:3) elution system with 2% TEA. Since the subsequent cyclization also uses Mukaiyama’s 
reagent, we decided not to purify 3-4 and proceed to carry out the cyclization in one-pot.  
First step involves the generation of carbodiimide 3-9 (Scheme 3.9). After which 3-1 was 
added and the reaction mixture was allowed to stir at room temperature for another 12 h to 
yield biguanidine benzyl sulfide 3-4. Thereafter, the corresponding carboxylic acid, DMAP, 
tertiary amine base and Mukaiyama’s reagent were added to the reaction mixture to facilitate 
the formation of the 1,3,5-triazine ring (Scheme 3.9). When the 1,3,5-triazine ring cyclization 
was carried out with acetic acid (R2 = Me) at 60 oC for 4 h (Table 3.1 entry 1 and 2), this 
gave 3-5 in 74 – 64% yields. 
  




Entry R1 R2 Temperature Solvent Base Time Yield 
1 Me Me 60 oC DMF TEA 4h 74% 
2 Bn Me 60 oC DMF TEA 4h 68% 
3 Me Me rt DCM TEA 4h 30%a 
4 Bn Me rt DCM TEA 4h 21%a 
5 Bn 
 





110 oC DMF Tributylamine 4 h 57% 
 (a) Side products were observed 
Table 3.1. Optimized reaction conditions for the one pot synthesis of 3-5. 
 
 
Cyclization using other carboxylic acids (R2 > Me) required the use of an additional 1.2 
equiv. tributylamine and a cyclization temperature of 110 oC. After 4 h, the reaction afforded 
3-5 in 40-53% (Table 3.1, entry 5 and 6).  
Comparing the yields of reaction listed in Table 3.1, the decrease in yield (Table 3.1, entry 
5-6) and increase in the cyclization temperature could be attributed to the steric congestion 
















Figure 3.1. Steric interaction between the R1 and R2 substituents  
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The structure of triazine analog 3-5c was confirmed using x-ray diffraction 




       
Figure 3.2. ORTEP plot of 3-5c 
 
3.3.4 Oxidation and cleavage of 3-7 
As planned, 3-5 was oxidized using different reagents at various temperatures as listed in 
Table 3.2. 
Entry Oxidant Temperature Time Yield1 
1 Oxone® rt 1 min Nil2 
2 MMPP rt 1 min Nil2 
3 MCPBA rt 1 min Nil2 
4 DMDO rt 1 min Nil2 
5 DMDO 0 oC 1 min Nil2 
6 DMDO -20 oC 10 min 70% 
1 Due to the labile nature of 3-6, the conversion was monitored using TLC; 2 No sulfone 
product observed, only side product arising from the cleavage of benzyl sulfone bond is 
observed. 





During the course of the optimization process, it was established that sulfone 3-6 was too 
unstable to be isolated. When 3-5 was completely oxidized to 3-6 (TLC monitoring), excess 
butylamine was introduced to the reaction mixture in one-pot to give 3-7 in 70% yield. In 
addition to the safety catch approach, microwave assisted cleavage was also explored but 3-5 
decomposed under sealed tube microwave conditions without any formation of 3-7.  
 
3.3.5 Solid-phase Synthesis of 3-7 
The solid-phase synthesis was carried out using analogous conditions that were 
established on solution-phase and the transformations were verified using FTIR 
spectroscopy.  
 
Scheme 3.10. Solid-phase Synthesis of 3-7 
Bromo methyl resin 2-3 was treated with 2 equiv. of thiourea in DMF and the reaction 
mixture was stirred at 80 oC for 3 h to yield solid supported thiouronium hydrobromide salt 
3-10. Transformations from 2-3 to 3-10 were verified via the appearance of a strong iminium 
C=N stretch at 1645 cm-1. The solvent for the solid phase S-alkylation reaction was changed 
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from acetonitrile to DMF due to the superior resin swelling properties of DMF. The 
temperature of the reaction was increased to 80 oC to increase the rate of reaction. The next 
step of the synthesis involved the solution-phase preparation of carbodiimide 3-9. 1.2 mmol 
of N-alkyl-N’-aryl thiourea 3-8 was treated with 1.2 mmol of Mukaiyama’s reagent in the 
presence of 6 mmol of TEA and 12 mL of DMF at room temperature for 1 h. Since 
carbodiimides are very moisture sensitive, it was used in situ without any purification and 
characterization. 1 mmol of 3-10 was then added to the freshly prepared solution of 3-9 and 
the reaction mixture was shaken at room temperature for 12 h. Subsequently, 1.2 mmol of 
Mukaiyama’s reagent, 1.2 mmol of tributylamine for (R2 > Me) and 1.2 mmol of carboxylic 
acid was added to the reaction mixture and the reaction was allowed to react at 60 oC (R2 = 
CH3) or 110 oC (R2 > CH3). The transformation of this step of the synthesis was verified via 
the appearance of strong iminium stretch peaks at 1628 cm-1 and 1561 cm-1. Resin 3-11 was 
then allowed to swell in DCM for 30 min at -20 oC. After which, 2.5 equiv. of DMDO 
solution was introduced and the reaction mixture was stirred at -20 oC for 10 min. Thereafter, 
1 mmol of the resin 3-12 obtained was added to a solution of 5 mmol of amine in DCM and 
the reaction mixture was allowed to stir at room temperature for 3 h to yield 3-7. Figure 3.3 
shows the structures and yields of the small library of 3-7 analogues which was synthesized 




































































































Figure 3.3. Library of 3-7 obtained via oxidative activation followed by the nucleophilic 
substitution of resin 3-12 
 
 
3.3.6 Experimental Section 
Solution-phase Synthesis of 2-Benzylisothiourea Hydrobromide salt (3-1) 
Thiourea (1.52 g, 20.0 mmol) dissolved in anhydrous acetonitrile (50 mL) was treated 
with benzyl bromide (2.55 mL, 15.0 mmol) and the reaction mixture was stirred at room 
temperature for 3 h. Upon completion of the reaction, the white crystalline solid which 
precipitated quantitatively was filtered and used without any further purification. 1H NMR: 
(DMSO-d6, 300 MHz): δ 9.17 (s, C=NH2, 4H),  7.44 – 7.29 (m, ArH, 5H),  4.56 (s, ArCH2S, 
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2H). 13C NMR (DMSO-d6, 75 MHz): δ 169.0, 135.0, 128.9, 128.7, 128.9, 34.2. HRMS (ESI) 
[M+H]+ calcd for C8H11N2S+: 167.0637; found 167.0643. 
  
Solution-phase Synthesis of 3-2 
Phenyl isothiocyanate (0.263 mL, 2.10 mmol) was added to a solution of 3-1 (0.494 g, 2.0 
mmol) and DiEA (0.384 mL, 2.10 mmol) in DMF (10 mL) at room temperature and the 
reaction mixture was stirred at room temperature for 1 h. After which the reaction mixture 
was dissolved in brine (50 mL) and extracted with diethyl ether (3 x 20 mL). The combined 
organic extracts were then dried over MgSO4 and purified using column chromatography 
EtOAc:hexane (1:3) to yield a 3-2 as white solid (0.511 g, 85% yield).1H NMR: (DMSO-d6, 
300 MHz): δ 10.67 (br, NH, 1H), 9.63 (br, N-H, 2H), 7.78 – 7.16 (m, ArH, 10H), 4.46 (br, 
ArCH2 tautomer, 1H),  4.17 (br, ArCH2 tautomer, 1H); 13C NMR (mixture of tautomers) 
(DMSO-d6, 75 MHz): δ 184.1, 168.6, 139.2, 138.0, 137.3, 128.7, 128.4, 128.1, 127.8, 127.1, 
124.4, 123.5, 33.4; HRMS (ESI) [M-H]- calcd for C15H14N3S2-, 300.0635; found 300.0636. 
 
General solution-phase synthesis of N-alkyl-N’-aryl thiourea (3-8) 
The corresponding primary amine (12.0 mmol) was added to a solution of phenyl 
isothiocyanate (1.30 mL, 12.0 mmol) in anhydrous acetonitrile (120 mL) and the reaction 
mixture was stirred at room temperature for 3 h. After which, the reaction mixture was 
concentrated in vacuo to yield a white solid. The crude product was washed with cold diethyl 
ether and filtered to yield a white solid as 3-8. This white solid was then used in the 
subsequent reactions without further purification. 
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1-Methyl-3-phenylthiourea 3-8a. Overall yield = 99.5%. 1H NMR: (CDCl3, 300 MHz): δ 
8.42 (br, N-H, 1H), 7.19 – 6.98 (m, ArH, 5H), 5.99 (br, N-H, 1H),  2.85 (d, J = 4.6 Hz, 
NHCH3, 3H); 13C NMR (CDCl3, 75 MHz): δ 180.9, 136.1, 129.8, 126.8, 124.9, 31.7 HRMS 
(EI) [M]+ calcd for C8H10N2S2+, 166.0565; found 166.0565. 
1-Butyl-3-phenylthiourea 3-8b. Overall yield = 99.5%. 1H NMR: (CDCl3, 300 MHz): δ 
8.11 (br, NH, 1H), 7.36 – 7.11 (m, ArH, 10H), 5.93 (br, NH, 1H),  3.53 (q, J = 6.4 Hz, 
NCH2CH2CH2CH3, 2H); 1.46 (m, NCH2CH2CH2CH3, 2H); 1.23 (m, J = 6.4 Hz, 
NCH2CH2CH2CH3, 2H); 0.82 (t, J = 7.0 Hz, NCH2CH2CH2CH3, 3H), 13C NMR (CDCl3, 75 
MHz): δ 180.3, 136.1, 130.0, 127.0, 125.0, 45.1, 30.9, 19.9, 13.6; HRMS (EI) [M]+calcd for 
C11H16N2S+, 208.1034; found 208.1028. 
1-Benzyl-3-phenylthiourea 3-8c. Overall yield = 99.5%. 1H NMR: (CDCl3, 300 MHz): δ 
8.60 (br, NH, 1H), 7.32 – 7.13 (m, ArH, 10H), 4.46 (br, ArCH2 tautomer, 1H),  6.32 (br, N-
H, 1H), 4.78 (d, J = 5.2 Hz, NHCH2Ar, 2H); 13C NMR (CDCl3, 75 MHz): δ 180.4, 137.1, 
135.9, 129.9, 128.5, 127.4, 127.0, 125.0, 49.0; HRMS (ESI) [M-H]- calcd for C14H14N2S-, 
242.0878; found 242.0876. 
1-Allyl-3-phenylthiourea 3-8d. Overall Yield 99.5%. 1H NMR: (CDCl3, 300 MHz): δ 
8.09 (br, NH, 1H), 7.44 – 7.21 (m, ArH, 5H), 6.05 (br, NH, 1H), 5.85 (m, NCH2CHCH2, 
1H),  5.16 (dd, J = 13.9 Hz, 1.2 Hz, NCH2CHCH2, 1Htrans), 5.13 (dd, J = 6.9 Hz, 1.8 Hz, 
NCH2CHCH2, 1Hcis),  4.27 (t, J = 5.7 Hz, NCH2CHCH2, 1H); 13C NMR (CDCl3, 75 MHz): δ 
180.2, 136.0, 133.0, 129.8, 124.9, 116.7, 47.3; HRMS (EI) [M+] cald for C10H12N2S+: 




Solution-phase synthesis of (E)-2-benzyl-1-(N'-benzyl-N-
phenylcarbamimidoyl)isothiourea (3-4) 
1-Benzyl-3-phenylthiourea (0.29 g, 1.2 mmol), Mukaiyama’s reagent (0.307 g, 1.2 mmol) 
and TEA (0.836 mL, 6 mmol) were dissolved in anhydrous DCM (12 mL). The solution was 
allowed to stir for 1 h at room temperature to afford 3-9. Compound 3-1 (0.247 g, 1 mmol) 
was added to the solution of carbodiimide 3-9 and the reaction mixture was stirred at room 
temperature for another 12 h to yield an orange solution. The reaction mixture was then 
adsorbed directly onto silica gel, loaded directly onto a column and purified using column 
chromatography with 2-propanol:hexane (2:3) with 2% TEA as the eluent system. The 
product obtained, compound 3-4, is a pungent clear yellowish syrup (0. 288 g, 77% yield). 
1H NMR: (CDCl3, 300 MHz): δ 7.34 – 7.21 (m, ArH, 12H), 7.10 – 7.05 (m, ArH, 3H),  4.55 
(s, ArCH2N, 2H), 4.19 (s, ArCH2S, 2H); 13C NMR (CDCl3, 75 MHz): δ 166.4, 154.8, 143.7, 
139.5, 137.3, 129.3, 128.5, 128.4, 128.2 (2 carbons), 126.8, 126.7, 123.6, 123.5, 45.3, 34.9; 
MS (ESI) [M+H]+ m/z: 375.0. 
 
General procedure for the one pot solution-phase synthesis of 3-5 
1-Benzyl-3-phenylthiourea (0.290 g, 1.2 mmol), Mukaiyama’s reagent (0.307 g, 1.2 
mmol) and TEA (0.836 mL, 6 mmol) were dissolved in anhydrous DMF (12 mL). The 
solution was allowed to stir for 1 h at room temperature to afford 3-12 (TLC monitoring). 
Compound 3-1 (0.247 g, 1 mmol) was then added to the solution of carbodiimide and the 
reaction mixture  was stirred at room temperature for 12 h to afford an orange solution of 3-
4. The corresponding acid (1.2 mmol), Mukaiyama’s reagent (0.307 g, 1.2 mmol), tertiary 
amine (1.2 mmol for R2 > Me) and DMAP (24.4 mg, 0.2 mmol) were added to the solution of 
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3-4 and the reaction mixture was heated to either 60 oC (R2 = Me) or 110 oC (R2 > Me) for 4h 
(Table 3.1). The reaction mixture was then added to brine (50 mL) and extracted with diethyl 
ether (3 x 20 mL). The combined organic extracts was dried over MgSO4 and concentrated to 
yield a yellowish syrup which was purified using column chromatography to yield 3-5. 
(Z)-N-(4-(benzylthio)-1,6-dimethyl-1,3,5-triazin-2(1H)-ylidene)benzenamine 3-5a. 
Column chromatography with EtOAc:hexane (1:3) to yield a yellowish solid. Yield : 74%, 
1H NMR: (CDCl3, 300 MHz): δ 7.20 – 6.82 (m, ArH, 10H), 3.85 (s, ArCH2S, 2H) 3.21 ( s, 
NCH3, 3H); 2.07 (s, CCH3, 3H); 13C NMR (CDCl3, 75 MHz): δ174.8, 165.1, 148.2, 146.1, 
137.2, 128.8, 128.0, 127.8, 126.5, 122.7, 122.1, 34.3, 32.6, 22.2; HRMS (ESI) [M+H]+ calcd 
for C18H19N4S+: 323.1325; found 323.1329. 
(E)-N-(1-benzyl-4-(benzylthio)-6-methyl-1,3,5-triazin-2(1H)-ylidene)benzenamine 3-
5b. Column chromatography with acetone:hexane (1:3) to yield a yellowish solid. Yield : 
68%, 1H NMR: (CDCl3, 300 MHz): δ 7.36 – 7.03 (m, ArH, 15H), 5.35 (s, ArCH2N, 2H), 
4.07 (s, ArCH2S, 2H), 2.29 (s, CCH3, 3H); 13C NMR (CDCl3, 75 MHz): δ 175.5, 165.8, 
148.1, 146.0, 137.2, 135.1, 129.1, 128.8, 128.3, 128.2, 127.7, 126.9, 126.6, 123.0, 122.5, 
48.5, 34.7, 22.4; HRMS (EI) [M]+ calcd for C24H22N4S+: 398.1565; found 398.1558.  
(E)-N-(1-benzyl-4-(benzylthio)-6-(4-methylstyryl)-1,3,5-triazin-2(1H)-ylidene)aniline 
3-5c. Column chromatography with EtOAc:hexane  (1:8) to yield a reddish orange solid. 
Yield : 40%, 1H NMR: (CDCl3, 300 MHz): δ 7.90 (d, J =  15.3 Hz, CH, 1Htrans), 7.33- 6.93 
(m, ArH, 19H), 6.69 (d, J =  15.3 Hz, CH, 1Htrans),  5.40 (s, ArCH2N, 2H), 4.01 (s, ArCH2S, 
2H), 2.26 (s, ArCH3, 3H); 13C NMR (CDCl3, 75 MHz): δ 175.4, 161.9, 148.4, 146.7, 145.7, 
141.4, 137.6, 136.0, 131.7, 129.7, 129.1, 129.0, 128.9, 128.4, 128.2, 128.2, 127.7, 126.8, 
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126.7, 123.2, 122.3, 115.4, 48.3, 34.9, 21.4; HRMS (EI) [M]+ calcd for C32H28N4S+: 
500.2035; found 500.2029. 
(Z)-N-(4-(benzylthio)-1-methyl-6-(4-methylstyryl)-1,3,5-triazin-2(1H)-ylidene)aniline  
3-5d. Column chromatography with EtOAc:hexane  (1:4) to yield a reddish orange 
solid.Yield : 53%, 1H NMR: (CDCl3, 300 MHz): δ 7.85 (d, J = 15.1 Hz, CH, 1Htrans), 7.30 – 
6.89 (m, ArH, 14H),  6.84 (d, J = 15.3 Hz, CH, 1Htrans),  3.90 (s, ArCH2S, 2H), 3.40 (s, 
NCH3, 2H), 2.21 (s, ArCH3, 3H); 13C NMR (CDCl3, 75 MHz): δ174.9, 161.3, 148.5, 147.0, 
145.5, 141.3, 137.5, 131.4, 129.5, 128.9, 128.3, 128.1, 128.0, 126.6, 123.1, 122.2, 114.6, 
34.6, 32.4, 21.3; HRMS (EI) [M]+ calcd for C26H24N4S+: 424.1722; found 424.1717. 
 
General procedure for solution-phase synthesis of 3-7a 
DMDO (0.08 M, 2.5 mL) was added to a chilled solution (-23 oC) of 3-5a (32 mg, 0.1 
mmol) in acetone (4 mL). The reaction mixture was stirred at -23 oC for 20 min, butylamine 
(50 µL, 0.5 mmol) was added and the reaction was allowed to warm slowly to room 
temperature. After 1 h, the reaction was concentrated to yield a crude product that was re-
dissolved in DCM (30 mL) and extracted with 1 M CuSO4 (10  mL). The organic phases was 
dried over MgSO4 and concentrated to yield a crude product which is purified using column 
chromatography with acetone:hexane (1:4) as eluent to afford 3-7a (73%) as a clear syrup. 
Yield: 73%.  
(E)-N-butyl-5,6-dimethyl-4-(phenylimino)-4,5-dihydro-1,3,5-triazin-2-amine 3-7a. 1H 
NMR (mixuture of tautomers): (CDCl3, 500 MHz): δ 7.18 – 6.85 (m, ArH, 5H), 5.08 4.97 
(br, N-H, 1H),  3.46 (s, NCH3, 3H), 3.13 (s, CH2CH2CH2CH3, 2H), 2.31, 2,24 (br, CCH3, 
3Htautomer), 1.40 (m; CH2CH2CH2CH3, 2H), 1.24 ( m, CH2CH2CH2CH3, 2H) 0.80 
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(CH2CH2CH2CH3, 3H); 13C NMR (CDCl3, 125 MHz)(mixture of tautomers): δ 165.3, 159.6, 
149.8, 149.7, 149.5, 148.9, 128.4, 123.7, 123.2, 121.6, 121.5, 40.4, 32.7, 31.3, 22.7, 19.8, 
13.6 HRMS (FAB) [M+H]+ calcd for C15H22N5+: 272.187; found 272.1865. 
 
General Procedure for the Synthesis of Resin Bound Thiouronium Hydrobromide salt 
3-10  
Thiourea (12.0 mmol) was added to a suspension of bromomethyl resin 2-3 (loading 1.5 
mmol/g, 5.33 g, 8 mol) in DMF (80 mL) under N2 and the reaction mixture was stirred at 80 
oC for 12 hours. After which, the resin was washed with DMF (3 x 50 mL), ethanol (3 x 50 
mL), acetone (3 x 50 mL), EtOAc (3 x 50 mL), THF (3 x 50 mL), DCM (3 x 50 mL), and 
diethyl ether (3 x 50 mL). The resin was then dried at 45 oC under vacuum for 3 h. FTIR:  
(C=N stretch) 1647 cm-1. 
 
General procedure for the Synthesis of 3-11  
The synthesis of carbodiimide 3-9 from 3-8 was modified from a procedure reported by 
Mukaiyama and associates.114 The corresponding thiourea 3-8 (1.2 mmol, 1.2 equiv.), 
Mukaiyama’s reagent (0.307 g, 1.2 mmol, 1.2 equiv.) and TEA (0.836 mL, 6 mmol, 6 equiv.) 
were dissolved in anhydrous DMF (12 mL). The solution was stirred for 1 h at room 
temperature to afford 3-9. 3-14 (1 mmol) was then added to the solution of 3-9 under N2 and 
the reaction mixture was shaken at room temperature for 12 h to afford an orange suspension. 
After which, the corresponding acid (1.2 mmol), Mukaiyama’s reagent (0.307 g, 1.2 mmol, 
1.2 equiv), tributylamine (1.2 mmol, 1.2 equiv. for R2 > Me) and DMAP (24.4 mg, 0.2 
mmol, 0.2 equiv.) were added. The suspension was stirred at either 60 oC (R2 = Me) or 110 
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oC (R2 > Me) for 4h to yield 3-11 as a dark orange red reaction mixture. After which, the 
resin was washed with DMF (3 x 20 mL), ethanol (3 x 20 mL), acetone (3 x 20 mL), EtOAc 
(3 x 20 mL), THF (3 x 20 mL), DCM (3 x 20 mL), and diethyl ether (3 x 20 mL). The 
isolated resin was dried at 45 oC under vacuum for 3 h. FTIR:  (C=N stretch) 1628 cm-1. 
 
General Procedure for the Synthesis of 3-12  
Resin 3-11 (1 mmol) was added to DCM (25 mL) and the suspension was left to swell at -
23 oC for 20 minutes before DMDO (0.08 M, 25 mL) was added. After which, the suspension 
was stirred at -20 oC for 10 minutes during which the resin turned from dark red to light 
orange. The resin was filtered and dried at 45 oC under vacuum for 3 h to give resin 3-12 
dried. FTIR:  (C=N stretch) 1628 cm-1. 
 
General Procedure for the Solid-phase Synthesis of 3-7 from 3-12  
Resin 3-12 (0.5 mmol) added to a solution of amine (2.5 mmol) in DCM (5 mL) and the 
suspension was shaken at room temperature for 3 h. After which the resin was removed via 
filtration and washed with DCM (2 x 10 mL). The combined filtrate and washings was then 
concentrated in vacuo to yield crude 3-7. 
 
(E)-N-butyl-5,6-dimethyl-4-(phenylimino)-4,5-dihydro-1,3,5-triazin-2-amine 3-7a 
The crude product was dissolved in DCM (30 mL) and extracted with 1 M CuSO4 (1 x 10 
mL) solution. The organic phase was dried over MgSO4 and concentrated in vacuo to yield a 
syrup which was purified using column chromatography with acetone:hexane  (1:4) to yield a 
syrup. Overall yield = 39%. 1H NMR (mixuture of tautomers): (CDCl3, 500 MHz): δ 7.18 – 
73 
 
6.85 (m, ArH, 5H), 5.08 4.97 (br, N-H, 1Htautomer),  3.46 (s, NCH3, 3H), 3.25, 3.13 (q, J = 6.3 
Hz, CH2CH2CH2CH3, 2H), 2.31, 2,24 (br, CCH3, 3Htautomer), 1.40 (m; CH2CH2CH2CH3, 2H), 
1.24 ( m, CH2CH2CH2CH3, 2H) 0.80 (t, J = 7.6 Hz,   CH2CH2CH2CH3, 3H); 13C NMR 
(CDCl3, 125 MHz)(mixture of tautomers): δ 165.3, 159.6, 149.8, 149.7, 149.5, 148.9, 128.4, 
123.7, 123.2, 121.6, 121.5, 40.4, 32.7, 31.3, 22.7, 19.8, 13.6 HRMS (FAB) [M+H]+ calcd for 
C15H22N5+: 272.1870; found 272.1863. 
 
(E)-5,6-dimethyl-N-phenyl-4-(phenylimino)-4,5-dihydro-1,3,5-triazin-2-amine 3-7b 
The crude product was dissolved in DCM (30 mL) and extracted with 1 M CuSO4 (1 x 10 
mL) solution.  The organic phase was dried over MgSO4  and concentrated in vacuo to yield 
a crude product which was purified using column chromatography with acetone:hexane  
(1:3) as eluent to afford 3-7b as a syrup.  Overall yield: 33%. 1H NMR (mixture of 
tautomers) (Acetone-d6, 500 MHz): δ 8.54 (s, N-H, 1H), 7.76 – 6.92  (m, ArH, 10H), 3.55 (s, 
NCH3, 3H),  2.40 (s, CCH3, 3H), 13C NMR (mixture of tautomers) (Acetone-d6, 125 MHz): 
δ 166.6, 158.0, 150.0, 149.1, 139.2, 128.0, 127.6, 123.2, 122.1, 120.9, 119.2, 31.9, 21.7. 
HRMS (ESI) [M+H]+ calcd for C17H18N5+: 292.1557; found 292.1568.  
 
(E)-N,5,6-trimethyl-N-phenyl-4-(phenylimino)-4,5-dihydro-1,3,5-triazin-2-amine 3-7c 
The crude product was dissolved in DCM (30 mL) and extracted with 1 M CuSO4 (1 x 10 
mL) solution.  The organic phase was dried over MgSO4 and concentrated in vacuo to yield a 
syrup which was purified using column chromatography with acetone:hexane  (1:4) as eluent 
to afford 3-7c as a syrup. Overall yield = 24%, 1H NMR : (CDCl3, 300 MHz): δ 7.36 – 6.93  
(m, ArH, 10H), 3.55 (s, NCH3, 3H), 3.37 (s, NCH3, 3H),  2.28 (s, CCH3, 3H), 13C NMR 
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(CDCl3, 75 MHz): δ 165.4, 159.5, 149.5, 149.0, 144.0, 128.5, 128.0, 126.6, 125.8, 123.7, 
121.5, 38.2, 32.7, 23.1 HRMS (ESI) [M+H]+ calcd for C18H20N5+: 306.1722; found 
306.1713. 
 
(E)-5,6-dimethyl-4-(phenylimino)-N,N-dipropyl-4,5-dihydro-1,3,5-triazin-2-amine 3-7d  
The crude product was dissolved in DCM (30 mL) and extracted with 1 M CuSO4 (1 x 10 
mL) solution.  The organic phase was dried over MgSO4 and concentrated in vacuo to yield a 
syrup which was purified using column chromatography with acetone:hexane  (1:4) as eluent 
to yield a syrup. Overall yield = 16%. 1H NMR : (CDCl3, 300 MHz): δ 7.31 – 6.96  (m, ArH, 
5H), 3.66 (s, NCH3, 3H), 3.49 (m, CH2CH2CH3, 2H), 3.28 (m, CH2CH2CH3, 2H), 2.41 (s, 
CCH3, 3H), 1.57 (m, CH2CH2CH3, 4H), 0.90 (t, J = 7.4 Hz, CH2CH2CH3, 3H), 0.83 (t, J = 
7.3 Hz, CH2CH2CH3, 3H); 13C NMR (CDCl3, 75 MHz): δ 164.9, 158.9, 150.8, 147.8, 127.9, 
124.0, 121.8, 49.2, 49.0, 33.1, 23.2, 21.7, 20.6, 11.2, 11.1; HRMS (ESI) [M+H]+ calcd for 
C17H26N5+: 300.2183; found 300.2188. 
 
(E)-5-benzyl-N-butyl-6-methyl-4-(phenylimino)-4,5-dihydro-1,3,5-triazin-2-amine 3-7e 
The crude product was dissolved in DCM (30 mL) and extracted with 1 M CuSO4 (1 x 10 
mL) solution.  The organic phase was dried over MgSO4 and concentrated in vacuo to yield a 
syrup which was purified using column chromatography with acetone:hexane  (1:4) as eluent 
to yield a syrup. Overall yield: 40%. 1H NMR : (CDCl3, 300 MHz): 7.25 – 6.88 (m, ArH, 
5H), 5.43, 5.39 (s, NCH3, 3Htautomer), 3.26, 3.16 (q, J = 6.3 Hz, CH2CH2CH2CH3, 2Htautomer), 
2.28, 2.16 (s, ArCH2N, 2Htautomer), 1.52 (m, CH2CH2CH2CH3, 2H), 1.32 (m, 
CH2CH2CH2CH3, 2H), 0.81 (t, J = 7.5 Hz, CH2CH2CH2CH3, 3H); 13C NMR (CDCl3, 75 
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MHz): δ 166.0, 159.5, 136.2, 128.7, 128.4, 127.9, 127.4, 126.6, 123.9, 123.3, 121.9, 48.1, 




The crude product was dissolved in DCM (30 mL) and extracted with 1 M CuSO4 (1 x 10 
mL) solution.  The organic phase was dried over MgSO4 and concentrated in vacuo to yield a 
syrup which was purified using column chromatography with acetone:hexane  (1:3) as eluent 
to yield a syrup. Overall yield: 34%. 1H NMR (mixture of tautomers) : (CDCl3, 500 MHz): 
7.23 – 6.84 (m, ArH, 10H), 5.78 (t, J = 5.6 Hz, N-H, 1H), 5.28, 5.24 (s, ArCH2N, 2Htautomer), 
4.41, 4.26 (d, J = 6.3 Hz, ArCH2N, 2Htautomer), 2.16, 2.01 (s, CCH3, 3Htautomer); 13C NMR 
(CDCl3, 125 MHz): δ 166.2, 159.3, 148.8, 148.7, 138.3, 136.4, 128.6, 128.3, 127.9, 127.8, 
127.3, 127.2, 126.6, 123.7, 121.5, 47.9, 44.8, 22.3; HRMS (ESI) [M+H]+ calcd for 




The crude product was dissolved in DCM (30 mL) and extracted with 1 M CuSO4 (1 x 10 
mL) solution.  The organic phase was dried over MgSO4 and concentrated in vacuo to yield a 
syrup which was purified using column chromatography with acetone:hexane  (1:3) as eluent 
to yield a syrup. Overall yield: 14%. 1H NMR: (CDCl3, 500 MHz): 7.41 – 6.88 (m, ArH, 
15H), 5.30 (s, ArCH2N, 2H), 2.15 (s, CCH3, 3H); 13C NMR (CDCl3, 125 MHz): δ 149.2, 
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148.8, 138.1, 136.0, 128.7, 128.6, 128.2, 127.5, 126.6, 123.3, 123.2, 122.0, 120.8, 119.2, 




The crude product was dissolved in DCM (30 mL) and extracted with 1 M CuSO4 (1 x 10 
mL) solution.  The organic phase was dried over MgSO4 and concentrated in vacuo to yield a 
syrup which was purified using column chromatography with acetone:hexane (1:3) as eluent 
to yield a syrup. Overall yield: 12%. 1H NMR: (CDCl3, 500 MHz): 7.36 – 7.21 (m, ArH, 
9H), 6.92 – 6.89 (m, ArH, 1H),  5.42 (s, ArCH2N, 2H), 3.46 (m, CH2CH2CH3, 2H), 3.29 (m, 
CH2CH2CH3, 2H); 2.26 (s, CCH3, 3H), 1.57 (m, CH2CH2CH3, 4H), 0.85 (m, CH2CH2CH3, 
6H); 13C NMR (mixture of tautomers) (CDCl3, 125 MHz): δ 165.2, 158.9, 159.7, 149.4, 
136.9,  128.6, 127.8, 127.2, 126.8, 123.9, 121.1, 49.2, 49.0, 47.8, 23.0, 21.8, 20.7, 11.2; 




The crude product was dissolved in DCM (30 mL) and extracted with 1 M CuSO4 (1 x 10 
mL) solution.  The organic phase was dried over MgSO4 and concentrated in vacuo to yield a 
syrup which was purified using column chromatography with acetone:hexane  (1:3) as eluent 
to yield a syrup. Overall yield: 19%. 1H NMR: (CDCl3, 500 MHz): 7.37 – 6.95 (m, ArH, 
10H), 5.50 (s, ArCH2N, 2H), 3.83 (s, Hmorpholine, 2H), 3.69 (s, Hmorpholine, 6H), 2.32 (s, CCH3, 
3H); 13C NMR (CDCl3, 125 MHz): δ 166.3, 158.7, 149.4 (2 carbons), 136.3, 128.8, 
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128.1,127.5, 126.7, 123.7, 121.7, 66.8, 66.6, 48.1, 44.1, 43.5, 23.0; HRMS (ESI) [M+H]+ 
calcd for C21H24N5+: 362.1975; found 362.1980. 
 
(E)-N,5-dibutyl-6-methyl-4-(phenylimino)-4,5-dihydro-1,3,5-triazin-2-amine 3-7j 
The crude product was dissolved in DCM (30 mL) and extracted with 1 M CuSO4 (1 x 10 
mL) solution.  The organic phase was dried over MgSO4 and concentrated in vacuo to yield a 
clear syrup which was purified using column chromatography with acetone:hexane  (1:3) as 
eluent to yield a colourless crystalline solid. Overall yield: 33%. 1H NMR: (CDCl3, 500 
MHz): 7.29 – 6.95 (m, ArH, 10H), 5.12 (s, N-H, 1H), 4.07 (m, NHCH2CH2CH2CH3, 2H), 
3.22 (q, J = 6.9 Hz, NCH2CH2CH2CH3, 2H), 2.36 (s, NCH3, 3H), 1.79 (m, 
NHCH2CH2CH2CH3, 2H), 1.46 (m, NCH2CH2CH2CH3 & NHCH2CH2CH2CH3, 4H), 1.36 
(m, NCH2CH2CH2CH3, 2H), 1.01 (t, J = 7.6 Hz, NHCH2CH2CH2CH3, 3H), 0.91 (t, J = 7.5 
Hz, NCH2CH2CH2CH3, 3H); 13C NMR (mixture of tautomers) (CDCl3, 125 MHz): δ 165.1, 
159.5, 148.5, 128.4, 128.0, 123.9, 123.3, 121.5, 45.2, 40.5, 31.3, 30.0, 22.3, 20.1, 19.9, 13.8, 
13.7; HRMS (ESI) [M+H]+ calcd for C18H28N5+: 314.2339; found 314.2339. 
 
 (E)-N-Benzyl-5-butyl-6-methyl-4-(phenylimino)-4,5-dihydro-1,3,5-triazin-2-amine 3-7k  
The crude product was dissolved in DCM (30 mL) and extracted with 1 M CuSO4 (1 x 10 
mL) solution.  The organic phase was dried over MgSO4  and concentrated in vacuo to yield 
a syrup which was purified using column chromatography with acetone:EtOAc:hexane  
(1:1:4) as eluent to yield a clear colourless solid. Overall yield: 28%. 1H NMR: (CDCl3, 300 
MHz): 7.21 – 7.02 (m, ArH, 9H), 6.87 – 6.82 (m, ArH, 1H),  5.79 (br, NH, 1H), 4.25 (d, J = 
6.1 Hz,  ArCH2NH, 1H),3.92 (t, J = 7.5 Hz, NCH2CH2CH2CH3, 2H), 2.17 (s, NCH3, 3H), 
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1.65 (m, NCH2CH2CH2CH3, 2H), 1.32 (m, NCH2CH2CH2CH3, 2H), 0.88 (t, J = 7.3 Hz, 
NCH2CH2CH2CH3, 3H); 13C NMR (CDCl3, 125 MHz): δ 165.3, 159.2, 149.2, 148.0, 138.4, 
128.3, 127.9, 127.8, 127.1, 123.6, 121.4, 45.1, 44.7, 29.8, 22.0, 20.0, 13.7; HRMS (ESI) 




The crude product is purified using column chromatography with acetone:hexane  (1:3) as 
eluent to yield a pale yellow crystalline solid. Overall yield: 19%. 1H NMR (mixture of 
tautomers)(CDCl3, 500 MHz): 8.72 (m, Hpyridinyl, 2H), 7.80 (m, Hpyridinyl, 1H), 7.37 (m, 
Hpyridinyl, 1H),  7.35 – 6.92 (m, ArH, 10H), 5.69 (s, N-H, 1H), 4.32 (d, J = 6.3 Hz, ArCH2NH, 
2H), 3.42 (s, NCH3, 3H); 13C NMR (CDCl3, 125 MHz): δ 164.2, 159.4, 151.8, 149.8, 148.7, 
137.9, 135.4, 129.9, 128.5, 128.2, 128.0, 127.4, 123.6, 123.3, 123.3, 122.3, 45.1, 36.4; 




The crude product was dissolved in DCM (30 mL) and extracted with 1 M CuSO4 (1 x 10 
mL) solution.  The organic phase was dried over MgSO4 and concentrated in vacuo to yield a 
pale orange syrup which was purified using column chromatography with acetone:hexane 
(1:4) as eluent to yield a reddish orange solid. Overall yield: 13%. 1H NMR (mixture of 
tautomers)(CDCl3, 500 MHz): 7.74 (d, J = 15.8 Hz, 1Htrans, 1H), 7.55 (d, J = 8.2 Hz, ArCl, 
2H), 7.31 (d, J = 8.8 Hz, ArCl, 2H), 7.10 – 7.01 (m, ArH & 1Htrans, 5H), 6.70 (m, J = 7.6 Hz, 
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ArH, 1H), 6.45 (t, J = 5.5 Hz, N-H, 1H), 5.93 (m, CH2CHCH2, 1H), 5.18 (dd, J = 1.2 Hz, 
17.6 Hz, NCH2CHCH2, 1H), 5.08 (dd, J = 1.2 Hz, 10.7 Hz, CH2CHCH2, 1H), 4.90 (d, J = 
5.0 Hz, NCH2CHCH2, 2H), 3.35, 3.13 (m, NCH2CH2CH2CH3, 2H), 1.43 (m, 
NCH2CH2CH2CH3, 2H), 1.22 (m, NCH2CH2CH2CH3, 2H), 0.77 (m, NCH2CH2CH2CH3, 
3H); 13C NMR (mixture of tautomers) (CDCl3, 125 MHz): δ 161.3, 159.9, 149.6, 148.6, 
140.4, 135.1, 133.7, 133.6, 129.6, 129.4, 128.8, 127.4, 127.3, 123.8, 123.4, 120.4, 119.1, 





The crude product was dissolved in DCM (30 mL) and extracted with 1 M CuSO4 (1 x 10 
mL) solution.  The organic phase was dried over MgSO4  and concentrated in vacuo to yield 
a reddish orange syrup which was purified using column chromatography with 
acetone:hexane (1:3) as eluent to yield a reddish orange solid. Overall yield: 20%. 1H NMR 
(mixture of tautomers)(CDCl3, 500 MHz): 7.80 (d, J = 15.1 Hz, 1Htrans), 7.44 – 6.26 (m, 
ArH, 14H), 6.97 (m, ArH, 1H), 6.86 (d, J = 15.1 Hz, 1Htrans),  5.61, 5.59 (s, NCH2Ar, 
2Htautomer), 5.26, 5.15 (t, J = 5.0 Hz , NH, 1H), 3.48, 3.34 (q, J = 6.3 Hz, CH2CH2CH2CH3, 
2Htautomer), 1.57 (m, CH2CH2CH2CH3, 2H), 1.38 (m, CH2CH2CH2CH3, 2H), 0.95 (t, J = 7.5 
Hz, CH2CH2CH2CH3, 3H); 13C NMR (mixture of tautomers) (CDCl3, 125 MHz): δ 162.0, 
159.9, 149.3, 148.8, 142.3, 141.3, 137.2, 136.2, 133.2, 129.2, 129.1, 128.8, 127.9, 127.4, 
126.7, 123.9, 123.3, 121.6, 118.6; 47.9, 40.7, 31.45, 20.0, 13.7; HRMS (ESI) [M+H]+ calcd 
for C28H29N5Cl+: 470.2106; found 470.2121. 
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3.4 Synthesis of 1,3,5-triazine Analogs via Guanidium Azolides 
In order to broaden the scope of 1,3,5-triazine synthesis via the thiouronium approach, we 
treated  3-10 with N,N’-carbodiimidiazole, CDI, to yield thiouroium azolides 3-18. We 
envisioned that 3-18 can be easily converted to the bisnucleophilic intermediate 3-19 leading 
to the synthesis of solid supported 1,3,5-triazine heterocycles with at least one carbonyl 




































































































3-20 3-34 3-41 3-40
3-44 3-393-283-293-17 3-38 3-39
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Scheme 3.11. Traceless solid-phase synthesis of 1,3,5-triazine analogs using solid supported 
thiuronium azolide 3-18 as the primary precursor. 
 
In order to assemble the 1,3,5-triazine substrate, 3-19 was cyclised with either CDI or 
TCDI under basic conditions for the synthesis of monocyclic and bicyclic compounds which 
would be evaluated for their inhibitory properties. Alternatively, 3-19 could undergo acid 
catalysed cyclization with orthoformates or orthoacetates to yield compounds that are 
structurally similar to anti DHFR compounds. After the cyclization, the solid supported 
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1,3,5-triazine substrate was released in a traceless manner via either microwave assisted 
cleavage or safety catch approach. In addition to using oxygen and nitrogen nucleophiles 
during the cleavage step, Lisbeskind Srogl coupling conditions119 was also applied to cleave 
the substrate, and in the process insert an aryl and alkene moiety at the point of cleavage. 
 
3.5 Synthesis of 1,3,5-triazine-2,4-diones 3-17 






























































Scheme 3.12. Solution-phase synthesis of 3,6-disubstituted-1,3,5-triazine-2,4(1H,3H)-dione 
 
The methodology reported by Staab was adopted to afford urea 3-14 in two steps.120 
Reaction of 3-1 with N,N’-carbonyldiimidazole in THF afforded 3-13 in 93% yield. 
Treatment of 3-13 with benzylamine under basic conditions afforded urea 3-14 in 90% yield. 
We explored different reaction conditions by excluding base and varying the reaction solvent 
and found that the reaction proceeded most rapidly at 80 oC in DMF (Table 3.3, entry 6) 
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under basic conditions. Besides treating the 3-13 with excess of primary amines at 80 oC, 
increasing the the amount of amine and TEA yielded 3-13b  in 67% yield after 1.5 h at 40 oC 
(Table 3.3, entry 2).  
Entry Amine Solvent Temperature TEA Reaction Time 
1 Allyl (4 equiv.) DMF rt Nil Incomplete after 12 h
2 Allyl (4 equiv.) DMF 40 oC 4 equiv. 1.5 h 
3 Bn (2 equiv.) DMF rt Nil 12 h 
4 Bn (2 equiv.) DMF 80 oC 2 equiv. 30 min 
5 Bn (2 equiv.) DMF rt 2 equiv. 12 ha  
6 Bn (2 equiv.) THF 50 oC 2 equiv. 12 ha  
a Decomposition of 3-14 observed 
Table 3.3. Reaction Conditions for the synthesis of 3-14 
 
The increase in the rate of the reaction in the presence of TEA was probably due to TEA 
mediated equilibrium between azolide 3-13 and the corresponding isocyanate121 (Figure 3.4). 
During this equilibrium, the isocyanate intermediate undergoes rapid nucleophilic attack by 
the primary amine to form 3-14. 
 
 
Figure 3.4. Reaction of 3-12 with primary amines under basic condition 
 
Although 3-14 can be obtained through a direct reaction between 3-1 and isocyanates, 
synthesis of 3-14 using isocyanates suffered from 3 drawbacks. First, only a small number of 
isocyanates are commercially available. Second, toxicity and moisture sensitivity of 
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isocyanates created difficulties in the small scale synthesis and isolation. Third, the 
electrophilicity of the isocyanates limited the R1 substituent to only simple alkyl, alkene and 
aryl groups. Using the proposed thiouronium azolide route (Scheme 3.12) these problems 
were easily circumvented. In addition, via the azolide route, we could even accommodate an 
unprotected hydroxyl group in the form of aminophenol. 
The subsequent base promoted cyclization of 3-14 is based on the procedure which 
describes the use of CDI as air stable and non-toxic substitute for phosgene as a carbonyl 
synthon122. 3-14 was treated with CDI in DMF in the presence of DiEA at 110 oC for 3 h to 
afford 3-15 in 79% yield. Subsequently 3-15 was oxidized using DMDO giving sulfone 3-
16123 which was concentrated in vacuo and treated with a solution of butylamine in DMF at 
60 oC to afford 3-17a in 70% yield (2 steps). 
 
3.5.2 Solid-Phase Synthesis of 3-Benzyl-6-(butylamino)-1,3,5-triazine-2,4(1H,3H)-dione 
3-17 
With the solution-phase pathway established, we proceeded to perform the solid phase 
synthesis (Scheme 3.13). Solid supported thiouronium resin 3-10 was treated with N,N’-
carbonyldiimidazole (1.5 equiv.) and TEA ( 2 equiv.) in THF at room temperature for 2 h to 
afford the solid supported thiouronium azolide 3-18. Solid supported thiouronium azolide 3-
18 was treated with primary amine (1.5 equiv) and TEA (2 equiv.) in DMF at 80 oC over 2 h 
to afford resin 3-19. Subsequently 3-19 was treated with N,N’-carbonyldiimidazole (3 equiv.) 
and DiEA (2 equiv.) at 110 oC for 3 h to afford solid supported 1,3,5-triazine-2,4-dione 3-20. 
Subsequently, 3-20 was swollen in DCM for 10 min and thereafter DMDO (2.5 equiv.) was 
added and the mixture was stirred for 5 min at room temperature to yield sulfone 3-21. Resin 
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3-21 was treated with the respective amine (5 equiv.) in DMF at 80 oC for 3 h to yield 3-17.  
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Scheme 3.13.  Solid-phase strategy for the synthesis of 6-amino-1,3,5-triazinan-2,4-diones 3-
17 
 
Initial attempts to cleave 3-21 with secondary amines failed to yield any corresponding 3-
17 and this was circumvented by adding 5 equiv. of DiEA to the reaction mixture when 
secondary amines were used during the safety catch cleavage step. 
In addition to applying the safety catch methodology for the release of substrate from the 
solid support, we also explored the use of microwave assisted cleavage conditions described 
in the preceding chapter. Initial attempts to perform the cleavage under sealed tube 
microwave condition at 180 oC using an excess of primary amine and DiEA in DMF did not 
yield any corresponding product. FTIR analysis of the post microwave resin shows substrate 
remaining intact on the resin. We rationalized that in the presence of DiEA, the acidic proton 
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adjacent to the carbonyl was removed and the resulting lone pair delocalized into the adjacent 
 imine sulfur bond and in the process stabilized it against substitution by the primary amine 
used for the cleavage reaction. We repeated the microwave reactions in the absence of DiEA 
and obtained 3-17 with yields of 27-53% (Table 3.4).  




1 Bn Me 33% 53% 
2 Bn Bu 25% 43% 
3 Bn Ph 32% 40% 
4 Ph Bu 25% 27% 
5 4-Aminophenol Bu 25% 42% 
Table 3.4. Yields of microwave assisted cleavage and safety catch cleavage 
 
We observed that yields from microwave assisted cleavage are significantly higher than 
the yields obtained via safety catch methodology (Table 3.4). In addition, using the 
microwave assisted cleavage allowed the synthesis of oxidation sensitive functionality like 
furan ring in good overall yields (46-55%). However, despite the significantly higher yields 
of the microwave reaction, the cleavage via the microwave cleavage is limited to primary 
amines. Attempts to perform the microwave assisted cleavage using secondary amines did 
not yield any corresponding products. 
Next, we sought to increase the diversity of our thiouronium approach by alkylating the 
N1 position of resin 3-20 using two different approaches. First, Mitsunobu N-alkylation 
condition124 on 3-21 gave 2-10 (Scheme 3.14) which was subsequently oxidized and cleaved 
using conditions described in the preceding chapter to give 2-1c12 in 29% overall yield. 
Second, base promoted N-alkylation with benzyl bromide and the subsequent cleavage gave 
2-1c14 in 37% overall yields (Scheme 3.15). Using analogous Mitsunobu and cleavage 
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conditions we devised an ameliorate route (Scheme 3.14) to 2-1c13, a key intermediate of a 








































































































































































































a Yield obtained via microwave assisted cleavage 
b Yield obtained via safety catch approach. 
 






Figure 3.6. Structure and yields of 2-1c synthesized via alkylation of 3-20 
 
3.5.3 Experimental Section 
3.5.3.1 Solution phase synthesis 
Synthesis of 2-benzylisothiouronium bromide 3-1 
Thiourea (1.522 g, 20.0 mmol) was added to acetonitrile (50 mL) under N2. Benzyl bromide 
(2.55 mL, 15.0 mmol) was then added and the reaction mixture was stirred at room 
temperature for 5 h. 3-1 was obtained as white crystalline solid in quantitative yield (3.708 g, 
15.0 mmol) via vacuum filtration. 1H NMR: (DMSO-d6, 300 MHz): δ 9.17 (s, NH2, 4H), 
7.44 – 7.29 (m, ArH, 5H), 4.56 (s, ArCH2, 2H). 13C NMR (DMSO-d6, 75 MHz): δ 169.09, 
135.06, 128.97, 128.75, 127.94, 34.26. HRMS (ESI) [M]+: calcd for C8H11N2S+ 167.0637, 
found 167.0643. 
 
Synthesis of Benzyl N’-1H-imidazole-1-carbonyl carbamimidothioate 3-13 
3-1 (3.708 g, 15.0 mmol) was added to anhydrous THF (50 mL) under N2 and the resin 
was allowed to swell for 10 min. Thereafter triethylamine (2.80 mL, 20.0 mmol) and N,N'-
carbonyldiimidazole (CDI) (3.243 g, 20.0 mmol) were added. Upon addition of CDI, a white 
suspension was formed and the reaction was stirred at room temperature for 2 h. Purification 
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by column chromatography with EtOAc:acetone:hexane (1:1:1) as eluent afforded 3-13 as a 
white solid (3.600 g, 13.9 mmol, 93%). 1H NMR: (CDCl3, 300 MHz): δ 9.43 (s, br, NH, 1H), 
8.26 (s, N=CH, 1H), 7.50 (s, N=CH, 1H), 7.49 – 6.95 (m, ArH, 5H), 6.95 (s, N=CH, 1H), 
4.35 (s, ArCH2, 1H). 13C NMR (CDCl3, 75 MHz): δ 175.71, 155.37, 137.42, 135.86, 129.70, 
128.85, 128.65, 127.80, 117.12, 35.28. HRMS (EI) [M]+: calcd for C12H12N4OS+ 260.0732, 
found 260.0733. 
 
Synthesis of Benzyl N'-benzylcarbamoylcarbamimidothioate 3-14a 
Compound 3-13 (2.861 g, 11 mmol), benzylamine (2.04 mL, 16.5 mmol) and 
triethylamine (3.02 mL, 22 mmol) were dissolved in DMF (50 mL) under N2 and stirred at 80 
oC for 30 min. Purification by column chromatography with acetone:hexane (1:2) as eluent 
afforded 3-14a as a clear syrup (2.9601 g, 9.9 mmol, 90%). 1H NMR: (CDCl3, 300 MHz): δ 
7.23 - 7.14 (m, ArH, 10H),  4.31 (d, ArCH2NH, J = 6.3 Hz, 2H) 4.13 (s, ArCH2, 2H). 13C 
NMR (CDCl3, 75 MHz)(mixture of tautomers): δ 169.3, 167.8, 163.2, 162.3, 138.6, 136.7, 
128.5, 128.2, 128.1, 127.0, 126.9, 126.7, 43.6, 34.3. HRMS (ESI) [M]+: calcd for 
C16H18N3OS+  300.1165 ; found 300.1172. 
 
Synthesis of (E)-benzyl N'-allylcarbamoylcarbamimidothioate 3-14b 
Allylamine hydrochloride (0.21 g, 2.25 mmol) was dissolved in DMF (10 mL). Thereafter 
Amberlyst A21 (1.5 g) was added, the reaction mixture was shaken at room temperature for 
30 mins and then transferred to a 25 mL round bottom flask. Triethylamine (0.309 mL, 2.25 
mmol) and 3-13 (0.146 g, 0.56 mmol) were added and the reaction was stirred under N2 at 40 
oC for 1.5 h. Thereafter the reaction mixture was quenched with brine (50 mL) and extracted 
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with diethyl ether (3 x 20 mL). The combined organic layer was dried with MgSO4, filtered, 
concentrated in vacuo to yield a clear syrup which was purified by column chromatography 
(EtOAc:hexane = 1:3) to give 3-14b (94 mg, 67% yield) as a pungent clear syrup. 1H NMR: 
(CDCl3, 300 MHz): δ 7.27 - 7.16 (m, ArH, 5H),  5.77 (m, NHCH2CHCH2, 1H), 5.44 (s, NH, 
1H), 5.12 (dd, NHCH2CHCH2, J = 17.2 Hz, 1.4 Hz,  1H), 5.03 (dd, NHCH2CHCH2, J = 
10.2 Hz, 1.4 Hz,  1H) 4.16 (s, ArCH2, 2H), 3.76 (t, NHCH2CHCH2, J = 5.5 Hz,  1H); 13C 
NMR (CDCl3, 75 MHz): δ 168.2, 162.7, 134.7, 128.7, 128.5, 127.3, 115.6, 42.3, 34.6; 
HRMS (EI) [M]+: calcd for C12H15N3OS+  249.0936 ; found 249.0936. 
 
Synthesis of 3-benzyl-6-(benzylthio)-1,3,5-triazine-2,4(1H,3H)-dione 3-15  
Compound 3-14a (0.300g, 1 mmol), DiEA ( 0.348 mL, 2 mmol) and CDI ( 0.324 g, 2 
mmol) were dissolved in DMF (10 mL) and the reaction solution was stirred at 110 oC for 3 
h. During which the reaction solution turned gradually from clear colourless to pale red. 
After 3 h, the reaction mixture was concentrated in vacuo to yield a white residue which was 
purified using column chromatography (acetone: DCM = 1:1) to yield 3-15 (0.253 g, yield = 
78%) as a white solid. 1H NMR: (Acetone-d6, 300 MHz): δ 7.47 - 7.24 (m, ArH, 10H),  4.99 
(s, ArCH2, 2H), 4.46 (s, ArCH2, 2H); 13C NMR (Acetone-d6, 75 MHz): δ 167.8, 151.4, 
151.3, 137.0, 136.3, 129.1, 128.4, 128.2, 128.1, 127.4, 127.2, 43.9, 33.9; HRMS (ESI) [M-
H]-: calcd for C17H14N3O2S- : 324.0812 ; found 324. 0807. 
 
Synthesis of 3-benzyl-6-(butylamino)-1,3,5-triazine-2,4(1H,3H)-dione 3-17a  
DMDO (0.08M, 10 mL) was added to a solution of 3-15 (0.130 g, 0.4 mmol) in acetone 
(10 mL) and the reaction was allowed to stir at room temperature for 5 min to yield 3-16. 
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After which the reaction solution was concentrated in vacuo to yield a white solid which was 
redissolved in DMF (5 mL). Butylamine (0.197 mL, 2 mmol) was added and the reaction 
mixture was stirred at 80 oC for 3 h. After which the reaction mixture was concentrated in 
vacuo and adsorbed onto silica gel and purified using column chromatography 
(acetone:hexane = 5:2) to yield 3-17a (76 mg, 70% yield) as a white solid. 1H NMR: 
(DMSO-d6, 500 MHz): δ 10.99 (br, NH, 1H), 7.30 - 7.21 (m, ArH, 5H),  7.00 (br, NH, 1H), 
4.84 (s, ArCH2, 2H), 3.37 (t, J = 6.9 Hz, NCH2CH2CH2CH3, 2H), 1.45 (m, 
NCH2CH2CH2CH3, 2H), 1.28 (m, NCH2CH2CH2CH3, 2H), 0.87 (t, J = 7.5 Hz, 
NCH2CH2CH2CH3, 2H); 13C NMR (DMSO-d6, 75 MHz): δ 155.0, 154.5, 151.1, 137.7, 
128.4, 127.4, 126.9, 43.2, 38.8, 30.7, 19.4, 13.6; HRMS (ESI) [M+H]+: calcd for 
C14H19N4O2+ : 275.1503 ; found 275.1054. 
 
3.5.3.2 Solid-Phase Synthesis 
Synthesis of Solid supported 2-benzylisothiouronium bromide 3-10 
Thiourea (0.931 g, 12.0 mmol) was added to bromomethyl resin (5.333 g, 8.0 mmol) in 
DMF (50 mL) under N2 and the reaction mixture was stirred at 80 oC for 12 h. The resin was 
then filtered and washed with DMF (3 x 20 mL), ethanol (3 x 20 mL), acetone (3 x 20 mL), 
EtOAc (3 x 20 mL), DCM (3 x 20 mL), THF (3 x 20 mL) and diethyl ether (3 x 20 mL). The 
resin was dried under vacuum for 3 h at 40 oC. FTIR:  (C=N stretch) 1647 cm-1. 
 
Synthesis of 1H-imidazole-1-carbonyl carbamimidothioate resin 3-18 
Resin 3-10 (5.681 g, 7.5 mmol), triethylamine (1.51 mL, 11.0 mmol) and N,N'-
carbonyldiimidazole (1.784 g, 11.0 mmol) were added to anhydrous THF (100 mL) under 
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N2. The reaction mixture was shaken at room temperature for 2 h. After which, the resin was 
filtered, washed thoroughly with DMF (3 x 100 mL), ethanol (3 x 100 mL), acetone (3 x 100 
mL), ethyl acetate (100 mL x 3) and THF ( 3 x 100 mL) respectively and dried for 3 h in a 
vacuum oven at 40 °C. FTIR:  (C=O stretch) 1734 cm-1,  (C=N stretch) 1681 cm-1. 
 
General procedure for the synthesis of resin 3-19 
Resin 3-18 (2.65 g, 3.50 mmol), triethylamine (0.96 mL, 7 mmol) and the corresponding 
primary amines (5.25 mmol) were added to DMF (30 mL) under N2. The reaction mixture 
was stirred at 80 oC for 30 min. After which, the resin was filtered and washed thoroughly 
with DMF (3 x 50 mL), acetone (3 x 50 mL), EtOAc (3 x 50 mL), DCM (3 x 50 mL) and 
THF (3 x 50 mL) respectively and dried for 3 h in a vacuum oven at 40 oC. FTIR:  (C=O 
stretch) 1637 cm-1,  (C=N stretch) 1596 cm-1. 
 
General procedure for the synthesis of resin 3-20 
Resin 3-19 (3.5 mmol), CDI (1.701 g, 10.5 mmol) and DiEA (1.82 mL, 10.5 mmol) were 
added to DMF (35 mL) under N2. The reaction mixture was stirred at 110 oC for 3 h. After 
which, the resin was filtered and washed thoroughly with DMF (3 x 50 mL), acetone (3 x 50 
mL), EtOAc (3 x 50 mL), DCM (3 x 50 mL) and THF (3 x 50 mL) respectively and dried for 
3 h in a vacuum oven at 40 oC. FTIR:  (C=O stretch) 1739 cm-1,  (C=N stretch) 1685 cm-1. 
 
General procedure for the synthesis of resin 3-21 
Resin 3-20 (0.5 mmol) was swollen in DCM at room temperature for 10 min before 
DMDO (0.08 M, 15.6 mL) was added. The reaction mixture was stirred at room temperature 
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for 5 min. After which, the resin was filtered and dried for 3 h in a vacuum oven at 40 oC. 
FTIR:  (C=O stretch) 1736 cm-1,  (C=N stretch) 1697 cm-1. 
 
General procedure for the synthesis of 3-17 using primary amine and resin 3-21 
Resin 3-21 (0.5 mmol) was swollen in DMF (5 mL) under N2 for 10 min. The 
corresponding amine (2.5 mmol) was added and the reaction mixture was stirred at 80 oC for 
3 h.  After which, the resin was filtered and washed thoroughly with DMF (2 x 10 mL). The 
filtrate and combined washings was concentrated in vacuo and purified using column 
chromatography to yield a white solid as 3-17. 
 
General procedure for the synthesis of 3-17 using secondary amine and resin 3-21 
Resin 3-21 (0.5 mmol) was swollen in DMF (5 mL) under N2 for 10 min. The 
corresponding amine (2.5 mmol) and DiEA (0.435 mL, 2.5 mmol) were added and the 
reaction mixture was stirred at 80 oC for 3 h.  After which, the resin was filtered and washed 
thoroughly with DMF (2 x 10 mL). The filtrate and combined washings was concentrated in 
vacuo and purified using column chromatography to yield a white solid as 3-17. 
 
General procedure for the synthesis of 3-17 using microwave assisted cleavage 
Resin 3-20 (0.5 mmol) and anhydrous THF (5 mL) were placed in a 5 mL microwave 
vessel and the resin was allowed to swell in DMF for 10 min. The corresponding primary 
amine (2.5 mmol) was added and the reaction mixture was microwave irradiated at 180 oC 
for 20 min at a pressure of 13 bars. After which, the reaction mixture was filtered and washed 
with THF (2 x 10 mL). The filtrate and combined washing was concentrated in vacuo and 
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washed with diethyl ether and acetonitrile to yield a white solid as 3-17. If the residue cannot 
be washed, the crude product was purified using column chromatography to yield 3-17 as a 
white solid. 
3-Benzyl-6-(butylamino)-1,3,5-triazine-2,4(1H,3H)-dione 3-17a. Column 
chromatography using acetone:hexane (5:2) as eluent to yield 3-17a as a white solid (overall 
yield 43% [microwave]; overall yield 25% [safety catch]). 1H NMR: (DMSO-d6, 500 MHz): 
δ 10.99 (br, NH, 1H), 7.30 - 7.21 (m, ArH, 5H),  7.00 (br, NH, 1H), 4.84 (s, ArCH2, 2H), 
3.37 (t, J = 6.9 Hz, NCH2CH2CH2CH3, 2H), 1.45 (m, NCH2CH2CH2CH3, 2H), 1.28 (m, 
NCH2CH2CH2CH3, 2H), 0.87 (t, J = 7.5 Hz NCH2CH2CH2CH3, 2H); 13C NMR (DMSO-d6, 
125 MHz): δ 155.0, 154.5, 151.1, 137.7, 128.4, 127.4, 126.9, 43.2, 38.8, 30.7, 19.4, 13.6; 
HRMS (ESI) [M+H]+: calcd for C14H19N4O2+ : 275.1503 ; found 275.1054. 
3-Benzyl-6-(methylamino)-1,3,5-triazine-2,4(1H,3H)-dione 3-17b. Column 
chromatography using acetone:EtOAc:hexane (2:3:2) as eluent to yield 3-17b as a white 
solid  (overall yield 53% [microwave]; overall yield 33% [safety catch]). 1H NMR: (DMSO-
d6, 300 MHz): δ 7.38 (m, ArH, 5H),  4.97 (s, ArCH2N, 2H), 2.87 (s, NCH3, 3H); 13C NMR 
(DMSO-d6, 75 MHz): δ 156.0, 155.3, 137.9, 128.2, 127.3, 126.8, 43.1, 27.3; HRMS (ESI) 
[M+Na]+: calcd for C11H12N4O2Na+ : 255.0852 ; found 255.0851. 
3-Benzyl-6-(phenylamino)-1,3,5-triazine-2,4(1H,3H)-dione 3-17c. Column 
chromatography using acetone:hexane (1:1) to yield 3-17c as a white solid (overall yield 
40% [microwave]; overall yield 32% [safety catch]). 1H NMR: (DMSO-d6, 300 MHz): δ 
10.95 (s, NH, 1H), 9.05 (s, NH, 1H) 7.57-7.11 (m, ArH, 10H),  4.89 (s, ArCH2N, 2H); 13C 
NMR (DMSO-d6, 75 MHz): δ 155.4 (2 carbons), 154.9, 138.1, 137.8, 128.5, 128.1, 127.4, 
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126.8, 123.4, 120.7, 43.3; HRMS (ESI) [M-H]-: calcd for C16H13N4O2- : 293.1044; found 
293.1047. 
3-Benzyl-6-(benzylamino)-1,3,5-triazine-2,4(1H,3H)-dione 3-17d. Column 
chromatography using acetone:hexane (1:1) to yield 3-17d as a white solid in 26% overall 
yield [safety catch]. 1H NMR: (DMSO-d6, 500 MHz): δ 11.14 (s, NH, 1H), 7.46 (s, NH, 1H) 
7.35-7.21 (m, ArH, 10H),  4.85 (s, ArCH2N, 2H), 4.48 (d, J = 5.7 Hz, ArCH2NH, 2H); 13C 
NMR (DMSO-d6, 75 MHz): δ 155.1, 154.7, 151.1, 138.3, 137.7, 128.4, 128.2, 127.4, 127.2, 
127.1, 127.0, 43.4, 43.3; HRMS (ESI) [M+Na]-: calcd for C17H16N4O2Na+ : 331.1178; found 
331.1165. 
3-Benzyl-6-(dipropylamino)-1,3,5-triazine-2,4(1H,3H)-dione 3-17e. Column 
chromatography using acetone:hexane (1:2) to yield 3-17e as a white solid  in 13% overall 
yield [safety catch]. 1H NMR: (Acetone-d6, 500 MHz): δ 7.36-7.21 (m, ArH, 5H),  4.95 (s, 
ArCH2N, 2H), 3.52 (t, J = 7.6 Hz, ArCH2NH, 2H), 1.66 (m, 2 x CH2CH2CH3, 4H), 0.89 (t, J 
= 7.5 Hz, 2 x CH2CH2CH3, 6H); 13C NMR (Acetone-d6, 125 MHz): δ 153.2 (3 carbons), 
137.9, 127.9, 126.8, 49.1, 43.3, 20.5, 10.1; HRMS (ESI) [M+Na]+: calcd for C16H21N4O2- : 
301.1670; found 301.1648. 
3-Benzyl-6-(furan-2-ylmethylamino)-1,3,5-triazine-2,4(1H,3H)-dione 3-17f. Column 
chromatography using MeOH:DCM (1:20) provides 3-17f as a white solid in 26% overall 
yield [safety catch]. 1H NMR: (DMSO-d6, 500 MHz): δ 11.07 (br, NH, 1H), 7.60 (s, Hfuran, 
1H),  7.31-7.21 (m, ArH, 5H), 6.40 (s, Hfuran, 1H), 6.32 (d, J = 2.5 Hz, Hfuran, 1H), 4.86 (s, 
ArCH2N, 2H), 4.48 (d, J = 5.0 Hz, FuranCH2NH, 2H); 13C NMR (DMSO-d6, 75 MHz): δ 
155.1, 154.5, 151.1, 150.8, 142.4, 137.6, 128.2, 127.4, 127.0, 110.5, 107.5, 43.3, 36.9; 
HRMS (ESI) [M-H]-: calcd for C15H13N4O3- : 297.0993; found 297.0984. 
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6-(Methylamino)-3-phenyl-1,3,5-triazine-2,4(1H,3H)-dione 3-17g. The crude product 
was washed with diethyl ether and acetonitrile to yield a 3-17g as a white solid. Overall yield 
33% (microwave cleavage). 1H NMR: (DMSO-d6, 500 MHz): δ 11.40 (br, NH, 1H), 7.45-
7.20 (m, ArH, 5H), 2.80 (d, J = 4.4 Hz, NHCH3, 3H); 13C NMR (DMSO-d6, 75 MHz): δ 
155.9, 155.8, 151.7, 136.0, 129.5, 129.4, 128.5, 28.0; HRMS (ESI) [M-H]-: calcd for 
C10H9N4O2- : 217.0731; found 217.0725. 
6-(Butylamino)-3-phenyl-1,3,5-triazine-2,4(1H,3H)-dione 3-17h. Purified using column 
chromatography with EtOAc:hexane (1:1) to acetone:hexane (1:1) as eluent to yield 3-17h as 
a white solid. Overall yield: 27% (microwave cleavage) 25% (safety catch). 1H NMR: 
(DMSO-d6, 500 MHz): δ 11.31 (br, NH, 1H), 7.64 (s, NH, 1H) 7.42-7.19 (m, ArH, 5H), 3.26 
(q, J = 6.3 Hz, NHCH2CH2CH2CH3, 3H), 1.46 (m,  NHCH2CH2CH2CH3, 2H), 1.33 (m, 
NHCH2CH2CH2CH3, 2H), 0.88 (t, J = 6.9 Hz, NHCH2CH2CH2CH3, 3H),  ; 13C NMR 
(DMSO-d6, 125 MHz): δ 155.3, 149.8 (2 carbons), 136.0, 128.9, 128.4, 127.4, 39.7, 30.7, 
19.4, 13.6; HRMS (ESI) [M-H]-: calcd for C13H15N4O2- : 259.1200; found 259.1189. 
6-(Butylamino)-3-(4-hydroxyphenyl)-1,3,5-triazine-2,4(1H,3H)-dione 3-17i. Purified 
using column chromatography with acetone:DCM (2:1) as eluent to yield 3-17i as a white 
solid. Overall yield: 42% (Microwave cleavage) 25% (safety catch). 1H NMR: (DMSO-d6, 
500 MHz): δ 7.99 (br, NH, 1H), 7.18 (s, OH, 1H) 7.03-6.74 (m, ArH, 4H), 3.25 (q, J = 4.4 
Hz, NHCH2CH2CH2CH3, 3H), 1.48 (m,NHCH2CH2CH2CH3, 2H), 1.32 (m, 
NHCH2CH2CH2CH3, 2H), 0.90 (t, J = 7.5 Hz, NHCH2CH2CH2CH3, 3H),  ; 13C NMR 
(DMSO-d6, 75 MHz): δ 157.2, 156.4, 155.3, 152.0, 130.4, 127.3, 116.1, 40.7, 31.3, 20.0, 
14.2; HRMS (ESI) [M+H]+: calcd for C13H17N4O3+ : 277.1295; found 277.1292. 
97 
 
3-(4-Hydroxyphenyl)-6-(methylamino)-1,3,5-triazine-2,4(1H,3H)-dione 3-17j. Purified 
using column chromatography with MeOH:DCM (1:6) as eluent to yield 3-17j as a white 
solid. Overall yield: 24% (safety catch). 1H NMR: (DMSO-d6, 500 MHz): δ 7.73 (br, NH, 
1H), 7.06 (s, OH, 1H) 6.97-6.76 (m, ArH, 4H), 2.78 (s, NCH3, 3H); (DMSO-d6, 125 MHz): δ 
157.3, 156.7, 156.6, 152.8, 130.4, 127.5, 116.1, 28.1; HRMS (ESI) [M-H]-: calcd for 
C10H9N4O3+ : 233.0680; found 233.0663. 
6-(Benzylamino)-3-(4-hydroxyphenyl)-1,3,5-triazine-2,4(1H,3H)-dione 3-17k. Purified 
using column chromatography with acetone:DCM (1:1) as eluent to yield 3-17k as a white 
solid. Overall yield: 25% (microwave). 1H NMR: (DMSO-d6, 300 MHz): δ 8.02 (br, NH, 
1H), 7.79-7.19 (m, ArH, 5H) 7.43-7.41 (m, ArH, 2H), 7.22-7.19 (m, ArH, 2H) 4.94 (s, 
NCH2Ar, 2H), 2.93 (s, OH, 1H); (DMSO-d6, 75 MHz): δ 156.7, 155.2, 155.1, 151.3, 138.5, 
129.7, 128.3, 127.2, 127.0, 126.9, 115.0, 43.4; HRMS (ESI) [M-H]-: calcd for C16H13N4O3- : 
309.0993; found 309.0983. 
3-(4-Hydroxyphenyl)-6-(phenylamino)-1,3,5-triazine-2,4(1H,3H)-dione 3-17l. Purified 
using column chromatography with isopropanol:DCM (1:8) as eluent to yield 3-17l as a 
white solid. Overall yield: 34% (microwave). 1H NMR: (DMSO-d6, 500 MHz): δ 9.45 (br, 2 
x NH and OH, 3H), 7.61-7.59 (m, ArH, 2H), 7.34-7.26 (m, ArH, 3H), 7.11-7.03 (m, ArH, 
2H), 6.81-6.80 (m, ArH, 2H); (DMSO-d6, 75 MHz): δ 156.7, 154.8 (2 carbons), 154.4, 137.7, 
129.7, 128.6, 127.0, 123.9, 121.3, 115.1; HRMS (ESI) [M-H]-: calcd for C15H13N4O3- : 
297.0982; found 297.0976. 
3-(Furan-2-ylmethyl)-6-(phenylamino)-1,3,5-triazine-2,4(1H,3H)-dione 3-17m. The 
crude product was concentrated in vacuo to yield a slurry which was then washed with 
diethyl ether and filtered to yield a white solid as product. Overall yield: 46% (microwave). 
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1H NMR: (DMSO-d6, 300 MHz): δ 9.14 (br, 2 x NH and OH, 3H), 7.57-7.54 (m, ArH, 3H), 
7.38-7.32 (m, ArH, 2H), 6.37 (m, HFuran, 1H), 6.28 (d, J = 2.9 Hz, HFuran, 1H); (DMSO-d6, 75 
MHz): δ 154.4, 153.2, 151.1, 150.4, 142.0, 137.1, 128.7, 124.3, 121.6, 110.5, 107.7, 36.8; 
HRMS (ESI) [M-H]-: calcd for C14H11N4O3- : 283.0837; found 283.0845. 
6-(Benzylamino)-3-(furan-2-ylmethyl)-1,3,5-triazine-2,4(1H,3H)-dione 3-17n. The 
crude product was concentrated in vacuo to yield a slurry which was washed with diethyl 
ether  and filtered to yield a white solid as product. Overall yield: 60% (microwave). 1H 
NMR: (DMSO-d6, 300 MHz)(mixture of tautomers) : δ 11.18 (br, NH, 1H), 7.52 (s, HFuran, 
1H), 7.44 (br, NH, 1H), 7.36-7.21 (m, ArH, 5H), 6.36 (m, HFuran, 1H), 6.24 (m, HFuran, 1H), 
4.83 (s, NCH2Furan, 2H), 4.47, 4.24 (d, J = 5.8 Hz, NHCH2Artautomers, 2H); (DMSO-d6, 75 
MHz)(mixture of tautomers): δ 154.6, 150.6, 141.9, 138.3, 128.3, 128.1, 127.2, 127.0,  126.9, 
126.5, 110.5, 107.6, 43.4, 42.9, 36.7; HRMS (ESI) [M-H]-: calcd for C15H13N4O3- : 297.0993; 
found 297.0990. 
6-(Benzylamino)-3-(furan-2-ylmethyl)-1,3,5-triazine-2,4(1H,3H)-dione 3-17o. The 
crude product was concentrated in vacuo to yield an off-white solid which was then washed 
with diethyl ether and acetonitrile to yield a white solid as product. Overall yield: 52% 
(microwave). 1H NMR: (DMSO-d6, 300 MHz): δ 10.98 (br, NH, 1H), 7.51 (d, J = 0.8 Hz, 
HFuran, 1H), 6.97 (br, NH, 1H), 6.35 (m, HFuran, 1H), 6.23 (d, J = 2.9 Hz, 1H), 4.83 (s, 
NCH2Ar, 2H), 3.22 (q, J = 5.8 Hz, NCH2CH2CH2CH3, 2H), 1.44 (m, NCH2CH2CH2CH3, 
2H), 1.27 (m, NCH2CH2CH2CH3, 2H), 0.87 (t, J = 7.3 Hz, NCH2CH2CH2CH3, 3H); 
(DMSO-d6, 75 MHz): δ 154.4, 150.7 (3 carbons), 141.9, 110.4, 107.6, 39.8, 36.6, 30.7, 19.3, 
13.5; HRMS (ESI) [M-H]-: calcd for C12H15N4O3- : 263.1150; found 263.1141. 
99 
 
3-(Furan-2-ylmethyl)-6-(methylamino)-1,3,5-triazine-2,4(1H,3H)-dione 3-17p. The 
crude product was concentrated in vacuo to yield an off-white solid which was then washed 
with diethyl ether and acetonitrile to yield a white solid as product. Overall yield: 58% 
(microwave). 1H NMR: (DMSO-d6, 300 MHz): δ 11.25 (br, NH, 1H), 7.52 (s, HFuran, 1H), 
6.96 (br, NH, 1H), 6.35 (m, HFuran, 1H), 6.22 (m, HFuran, 1H), 4.83 (s, NCH2Furan, 2H), 2.75 
(d, J = 3.8 Hz, NHCH3, 3H); (DMSO-d6, 125 MHz): δ 155.0 (2 carbons), 154.3, 150.7, 
141.8, 110.4, 107.4, 27.3; HRMS (ESI) [M-H]-: calcd for C9H9N4O3- : 221.0680; found 
221.0680. 
3-Allyl-6-(piperidin-1-yl)-1,3,5-triazine-2,4(1H,3H)-dione 3-17q. The crude product 
was concentrated in vacuo to yield an off-white solid which was purified with column 
chromatography using acetone:hexane (1:1) as eluent to yield a white solid as product. 
Overall yield: 26% (Safety catch). 1H NMR: (MeOD-d4, 500 MHz): δ 5.87 (m, 
NCH2CHCH2, 1Hallyl), 5.18 (dd, J = 17.6 Hz, 1.8 Hz, NCH2CHCH2, 1Htrans), 5.13 (dd, J =  
10.1 Hz, 1.2 Hz, NCH2CHCH2, 1Hcis), 4.39 (dd, J = 5.6 Hz, 1.2 Hz, NCH2CHCH2, 2H), 3.65 
(m, Hpiperidine, 4H), 1.70 (m,  Hpiperidine, 2H), 1.63 (m,  Hpiperidine, 4H); (MeOD-d4, 125 MHz): δ 
155.0(2 carbons), 155.4, 154.7 (2 carbons), 133.4, 117.4, 46.9, 44.0, 26.6, 25.0; HRMS (ESI) 
[M-H]-: calcd for C11H15N4O2- : 235.1200; found 235.1195. 
3-Allyl-6-(butylamino)-1,3,5-triazine-2,4(1H,3H)-dione 3-17r. The crude product was 
concentrated in vacuo to yield an off-white solid which was purified using column 
chromatography using DCM:MeOH (1:40) as eluent to yield a white solid as product. 
Overall yield: 28% (safety catch). 1H NMR: (MeOD-d4, 500 MHz): δ 5.87 (m, 
NCH2CHCH2, 1Hallyl), 5.18 (dd, J = 17.0 Hz, 1.2 Hz, NCH2CHCH2, 1Htrans), 5.13 (dd, J =  
10.7 Hz, 1.2 Hz, NCH2CHCH2, 1Hcis), 4.39 (d, J = 5.6 Hz, NCH2CHCH2, 2H), 3.33 (t, J = 
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6.9 Hz, NHCH2CH2CH2CH3, 2H), 1.57 (m,  NHCH2CH2CH2CH3, 2H), 1.38 (m, 
NHCH2CH2CH2CH3, 2H), 0.95 (t, J = 6.9 Hz, NHCH2CH2CH2CH3, 3H); (mixture of 
tautomers) (MeOD-d4, 75 MHz): δ 154.5(2 carbons), 150.8, 141.8, 133.1, 116.0, 42.1, 39.8, 
30.7, 19.4, 13.6; HRMS (ESI) [M-H]-: calcd for C10H15N4O2- : 223.1195; found 223.2100. 
 
General procedure for the Mitsunobu N-alkylation of 3-20 to yield resin 2-10 
Resin 3-20 (3.22 mmol) was allowed to swell in anhydrous THF (48 mL) for 10 min. 
After which PPh3 (1.52 g, 5.79 mmol) and 4-methoxybenzyl alcohol (0.679 mL, 5.47 mmol) 
were added. The reaction mixture was then place in ice bath before diisopropyl 
azodicarboxylate (0.951 mL, 4.83 mmol) was added dropwise. After complete addition of the 
diisopropyl azodicarboxylate solution, the reaction mixture was shaken at room temperature 
for 12 h. After which, the resin was filtered and washed thoroughly with DMF (3 x 50 mL), 
acetone (3 x 50 mL), EtOAc (3 x 50 mL), DCM (3 x 50 mL) and THF (3 x 50 mL) 
respectively and dried for 3 h in a vacuum oven at 40 oC. FTIR:  (C=O stretch) 1734 cm-1,  
(C=N stretch) 1681 cm-1. 
 
General procedure for the N-alkylation of 3-20 using alkyl bromide to yield resin 2-10 
Resin 3-20 (1 mmol) was allowed to swell in anhydrous DMF (10 mL) for 10 min. After 
which BnBr (0.594 g, 5 mmol) and DiEA (0.870 mL, 5mmol) were added and the reaction 
mixture was stirred at 60 oC for 5 h. The reaction mixture turned to orange red The resin was 
filtered, washed thoroughly with DMF (3 x 20 mL), acetone (3 x 20 mL), EtOAc (3 x 20 
mL), DCM (3 x 20 mL) and THF (3 x 20 mL) respectively and dried for 3 h in a vacuum 
oven at 40 oC. FTIR:  (C=O stretch) 1734 cm-1,  (C=N stretch) 1681 cm-1. 
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General procedure for the synthesis of 2-11 
The corresponding resin 2-10 (1 mmol) was allowed to swell in DCM (10 mL) for 10 min. 
After which DMDO (0.08 M, 25 mL) was added and the reaction mixture was stirred for 10 
min to allow 2-10 to fully oxidize to resin 2-11 before the resin was filtered and dried for 3 h 
in a vacuum oven at 40 oC. FTIR:  (C=O stretch) 1730 cm-1,  (C=N stretch) 1681 cm-1. 
 
Procedure for the synthesis of 2-1c12 
The corresponding resin 2-11 (0.364 mmol) was allowed to swell in anhydrous DMF (10 
mL) for 10 min. After which butylamine (0.182 ml, 1.82 mmol) was added and the reaction 
mixture was stirred at 80 oC for 3 h. Thereafter, the resin was filtered and washed thoroughly 
with DMF (2 x 10 mL). The filtrate and combined washing was concentrated in vacuo and 
purified using column chromatography using DCM:acetone:hexane (40:2:5) as eluent to 
yield 2-1c12 as a clear syrup. Overall yield: 29%. 1H NMR: (CDCl3, 300 MHz): δ 7.41 – 
6.77 (m, ArH, 9H),  5.39 (t, J = 4.6 Hz, NH, 1H), 5.01 (s, ArCH2N, 2H), 4.95 (s, ArCH2N, 
2H), 3.70 (s, ArOCH3, 3H), 3.23 (q, J = 5.5 Hz, NCH2CH2CH2CH3, 2H), 1.28 (m, 
NCH2CH2CH2CH3, 2H), 0.97 (m, NCH2CH2CH2CH3, 2H), 0.70 (t, J = 7.5 Hz 
NCH2CH2CH2CH3, 3H); 13C NMR (CDCl3, 75 MHz): δ 159.7, 154.7, 154.0, 151.6, 136.9, 
128.7, 128.3, 127.9, 127.4, 125.9, 114.7, 55.2, 45.5, 45.1, 41.6, 30.6, 19.5, 13.5; HRMS 
(ESI) [M+Na]+: calcd for C22H26N4O3Na+ : 417.1903; found 417.1907. 
 
Procedure for the synthesis of 2-1c13 
The corresponding resin 2-11 (1.198 mmol) was allowed to swell in anhydrous THF (10 mL) 
for 10 min. After which ethylenediamine (0.433 mL, 5.4 mmol) was added and the reaction 
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mixture was stirred at 50 oC for 12 h to yield a reaction mixture with white precipitate. 
Thereafter the resin was filtered and washed thoroughly with THF (2 x 10 mL). The filtrate 
and combined washing was concentrated in vacuo to yield a translucent residue which was 
redissolved in EtOAc (50 mL) and extracted with deionised water (2 x 20 mL). The organic 
phase was dried over Na2SO4 and concentrated to yield a yellow syrup which was purified 
using preparative reverse phase HLPC 0-100%, 0-35 min (H2O/Acetonitrile) to yield 2-1c13 
as a clear syrup. Overall yield: 33%. 1H NMR: (MeOD-d4, 500 MHz): δ 7.28 – 6.83 (m, 
ArH, 8H),  5.05 (s, ArCH2N, 2H), 4.96 (s, ArCH2N, 2H), 3.71 (s, ArOCH3, 3H), 3.64 (t, J = 
5.5 Hz, NHCH2CH2NH2, 2H), 3.12 (t, J = 5.6 Hz, NCH2CH2NH2, 2H), 2.56 (q, J = 7.5 Hz, 
ArCH2CH3, 2H), 1.16 (t, J = 7.5 Hz ArCH2CH3, 3H); 13C NMR (MeOD-d4, 75 MHz): δ 
160.7, 157.1, 156.6, 152.5, 144.8, 135.4, 129.3, 129.0, 128.7, 127.5, 115.1, 55.6, 46.2, 45.9, 
40.4, 40.3, 29.4, 16.1; HRMS (ESI) [M+H]+: calcd for C22H28N5O3+ : 410.2187; found 
410.2190. 
 
Procedure for the synthesis of 2-1c14 
The corresponding resin 2-11 (0.701 g, 0.760 mmol) was allowed to swell in anhydrous 
DMF (10 mL) for 10 min. After which allylamine hydrochloride salt (0.355 g, 3.8 mmol) and 
TEA (1.04 mL, 7.6 mmol) were added and the reaction mixture was stirred at 50 oC for 12 h. 
Thereafter, the resin was filtered and washed thoroughly with DMF (2 x 10 mL). The filtrate 
and combined washing was concentrated in vacuo and purified using column 
chromatography using EtOAc:acetone:hexane (1:1:2) as eluent to yield 2-1c14 as a clear 
syrup. Overall yield: 37%. 1H NMR: (CDCl3, 300 MHz): δ 7.43 – 7.18 (m, ArH, 10H),  6.37 
(br, NH, 1H), 5.64 (m, NCH2CHCH2, 1H), 5.12 (s, ArCH2N, 2H), 5.04 (s, ArCH2N, 2H), 
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4.91 (d, J = 10.3 Hz, NCH2CHCH2, 1Hcis), 4.79 (d, J = 17.1 Hz, NCH2CHCH2, 1Htrans),   
3.90 (t, J = 5.2 Hz, HNCH2CHCH2, 2H); 13C NMR (CDCl3, 75 MHz): δ 154.9, 153.8, 151.4, 
136.7, 134.1, 132.7, 129.0, 128.5, 128.2, 128.2, 127.4, 126.5, 116.3, 45.4, 45.2, 43.8; HRMS 
(ESI) [M+Na]+: calcd for C20H20N4O2Na+ : 317.1478; found 371.1485. 
 
3.6 Synthesis of 2-(methylamino)-6,7,8,9-tetrahydropyrimido [1,2-a][1,3,5]triazin-4-ones 




































































80 oC, 30 min
DiEA, DMF 
60 oC, 36 h
Phenol:TMSCl
      3  M :    1 M























Scheme 3.16. Solution phase synthetic route for 3-28. 
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Besides the generation of monocyclic 1,3,5-triazine-2,4-dione analogs, we modified the 
thiouronium approach towards the synthesis of  bicyclic triazine 2-(methylamino)-6,7,8,9-
tetrahydropyrimido [1,2-a][1,3,5]triazin-4-ones 3-28 which bears structural resemblance to 
tetrahydrobiopterins. (Scheme 3.16) 
Treating 3-13 with mono-protected 1,3-diaminopropane  3-22a125,126 gave 3-23 which 
was cyclized using 1,1'-thiocarbonyldiimidazole, TCDI, as the thiocarbonyl transfer 
reagent127 to provide 3-24.  The thiocarbonyl cyclization reaction was carried out at 60 oC for 
36 hours. Attempts to shorten the reaction time by increasing the temperature resulted in the 
decomposition of TCDI and thus reduction in yield of the desired product. Due to the poor 
solubility of 3-24 in the solvent system used for the column chromatography, the isolated 














Scheme 3.17. Preparation of 3-22a 
 
To circumvent the solubility problem, TCDI cyclizaton and S-methylation were performed in 
one-pot to obtain 3-25 in 58% overall yield. The one-pot approach gave significantly higher 
yield when compared to performing cyclization and S-methylation in two individual steps. 
Next, carbamate deprotection under neutral conditions using chlorotrimethylsilane in 
phenol128,129 released the free amine which concomitantly displaced the methyl sulfide group 
to provide the bicyclic triazine 3-26 in 70% yield. Attempts to oxidize 3-26 using DMDO 
failed to give the corresponding sulfone 3-27. This is attributed to the highly polar nature of 
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3-26 which was insoluble in the DMDO/DCM solution. Other oxidants such as m-CPBA, 
potassium monoperoxysulfate and Oxone were not viable reagents for the sufide oxidation 
reaction because the water present in the oxidation conditions readily hydrolyzed 3-27 to 

































Figure 3.7. Hydrolysis of 3-27 to 3-29 
Since the challenge of performing the solution phase synthesis of 3-27 proved to be 
insurmountable, we decided to proceed directly to the solid phase synthesis of 3-28. It is 
rationalized that since we have demonstrated the applicability of the safety catch approach on 
other triazine analogs, we should be able to apply the analogous DMDO oxidation conditions 
on solid supported 3-26 to yield solid supported sulfone 3-27 which could be isolated with 
ease.  
 
3.6.2 Solid phase synthesis of 2-(methylamino)-6,7,8,9-tetrahydropyrimido [1,2-
a][1,3,5]triazin-4-ones 3-28 
The solid phase synthesis involved treating solid supported thiouronium azolide 3-18 with 
mono-protected 1,3-diaminopropane 3-22a under basic condition to yield 3-30 (Scheme 
3.18). Cyclization of 3-30 with TCDI under basic conditions at 60 oC afforded the cyclized 
triazine intermediate 3-31 which was subsequently S-methylated with MeI to give 3-32. The 
protected amine was deprotected with a mixture of Phenol:TMSCl (3M:1 M) to generate the 
free amine 3-33. Since the macro environment in solid phase is different from solution phase, 
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the carbamate deprotection on solid phase may not lead to the concomitant intramolecular 
cyclization that was observed during solution phase studies. An additional step of base-
promoted intramolecular cyclization was included by heating 3-33 at 60 oC in a solution of 
DiEA in THF for 1 h. 
 
 





Next 3-34 was oxidized using a solution of DMDO in DCM for 20 min at -20 oC to 
furnish sulfone 3-35 and subsequent treatment of 3-35 in a solution of butylamine in DMF at 
80 oC released 3-28a in 34% overall yield.  The transformations on solid phase were 
monitored via their corresponding infra red adsorptions. 
Having validated the feasibility of using solid phase approach for the synthesis of the 
bicyclic triazine, we planned to generate a library of compounds containing various 
substituents on the exocyclic N and varying the ring size of the bicyclic system.  Using the 
established synthetic strategy, we obtained 3-28a, 3-28b and 3-28c using the safety catch 
approach with moderate overall yields of 12-26% for the 9-step solid phase synthesis. 
 
3.6.3 Microwave assisted cleavage of 3-28 
Despite having successfully applied the safety catch methodology for generation of 3 
analogs of 3-28, attempts to synthesize 3-28 with B ring size of five and seven members were 
not successful. Isolation of post oxidation filtrate yielded the respective hydrolyzed bicyclic 
dione 3-29. This led us to conclude that sulfone 3-35 was too unstable for quantitative 
isolation and the focus of the synthesis was shifted to using microwave assisted cleavage for 
the synthesis of 3-34. Next, we applied the analogous microwave cleavage conditions of 3-17 
















3-28a  n = 2, R1 = Bu, R2 = H
3-28b  n = 2, R1= Me, R2 = H
3-28m n = 0, R1 = R2 = Me




Scheme 3.19. Cleavage of 3-34 under microwave conditions 
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We subjected resin 3-34 to sealed tube microwave conditions at 150 oC and 180 oC (Table 
3.5, entry 1-3) but this gave incomplete reaction. Complete cleavage of the bicyclic substrate 
was only possible when we subjected the 3-34 to sealed tube microwave condition at 190 oC 
for 20 min. The microwave assisted cleavage gave higher yields (Table 3.5, entry 4-6) due to 
the elimination of the potential hydrolysis reactions associated with the sulfone linker.  
Entry Product Temp Reaction 
Time
Result Yield, %
1 3-28a 150 oC 20 min Incomplete reactiona n/a 
2 3-28a 180 oC 20 min Incomplete reactiona n/a 
3 3-28a 180 oC 40 min Incomplete reactiona n/a 
4 3-28a 190 oC 20 min Reaction completea 34%b, 32%c
5 3-28b 190 oC 20 min Reaction completea 12%b, 25%c
6 3-28c 190 oC 20 min Reaction completea 26%b, 29%c
7 3-28m 250 oC 20 min Reaction completea 40% 
8 3-28n 250 oC 20 min Reaction completea 43% 
a Progress of the reaction was determined via FTIR analysis of the post microwave resin. 
b Overall yield after safety catch cleavage 
c Overall yield after microwave assisted cleavage 
Table 3.5. Conditions of various attempts to obtain 3-28 from 3-33 under sealed tube 
microwave irradiation 
 
Since it is well known that DMF undergoes thermal degradation130,131 to give 
dimethylamine and carbon monoxide under high temperature, we were able to harness the in-
situ generated dimethylamine to cleave 3-34 to yield 3-28m and 3-28n (Table 3.5, entry 6-7) 
with a N,N-dimethyl substituent at the point of cleavage. 
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Having established the conditions for the microwave assisted synthesis of 3-28, we 
proceeded to incorporate the microwave cleavage strategy into our overall synthetic strategy 






















































































60 oC, 36 h
Phenol:TMSCl
      3  M :    1 M













W, 190 oC, 20 min
DMF, W, 
250 oC, 20 min
n = 1-3
n = 1-3 n = 2-3
R1 = Alkyl, piperidine, morpholine
R2 = H or piperidine, morpholine
 
Scheme 3.20. Overall solid-phase strategy for the synthesis of bicyclic triazine 3-28 and 3-29 
 
With the revised synthetic route, a small library of 16 bicyclic triazine of varying B ring 
size was generated (Figure 3.8). Two bicyclic triazinediones were also generated via 
oxidizing 3-33 into the corresponding sulfones before adding a mixture of DMF/H2O (1:5) to 



























































































































































Figure 3.9. Structures of compound 3-29 
 
The structure of triazine analog 3-28h was confirmed using x-ray diffraction 




Figure 3.10. ORTEP diagram of 3-28h 
 
3.6.4 Solution-Phase Synthesis  
General procedures for the preparation of 3-22 
Compound 3-22a was synthesized according to a procedure reported by Jensen and 
coworkers.126 BOC2O (6.85  mL, 30 mmol) dissolved in anhydrous DCM (450 mL) was 
added dropwise over 6 hours into a solution of the respective diamine (180 mmol) in 
anhydrous DCM (50 mL), The reaction mixture was stirred for 16 h at room temperature 
during which the reaction mixture turned from clear to a milky suspension. The reaction 
mixture was extracted with Na2CO3 (300 mL). The aqueous phase was extracted with DCM 
(3 x 100 mL). The combined organic extracts were dried with MgSO4, concentrated in vacuo 
and purified using column chromatography to yield 3-22 as clear syrup.  
tert-butyl 3-aminopropylcarbamate 3-22a. Purified with DCM:MeOH (20:1) as eluent. 
Yield: 85%. 1H NMR: (CDCl3, 300 MHz): δ 4.99 (s, NH, 1H), 3.17 (q, NHCH2CH2NH2, J = 
5.7 Hz, 2H), 2.72 (t, NH2CH2CH2NH, J = 6.7 Hz, 2H), 1.58 (m, CH2CH2CH2, 2H), 1.39 (s, 
3 x CH3, 9H). 13C NMR (CDCl3, 75 MHz): δ 156.1, 78.9, 39.3, 38.2, 33.1, 28.3. 
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tert-butyl 2-aminoethylcarbamate 3-22b. Purified with DCM:MeOH (10:1) as eluent. 
Yield: 82%. 1H NMR: (CDCl3, 300 MHz): δ 5.29 (s, NH, 1H), δ 3.04 (t, NHCH2CH2NH2, J 
= 5.2 Hz, 2H), 2.65 (t, NHCH2CH2NH2, J = 5.5 Hz, 2H), 1.31(s, 3 x CH3, 9H). 13C NMR 
(CDCl3, 75 MHz): δ 155.6, 77.6, 42.6, 41.0, 27.5. 
tert-butyl 4-aminobutylcarbamate 3-22c. Purified with DCM:MeOH (30:1) as eluent. 
Yield: 87%. 1H NMR: (CDCl3, 300 MHz): δ 5.16 (s, NH, 1H), 2.88 (m, 
NHCH2CH2CH2CH2NH2, 2H),  2.48 (t, NHCH2CH2CH2CH2NH2, J = 6.3 Hz, 2H,),  1.28 – 
1.21 (m, 2 x CH2, 4H),  1.26 (s, 3 x CH3, 9H). 13C NMR (CDCl3, 75 MHz): δ 155.7, 78.2, 
41.2, 39.8, 30.3, 27.9, 26.9. 
 
Synthesis of tert-butyl 3-(3-(amino(benzylthio)methylene)ureido)propylcarbamate 3-23 
Anhydrous DMF (100 mL), tert-butyl 3-aminopropylcarbamate 3-22a (3.831g, 22 mmol) 
and triethylamine (3.08 mL, 22.0 mmol) were added to 3-13 (2.861 g, 11.0 mmol) under N2 
and stirred at 80 oC for 30 min. Thereafter, the reaction mixture was dissolved in 250 mL 
brine and extracted with diethyl ether (3 x 100 mL). The combined organic extracts were 
then dried over over MgSO4 and concentrated in vacuo to yield a clear syrup which was 
purified by column chromatography with acetone:hexane (1:2) as eluent to obtain 3-23 as a 
clear syrup (3.18 g, 79% yield). 1H NMR: (CDCl3, 300 MHz): δ 7.34-7.22 (m, ArH, 5H), 
5.84 (s, NH, 1H), 5.22 (m, C=NH, 1H) 4.22 (s, ArCH2, 2H), 3.21 (m, NCH2CH2NH, 2H), 
3.13 (m, NCH2CH2NH, 4H), 1.61 (m, NCH2CH2CH2N, 2H), 1.43 (s, 3 x CH3, 9H); 13C NMR 
(CDCl3, 75 MHz): δ 167.8, 163.1, 156.0, 137.0, 128.6, 128.3, 127.1, 37.1, 36.5, 34.4, 30.1, 




Synthesis of tert-butyl 3-(4-(benzylthio)-2-oxo-6-thioxo-5,6-dihydro-1,3,5-triazin-1(2H)-
yl)propylcarbamate 3-24 
1,1'-Thiocarbonyldiimidazole (2.138 g, 12.0 mmol) and DiEA (2.09 mL, 12.0 mmol) were 
added to 3-23 (2.93 g, 8.0 mmol) in anhydrous DMF solvent under N2 and the reaction 
mixture was stirred at 60 oC for 36 hours. The resultant mixture, a yellowish red coloured 
solution, was adsorbed directly onto  a small amount of silica gel, concentrated in vacuo to 
yield a slurry and purified by flash column chromatography with DCM:EtOAc (7:1) as eluent 
to yield a yellowish solid as 3-24 (2.27 g, 70% yield). Various attempt to purify the 3-24 
failed to yield sufficiently pure product for NMR characterization. HRMS (ESI)[M-H]-: 
calcd for C18H23N4O3S2-: 407.1217; found 407.1208. Subsequent optimization reactions 
involved a one pot S-methylation of 3-24 to give 3-25 in 58% overall yield. 
 
Synthesis of tert-butyl 3-(4-(benzylthio)-6-(methylthio)-2-oxo-1,3,5-triazin-1(2H)-
yl)propylcarbamate 3-25  
Methyl iodide (1.87 mL, 30.0 mmol), DiEA (5.22 mL, 30.0 mmol) and 3-24 (2.44 g, 6 
mmol) were added to anhydrous THF (60 mL). The reaction solution turned from dark red to 
light red upon the addition of methyl iodide and was allowed to stir for 30 minutes at room 
temperature. Upon completion of the reaction, the reaction mixture appeared as a red solution 
with yellowish precipitate. The reaction mixture was concentrated to dryness and purified by 
column chromatography with acetone:hexane (1:1) as eluent to obtain 3-25 (2.00 g, 79% 
yield). 1H NMR: (CDCl3, 500 MHz): δ 7.35-7.20 (m, ArH, 5H), 5.27 (s, NH, 1H), 4.32 (s, 
ArCH2S, 2H), 4.00 (t, J = 7.0 Hz, NHCH2, 2H), 3.13 (d, J =  5.7 Hz, NHCH2, 2H,), 2.48 (s, 
SCH3, 3H,), 1.89 (m, CH2CH2CH2, 2H), 1.40 (s, 3 x CH3, 9H); 13C NMR (CDCl3, 125 
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MHz): δ 179.5, 171.3, 155.8, 152.8, 136.1, 128.7, 128.3, 127.1, 78.8, 42.8, 37.1, 35.1, 28.1, 
27.3, 14.5; HRMS (ESI)[M+Na]+: calcd for C19H26N4O3S2Na+: 445.1339; found 445.1360. 
 
Synthesis of 2-(Benzylthio)-6,7,8,9-tetrahydropyrimido[1,2-a][1,3,5]triazin-4-one  
3-26 
The deprotection procedure was adopted from reported procedure by Merrifield and 
coworkers129. TMSCl (13.73 mL, 108 mmol) and phenol (29.86 g, 317 mmol) were added to 
a solution of 3-25 (2.12 g, 5 mmol) in anhydrous DCM (97 mL) under N2 and the reaction 
mixture was stirred at room temperature for 1 hour. Thereafter, the resultant mixture, which 
appeared as a clear syrup, was adsorbed onto silica gel, concentrated in vacuo to dryness, 
loaded onto a silica column and purified by column with EtOAc:hexane (1:1) as eluent to 
elute out the TMSCl-phenol mixture before switching to 1:1 2-propanol:acetone with 1% 
TEA as eluent to obtain product 3-26 as a yellowish solid (0.959 g, 70% yield). 1H NMR: 
(DMSO-d6, 300 MHz): δ 8.74 (s, NH, 1H), 7.40–7.20 (m, ArH, 5H), 4.25 (s, ArCH2, 2H), 
3.71 (t, J =  5.6 Hz, NCH2CH2CH2NH, 2H,), 3.26 (t, J =  5.6 Hz, NCH2CH2CH2NH, 2H), 
1.92 (m, CH2CH2CH2, 2H); 13C NMR (CDCl3, 75 MHz): δ 178.1, 155.3, 153.1, 138.2, 128.8, 
128.3, 126.9, 38.6, 37.9, 33.5, 18.9; HRMS (ESI) [M+H]+: calcd for 
C13H15N4O1S1+:275.0961 ; found 275.0959. 
 
3.6.5 Solid-phase synthesis 
General procedure for the synthesis of resin 3-30 
Compound 3-22 (14.4 mmol) and triethylamine (2 mL, 14.4 mmol) were added to resin 3-
18 (7 mmol) in anhydrous DMF (70 mL) under N2. The reaction mixture was stirred at 80 oC 
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for 30 minutes. Thereafter, the resin was washed with DMF (3 x 50 mL), acetone (3 x 50 
mL), ethyl acetate (3 x 20 mL), DCM (3 x 20 mL), THF (3 x 20 mL) and diethyl ether (3 x 
20 mL).  The resin was then dried under vacuum for 3 h.  
  
General procedure for the synthesis of 3-31 
DiEA (1.73 mL, 10.5 mmol), 1,1'-thiocarbonyldiimidazole (1.86 g, 10.5 mmol) and 3-30 
(7 mmol) were added to anhydrous DMF (70 mL) under N2. The reaction mixture was stirred 
at 60 oC for 36 h. After which the resin was washed with DMF (3 x 50 mL), acetone (3 x 50 
mL), EtOAc (3 x 50 mL), DCM (3 x 50 mL), THF (3 x 50 mL) and diethyl ether (3 x 50 
mL).  The resin was then dried under vacuum for 3 h. 
 
General procedure for the synthesis of resin 3-32  
Methyl iodide (1.85 mL, 30 mmol), DiEA (5.2 mL, 30 mmol) and 3-31 (6 mmol) were 
added to THF (60 mL) and the reaction mixture was shaken at room temperature for 1 h. 
After which, the resin was washed with DMF (3 x 50 mL), acetone (3 x 50 mL), EtOAc (3 x 
50 mL), DCM (3 x 50 mL), THF (3 x 50 mL) and diethyl ether (3 x 50 mL).  The resin was 
then dried under vacuum for 3 h at 50 oC.  
 
General procedure for the synthesis of 3-33  
TMSCl (13.7 mL, 10.8 mmol) and phenol (29.8 g, 31.7 mmol) were added to resin 3-32 
(5.00 mmol) in anhydrous DCM (97.0 mL) under N2 and the reaction mixture was shaken at 
room temperature for 1 hour. After which, the resin was washed with DMF (3 x 30 mL), 
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acetone (3 x 30 mL), EtOAc (3 x 30 mL), DCM (3 x 30 mL), THF (3 x 30 mL) and diethyl 
ether (3 x 30 mL).  The resin was then dried under vacuum at 50 oC for 3 h.  
 
 General procedure for the synthesis of 3-34 
DiEA (8 mmol, 1.39 mL) was added to resin 3-33 (4 mmol) in anhydrous THF (40 mL) 
under N2. The reaction mixture was shaken at room temperature for 1 h. After which, the 
resin was filtered and washed with DMF (3 x 50 mL), acetone (3 x 50 mL), ethyl acetate (3 x 
50 mL), DCM (3 x 50 mL), THF (3 x 50 mL) and diethyl ether (3 x 50 mL).  The resin was 
then dried under vacuum at 50 oC for 3 h.  
 
General procedure for the synthesis of 2-(alkylsulfone)-bicyclic-[1,3,5]triazin-4(6H)-one 
resin 3-35 
Resin 3-34 (0.50 mmol, 1.39 mL) was added to DCM (15 mL) and the reaction mixture 
was stirred at -20 oC for 20 mins. The resin was then filtered and dried under vacuum at 50 
oC for 3 h. 
 
General procedure for the synthesis of 2-(alkylamino)-bicyclic-[1,3,5]triazin-4-one 3-28 
from resin 3-35 
Resin 3-35 (0.5 mmol) and amine (2.5 mmol) were added to anhydrous DMF (5 mL) and 
the reaction was heated under N2 at 80 oC for 3 h. Thereafter, the reaction mixture was 
filtered and washed with DMF (2 x 10 mL). The filtrate and combined washings was 





General procedure for the microwave assisted synthesis of 2-(alkylamino)-bicyclic-
[1,3,5]triazin-4-one 3-28  
Resin 3-34 (1 mmol) and amine (10 mmol) were added to DMF (5 mL) in a 5 mL 
microwave vessel. The microwave vessel was sealed and subjected to microwave irradiation 
at 190 oC for 20 minutes. (Pressure = 7–13 bar).  After which, the reaction mixture was 
filtered and washed with DMF (2 x 10 mL). The filtrate and combined washings was 
concentrated in vacuo to yield a yellowish brown residue and purified using column 
chromatography. 
2-(Butylamino)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a][1,3,5]triazin-4-one 3-28a. 
Pressure used in the microwave reaction = 10 bar. Crude compound was purified using 
MeOH : DCM (1:10) as eluent. The purified product is a white solid. Overall yield: 35%. 1H 
NMR: (MeOD-d4, 500 MHz): δ 3.82 (t, J = 5.0 Hz, NCH2, 2H), 3.38–3.31 (m, NCH2, 2H), 
3.28 (m, NHCH2, 2H), 2.03 (m, NCH2CH2CH2NH, 2H), 1.54–1.48 (m, CH2CH2CH2CH3, 
2H), 0.93 (t, J = 7.6 Hz NCH2CH2CH2CH3, 3H); 13C NMR (MeOD-d4, 125 MHz)(mixture 
of tautomers): δ 165.4, 165.2, 159.1, 158.3, 157.2, 157.2, 41.5, 41.3, 41.2, 41.1, 39.7, 32.8, 
32.7, 21.3, 21.1, 21.0, 14.1; HRMS (EI)[M]+: Calcd for C10H17N5O+ 223.1433; found 
223.1429. 
2-(Methylamino)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a][1,3,5]triazin-4-one 3-28b. 
Pressure used in the microwave reaction = 13 bar. Crude compound was purified using 
MeOH:DCM (1:15) as eluent. The purified product is a white solid. Overall yield: 25%. 1H 
NMR: (DMSO-d6, 500 MHz)(mixture of tautomers): δ 8.07, 7.75 (s, NH, 1H), 6.83, 6.70 (s, 
NH, 1H), 3.65 (t, J = 5.7 Hz, NCH2CH2CH2NH, 2H), 3.20 (t, J =  3.2 Hz, 
118 
 
NCH2CH2CH2NH, 2H), 2.68 (s, NHCH3, 3H), 1.87 (m, NCH2CH2CH2NH, 2H); 13C NMR 
(DMSO-d6, 125 MHz)(mixture of tautomers): δ 164.6, 164.2, 156.7, 155.4, 155.4, 154.8, 
39.1, 39.0, 38.1, 38.0, 27.3, 27.1, 20.0, 19.3; HRMS (EI)[M]+: Calcd for C7H11N5O+ 
181.0964; found 181.0957. 
2-(Piperidin-1-yl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a][1,3,5]triazin-4-one 3-28c: 
Pressure used in the microwave reaction = 9 bar. Crude compound was purified using 
MeOH:DCM (1:20) as eluent. The purified product is a pale yellow solid. Overall yield: 
29%. 1H NMR: (MeOD-d4, 500 MHz): δ 3.81 (t, J = 6.4 Hz, NCH2CH2CH2NH, 2H,), 3.70 
(m, Hpiperidine, 4H), 3.36 (m, NCH2CH2CH2NH, 2H, J = 5.7 Hz), 2.02 (m, Hpiperidine, 2H) 1.65 
(m, NCH2CH2CH2NH, 2H) 1.52 (m, Hpiperidine, 4H). 13C NMR (MeOD-d4, 125 MHz): δ 
163.6, 159.3, 157.3, 45.6, 41.1, 39.7, 26.9, 25.7, 21.3; HRMS (ESI)[M+H]+: Calcd for 
C11H18N5O+ 236.1506; found 236.1508. 
2-Morpholino-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a][1,3,5]triazin-4-one 3-28d: 
Pressure used in the microwave reaction = 10 bar. Crude compound was purified using EtOH 
: DCM (1:20) as eluent. The purified product is a white solid. Overall yield: 27%. 1H NMR: 
(CDCl3, 500 MHz): δ 3.82 (m, NCH2CH2CH2NH, 2H), 3.71 (m, Hmorpholine, 3H), 3.63 (m, 
Hmorpholine, 3H),   3.36 (m, NCH2CH2CH2NH, 2H), 3.06 (s, Hmorpholine, 2H), 1.02 (m, 
NCH2CH2CH2NH, 2H). 13C NMR (MeOD-d4, 125 MHz)(mixture of tautomers): δ 164.8, 
164.2, 159.1, 158.8, , 157.5, 157.1, 67.7, 45.1, 41.2, 41.1, 39.6, 21.2; HRMS (EI)[M]+: Calcd 
for C10H15N4O2+ 237.1226; found 237.1221. 
2-(Butylamino)-7,8-dihydroimidazo[1,2-a][1,3,5]triazin-4(6H)-one 3-28e: Pressure 
used in the microwave reaction = 11 bar. Crude compound was purified using MeOH:DCM 
(1:20) as eluent. The purified product is a white solid. Overall yield: 39%. 1H NMR: 
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(DMSO-d6, 500 MHz)(mixture of tautomers): δ 8.35, 8.26, 8.04 (s, NH, 1H), 7.31, 7.15 (m, 
NH, 1H), 3.84 (m, NCH2CH2NH, 2H), 3.52 (m, NCH2CH2NH, 2H), 3.14 (m, 
NHCH2CH2CH2CH3, 2H), 1.41 (m, NHCH2CH2CH2CH3, 2H), 1.29-1.22 (m, 
NHCH2CH2CH2CH3, 2H), 0.85 (m, NHCH2CH2CH2CH3, 3H). 13C NMR (DMSO-d6, 125 
MHz)(mixture of tautomers): δ 166.6, 166.0, 165.8, 161.6, 161.1, 160.9, 155.0, 154.5, 154.5,  
42.1, 42.0, 40.1, 39.0, 38.9, 38.8, 31.4, 31.0, 19.5, 19.4, 13.7; HRMS (EI)+: Calcd for 
C9H15N5O+ 209.1277; found 209.1267. 
2-(Methylamino)-7,8-dihydroimidazo[1,2-a][1,3,5]triazin-4(6H)-one 3-28f: Pressure 
used in the microwave reaction = 10 bar. Crude compound was purified using MeOH:DCM 
(1:20) as eluent. The purified product is a pale brown solid. Overall yield: 23%. 1H NMR: 
(DMSO-d6, 500 MHz)(mixture of tautomers): δ 8.36, 8.04 (m, NH, 1H), 7.18, 7.05 (m, NH, 
1H), 3.84 (m, NCH2CH2NH, 2H), 3.53 (m, NCH2CH2NH, 2H), 2.70 (s, NCH3, 3H); 13C 
NMR (DMSO-d6, 125 MHz)(mixture of tautomers): δ 167.2, 166.5, 161.8, 160.8, 154.5, 
42.1, 41.9, 39.0, 38.8, 27.5, 27.5; HRMS (FAB) [M+]: Calcd for C6H9N5O+ 167.0807; found 
167.0806 
2-(Piperidin-1-yl)-7,8-dihydroimidazo[1,2-a][1,3,5]triazin-4(6H)-one 3-28g: Pressure 
used in the microwave reaction = 11 bar. Crude compound was purified using MeOH:DCM 
(1:20) as eluent. The purified product is a pale yellow solid. Overall yield: 21%. 1H NMR: 
(DMSO-d6, 500 MHz): δ 8.21 (s, NH, 1H), 3.85 (t, J = 8.8 Hz, NCH2CH2NH, 2H) 3.64 (t, J 
= 5.6 Hz, Hpiperidine, 4H), 3.53 (m, J = 9.4 Hz, NCH2CH2NH , 2H), 1.59 (t, J =  5.7 Hz, 
Hpiperidine, 2H), 1.45 (m, Hpiperidine, 4H); 13C NMR (DMSO-d6, 75 MHz): δ 164.5, 161.3, 154.6, 




2-Morpholino-7,8-dihydroimidazo[1,2-a][1,3,5]triazin-4(6H)-one 3-28h: Pressure used 
in the microwave reaction = 7 bar. Crude compound was purified using MeOH : DCM (1:20) 
as eluent. The purified product is a white solid. Overall yield: 20%. 1H NMR: (MeOD-d4, 
500 MHz): δ 4.03 (t, J = 8.8 Hz, NHCH2CH2NH, 2H), 3.77 (m, Hmorpholine, 4H), 3.70 (t, J = 
8.8 Hz, NHCH2CH2NH, 2H,), 3.65 (m, Hmorpholine, 4H,); 13C NMR (MeOD-d4, 125 MHz): δ 
166.9, 162.9, 158.6, 67.6, 45.6, 43.6, 40.6; HRMS (EI)[M+]:Cald for C19H13N5O2+ 223.1069; 
found 223.1065. 
2-(Methylamino)-7,8,9,10-tetrahydro-[1,3,5]triazino[1,2-a][1,3]diazepin-4(6H)-one 3-
28i: Pressure used in the microwave reaction = 13 bar. Crude compound was purified using 
MeOH:DCM (1:50) as eluent. The purified product is a colourless liquid. Overall yield: 21%. 
1H NMR: (DMSO-d6, 500 MHz): δ 7.51, 7.16 (s, NH, 1H), 7.69, 6.81 (s, NH, 1H) 3.96 (m, 
NCH2, 2H), 3.28 (m, NCH2CH2CH2CH2NH, 2H), 2.66 (m, NHCH3, 3H),1.79 (m, 
NCH2CH2CH2CH2NH, 4H); 13C NMR (mixture of tautomers) (DMSO-d6, 75 MHz): δ 164.6, 
164.3, 161.9, 161.4, 156.6, 156.0, 41.8, 41.8, 41.7, 41.5, 27.3, 27.2, 25.4, 25.2, 24.6, 24.4; 
HRMS (EI) [M]+: Calcd for C8H13N5O1+ 195.1120; found 195.1119. 
2-Morpholino-7,8,9,10-tetrahydro-[1,3,5]triazino[1,2-a][1,3]diazepin-4(6H)-one 3-
28j: Pressure used in the microwave reaction = 8 bar. Crude compound was purified using 
EtOH:DCM (1:40) as eluent. The purified product is a brown solid. Overall yield: 20%. 1H 
NMR: (MeOD-d4, 500 MHz): δ 4.14-4.10 (m, NCH2CH2CH2CH2NH, 2H), 3.73–3.72 (m, 
Hmorpholine, 3H), δ 3.65–3.63 (m, Hmorpholine, 3H), 3.41-3.38 (m, NCH2CH2CH2CH2NH, 2H), 
3.07 (m, Hmorpholine, 3H), 1.92 (m, NCH2CH2CH2CH2NH, 4H); 13C NMR (MeOD-d4, 125 
MHz): δ 164.9, 164.2, 163.4, 163.1, 160.3, 160.1, 67.7, 45.1, 44.0, 43.6, 43.5, 26.6, 26.6, 




28k: Pressure used in the microwave reaction = 11 bar. Crude compound was purified using 
acetone:DCM (1:3) as eluent. The purified product is a yellow paste. Overall yield: 29%. 1H 
NMR: (CDCl3, 300 MHz): δ 5.40 (s, NH, 1H), δ 4.05 (m, NCH2CH2CH2CH2NH, 2H) 3.63 
(m, Hpiperidine, 4H), 3.29 (m, NCH2CH2CH2CH2NH, 2H), 1.81 (s, NCH2CH2CH2CH2NH, 
4H), 1.54-1.53 (m, Hpiperidine, 4H),  1.45 (m, Hpiperidine, 2H); 13C NMR (CDCl3, 75 MHz): δ 
162.2, 162.0, 157.5, 44.3, 43.6, 42.9, 25.9, 25.7, 24.9, 24.4; HRMS (ESI)[M+H]+: Calcd for 
C12H20N5O+ 250.1662; found 250.1650. 
 
General procedure for the synthesis of 2-(dimethylamino)-bicyclic-[1,3,5]triazin-4-one 
(3-28l to 3-28n) 
Anhydrous DMF (5 mL) was added to resin 3-34 (1 mmol) in a 5 mL microwave vessel. 
The microwave vessel was sealed and microwave irradiated at 250 oC for 20 min (Pressure = 
14-16 bar).  After which, the reaction mixture was filtered and washed with DMF (2 x 10 
mL). The combined filtrate and washings were concentrated in vacuo to yield a yellow solid 
which was purified by column chromatography. 
2-(Dimethylamino)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a][1,3,5]triazin-4-one 3-28l: 
Pressure used in the microwave reaction = 16 bar. Crude compound was purified using 
EtOH:DCM (1:30) as eluent. The purified product is a white solid. Overall yield: 43%. 1H 
NMR: (MeOD-d4, 300 MHz): δ 3.82 (t, J = 5.9 Hz, NCH2CH2CH2NH, 2H,), 3.36 (t, J =  5.5 
Hz, NCH2CH2CH2NH, 2H,), 3.06 (s, 2 x NCH3, 6H), 2.02 (m, NCH2CH2CH2NH, 2H); 13C 
NMR (MeOD-d4, 75 MHz): δ 164.9, 158.9, 157.1, 41.1, 39.6, 36.8, 21.3; HRMS (EI)[M]+: 




Pressure used in the microwave reaction = 14 bar. Crude compound was purified using 
EtOH:DCM (1:20) as eluent. The purified product is a white solid. Overall yield: 40%. 1H 
NMR: (DMSO-d6, 500 MHz): δ 8.25 (s, NH, 1H), 3.85 (t, J = 8.2 Hz, NCH2CH2NH, 2H), 
3.54 (t, J = 8.8 Hz, NCH2CH2NH, 2H), 3.01 (s, NCH3, 3H), 3.00 (s, NCH3, 3H); 13C NMR 
(DMSO-d6, 125 MHz): δ 165.8, 161.1, 154.5, 42.0, 38.9, 36.5, 36.3; HRMS (EI)[M]+: calcd 
for C7H11N5O1+: 181.0964; found 181.0967. 
2-(Dimethylamino)-7,8,9,10-tetrahydro-[1,3,5]triazino[1,2-a][1,3]diazepin-4(6H)-one 
3-28n: Pressure used in the microwave reaction = 16 bar. Crude compound was purified 
using EtOH:DCM (1:30) as eluent. The purified product is a yellowish paste. Overall yield: 
39%. 1H NMR: (CDCl3, 500 MHz): δ 5.33 (s, NH, 1H), 4.09 (t, J = 5.6 Hz, 
NCH2CH2CH2CH2NH, 2H), 3.33 (q, J = 5.0 Hz, NCH2CH2CH2CH2NH, 2H), 3.07 (s, NCH3, 
3H), 3.01 (s, NCH3, 3H), 1.86–1.84 (m, NCH2CH2CH2CH2NH, 4H); 13C NMR (CDCl3, 125 
MHz): δ 163.3, 162.0, 157.3, 43.6, 42.9, 36.5, 36.3, 25.8, 24.9; HRMS (ESI)[M+Na]+: Calcd 
for C9H15N5NaO+: 232.1169; found 232.1160. 
 
General procedure for the synthesis of bicyclic-[1,3,5]triazine-2,4-dione 3-29 
Resin 3-34 (1 mmol) was swollen in DCM (25 mL) at -20 oC for 10 min. After which 
DMDO (0.08 M, 25 mL) was added and the reaction mixture was stirred for another 15 min. 
Thereafter, a mixture of DMF:Water (1:5, 20 mL) was added and the reaction mixture was 
stirred for 2 h to generate a pale brown solid which was filtered and washed with MeOH to 
yield a white solid. 
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6,7,8,9-Tetrahydro-2H-pyrimido[1,2-a][1,3,5]triazine-2,4(3H)-dione 3-29a: Overall 
yield: 25%. 1H NMR: (DMSO-d6, 500 MHz): δ 3.71 (t, J = 5.7 Hz, NCH2CH2CH2NH, 2H,), 
3.34 (t, J =  5.6 Hz, NCH2CH2CH2NH, 2H), 1.94 (m, NCH2CH2CH2NH, 2H); 13C NMR 
(DMSO-d6, 125 MHz): δ 152.1, 149.7, 148.7, 39.6, 38.8, 18.4; HRMS (EI)[M]+: calcd for 
C6H8N4O2+  168.0647; found 168.0647. 
7,8,9,10-Tetrahydro-[1,3,5]triazino[1,2-a][1,3]diazepine-2,4(3H,6H)-dione 3-29b: 
Overall yield: 25%. 1H NMR: (DMSO-d6, 500 MHz): δ 10.64 (s, NH, 1H), 7.98 (s, NH, 1H), 
3.95 (m, NCH2CH2CH2CH2NH, 2H), 3.32 (m, NCH2CH2CH2CH2NH, 2H,), 1.79 (m, 
NCH2CH2CH2CH2NH, 4H); 13C NMR (DMSO-d6, 75 MHz): δ 160.5, 154.6, 151.7, 41.8, 
41.6, 24.7, 24.1; HRMS (EI): calcd for C7H10N4O2+:182.0804; found 182.0807. 
 
3.7 Acid catalysed cyclization to yield 1,3,5-triazine analogs 3-38, 3-39, 3-44, 3-45, 3-47. 
In addition to the subjecting 3-14 to base promoted cyclization with TCDI and CDI, we 
could also subject 3-14 to acid catalysed ketal formation conditions with orthoacetates and 
orthoformates to yield either monocyclic or bicyclic 1,3,5-triazine with non-heteroatom 


















R1 = Substituted Benzyl
R2 = Dimethyl, Cyclohexyl
X = n-BuNH, BnNH, =O  




These triazine substrates with various substituted benzyl groups at R1 and X being oxygen 
or amino groups are structurally similar to antibacterial DHFR reagents (Figure 3.12) and 
and therefore may be potential candidates for new antibacterial DHFR drugs to counter the 

















Piritrexim (PTX)  
Figure 3.12. Examples of antibacterial DHFR inhibitors. 
 


































3-14 was cyclized under acid catalysed conditions132 with 2,2-dimethoxypropane to give 
the desired triazine 3-35 in 97% yield. In addition to cyclization with ketals, acid catalysed 
cyclization with trimethylorthoformate under similar conditions gave 3-36 in moderate yield 
of 71%. The structure of triazine analog 3-35 was confirmed using x-ray diffraction 
crystallography. (Figure 3.13) 
 
 
Figure 3.13. ORTEP diagram of 3-35. 
 
Next we proceeded to apply the safety catch methodology on 3-35 to mimic the release of 







































Triazine-dione 3-38a was readily obtained via DMDO oxidation of 3-35 at room 
temperature for 15 min. The formation of 3-38a occured via rapid hydrolysis of the sulfone 
3-37 (Scheme 3.22). Due to the labile nature of sulfone 3-37, the compound can only be 
characterised by nominal ESI mass spectrometry. Attempts to isolate 3-37 for the subsequent 
treatment with n-butylamine failed to afford 3-39a. Since the competing hydrolysis reaction 
was occurring too rapidly for quantitative isolation of 3-37 on solution phase, we decided to 
proceed directly onto solid phase where the isolation of solid supported 3-37 can be achieved 
via simple filtration. The structure of triazine analog 3-38a was confirmed using x-ray 
diffraction crystallography. (Figure 3.14) 
 
  
Figure 3.14. ORTEP diagram of 3-38a. 
 
3.7.2 Solid phase library synthesis of 3-38, 3-39, 3-44, 4-45 and 3-47 
The solid phase synthesis of the triazine library was synthesized using analogous 











































C=N (1647 cm-1)  
Scheme 3.23. Solid phase synthesis of triazines 3-40, 3-41 and 3-42. 
 
 
3-19 was cyclized using the corresponding ketals under acid catalysed conditions to afford 
triazines 3-40, 3-41 and 3-42 on solid support. Successful cyclization was monitored through 
the C=O stretching bands at 1673 cm-1, 1707 cm-1 and 1675 cm-1 as well as the C=N 
stretching bands at 1645 cm-1, 1598 cm-1 and 1601 cm-1 for 3-40, 3-41 and 4-42 respectively. 
The blue shift in C=O stretching bands is a likely consequence of the rigidity imposed by the 
cyclic structure, thereby restricting the proper orientation of the nitrogen lone pair with the 
C=O π* orbital. This would result in an increase of the C=O bond order and thus higher 
stretching band. The C=O stretching band is the highest at 1707 cm-1 which can be explained 
by the orthogonal orientation of the lone pair on the sp2 nitrogen. The general increase in 
C=N stretching band can be explained by the breaking of conjugation of the imine bond with 
the carbonyl bond on the triazines. 
The assembled triazines 3-40, 3-41 and 3-42 on solid support were oxidized and cleaved 
to afford the desired triazine products as shown in Scheme 3.24. DMDO oxidation of resin 3-
40 at room temperature for 30 min afforded triazine-dione 3-38 with yields ranging from 78–
80%. Oxidation of triazine-ketal 3-40 at -20 oC yielded sulfone 3-43 which was isolated via a 
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quick filtration and cleaved under basic conditions with primary amines to yield 3-39 in 30-
39% yields. IR analysis of the post cleavage resin showed the presence of residual triazine 3-
40 on solid support which indicated the incomplete oxidation of sulfide 3-40. Various 
oxidation conditions were explored (Table 3.6). During these experiments, the occurrence of 
the hydrolysis reaction was deduced from examination of the post oxidation filtrate for 
presence of 3-38. Oxidation of resin 3-40 at -20 oC for 5 min (Table 3.6, entry 4) gave the 









Table 3.6. Presence of hydrolysed product 3-38 vs reaction conditions. 
 
Although the hydrolysis reaction was due to the presence of water in the DMDO solutions, 
attempts to decrease the moisture content of the DMDO133 or changing the oxidant to dried 
mCPBA134 failed to offer better result and thus the original 5 min DMDO oxidation at -20 oC  
was retained. The chemistry of 3-42 was found to be largely similar to that of 3-40. 
Oxidation and hydrolysis of 3-42 afforded triazine dione 3-45 with yields ranging from 70–
80% (Figure 3.18). 
Entry Oxidation Conditions Presence of 3-38 in Filtrate 
1 Room temperature, 5 min Yes
2 0 °C, 5 min Yes
3 -20 °C, 10 min Yes




Scheme 3.24. Cleavage of 3-40, 3-41 and 3-42 
 
The synthesis of triazine 3-47 from 3-42 required 10 min of oxidation instead of 5 min, 
suggesting a steric effect conferred by the bulkier cyclohexyl ring on the rate of oxidation. 3-
47 was obtained in yields ranging from 16–27% (Figure 3.19t). 
When the analogous DMDO oxidation conditions was applied on resin 3-41 to yield 3-44, 
we found that the corresponding sulfone was too unstable to be isolated and as a result a one-
pot oxidation and cleavage in one-pot strategy was used to obtain 3-44 in 21-35% yields. 
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Although 3-44 could be obtained using one-pot oxidation and cleavage reactions, but post 
cleavage FTIR analysis of the resin showed the presence of residual 3-41. Next we subjected 
resin 3-41 to microwave assisted cleavage conditions (Scheme 3.24) and obtained 3-44a in 
56% yield (Scheme 3.25). FTIR analysis of the post cleavage resin also showed that the 



























 Scheme 3.25. Proposed mechanism of microwave assisted cleavage of 3-41. 
 
 
However, attempts to use the analogous cleavage conditions on 3-40 and 3-42 were 
unsuccessful.  Post microwave analysis of resin indicated that 3-40 and 3-42 showed triazine 
substrate remaining intact on the solid support. Comparison between the structures of 3-41, 
3-40 and 3-42 showed that the absence of the acidic NH was essential for the successful 
release of triazine under microwave conditions. It was rationalized that the acidic NH proton 
adjacent to the carbonyl group on both 3-40 and 3-42 were removed in the presence of DiEA. 
The resulting lone pair delocalized into the π* of the adjacent sulfide imine bond and in the 




































































































































































Figure 3.17. Yields of 3-44. (a Synthesized via one-pot synthesis; b Synthesized via 
















































































































Figure 3.19. Yields of 3-47. 
 
3.7.3 Experimental Section 
3.7.3.1 Solution Phase Synthesis 
Synthesis of 3-benzyl-6-(benzylthio)-4,4-dimethyl-3,4-dihydro-1,3,5-triazin-2(1H)-one 3-
35 
Compound 3-14 (2.39 g, 8 mmol), 2,2-dimethoxypropane (9.84 mL, 80 mmol) and p-
toluenesulfonic acid monohydrate (0.304 g, 1.6 mmol) were dissolved in DMF (50 mL) and 
stirred at 80 oC for 4 h. Purification by column chromatography using acetone:hexane (1:3) 
as eluent afforded 3-35 as a white solid (2.64 g, 97% yield).  1H NMR: (CDCl3, 300 MHz): δ 
9.51 (s, NH, 1H), 7.24–7.09 (m, ArH, 10H), 4.53 (s, ArCH2, 2H), 4.07 (s, ArCH2, 2H), 1.28 
133 
 
(s, CH3, 6H);  13C NMR (CDCl3, 75 MHz): δ 153.3, 149.8, 138.9, 137.2, 129.0, 128.2, 128.2, 
127.3, 127.1, 126.8, 76.2, 45.3, 34.3, 28.0; HRMS (ESI) [M+Na]+: calcd for 
C19H21N3NaOS+:  362.1298; found 362.1300.  
 
Synthesis of 3-benzyl-6-(benzylsulfonyl)-4,4-dimethyl-3,4-dihydro-1,3,5-triazin-2(1H)-
one 3-36  
Compound 3-35 (0.339 g, 1 mmol) was dissolved in DCM (5 mL). Dimethyldioxirane (25 
mL, 0.08 M) was added and the reaction mixture was stirred at -20 °C for 5 min. After which 
the solvent was removed in vacuo. ESI nominal mass : 372.1. No spectroscopic data is 
available for 3-36 due to its susceptibility towards hydrolysis. 
 
Synthesis of 1-benzyl-6,6-dimethyl-1,3,5-triazinane-2,4-dione 3-38 
Compound 3-35 (0.3391 g, 1 mmol) was stirred in DCM (5 mL) before the addition of 
dimethyldioxirane (25 mL, 0.08 M). The reaction mixture was stirred at room temperature 
for 15 min. Removal of the solvent using a rotary evaporator afforded 3-38 as a white solid 
in quantitative yield (0.231 g, 0.99 mmol). 1H NMR: (DMSO-d6, 500 MHz): δ 9.67 (s, NH, 
1H), 7.85 (s, NH, 1H) 7.34 – 7.22 (m, ArH, 5H, J = 6.6 Hz), 4.55 (s, ArCH2, 2H), 1.32 (s, 
CH3, 6H); 13C NMR (DMSO-d6, 125 MHz): δ 152.4, 152.0, 139.5, 128.3, 126.6, 126.6, 69.2, 
44.0, 26.6; HRMS (ESI) [M-H]-: calcd for C12H14N3O2-: 232.1092; found 232.1085. 
 
Synthesis of 1-benzyl-4-(benzylthio)-1,3,5-triazin-2(1H)-one 3-39 
Compound 3-14 (2.392 g, 8 mmol), trimethyl orthoformate (8.75 mL, 80 mmol) and p-
toluenesulfonic acid monohydrate (0.3044 g, 1.6 mmol) were dissolved in DMF (50 mL) and 
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stirred at 110 oC for 4 h. Purification by column chromatography using acetone:hexane (1:2) 
as eluent afforded 3-39 as a white solid (1.75 g, 71% yield).  1H NMR: (CDCl3, 300 MHz): δ 
8.01 (s, =CH, 1H), 7.36 – 7.27 (m, ArH, 10H), 4.97 (s, ArCH2, 2H), 4.35 (s, ArCH2, 2H);  
13C NMR (CDCl3, 75 MHz): δ 182.9, 156.4, 151.8, 135.8, 133.8, 129.1, 129.0, 128.7, 128.5, 
128.3, 127.43, 50.9, 35.5; HRMS (ESI) [M+Na]+: calcd for C17H15N3NaOS+:  332.0828; 
found 332.0839.  
 
3.7.3.2 Solid phase synthesis 
General Procedure for the synthesis of resin 3-40 
Resin 3-19 (3.5 mmol), 2,2-dimethoxypropane (4.30 mL, 35.0 mmol) and p-
toluenesulfonic acid monohydrate (0.133 g, 0.7 mmol) were added to anhydrous DMF (15 
mL) under N2. The reaction mixture was stirred at 80 0C for 4 h. The resin was washed with 
DMF (3 x 20 mL), acetone (3 x 20 mL), EtOAc (3 x 20 mL), DCM (3 x 20 mL), THF (3 x 20 
mL) and diethyl ether (3 x 20 mL).  The resin was dried under vacuum overnight.  
 
General procedure for the synthesis of resin 3-41  
Resin 3-19 (3.5 mmol), trimethyl orthoformate (4.20 mL, 35.0 mmol) and p-
toluenesulfonic acid monohydrate (0.133 g, 0.7 mmol) were added to anhydrous DMF (15 
mL) under N2. The reaction mixture was stirred at 110 oC for 4 h. The resin was washed with 
DMF (3 x 20 mL), acetone (3 x 20 mL), EtOAc (3 x 20 mL), DCM (3 x 20 mL), THF (3 x 20 
mL) and diethyl ether (3 x 20 mL).  The resin was dried under vacuum overnight.  
 
General procedure for the synthesis resin 3-42  
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Resin 3-19 (3.5 mmol), 1,1-dimethoxycyclohexane (5.30 mL, 35.0 mmol) and p-
toluenesulfonic acid monohydrate (0.133 g, 0.7 mmol) were added to anhydrous DMF (15 
mL) under N2. The reaction mixture was stirred at 80 oC for 4 h. The resin was washed with 
DMF (3 x 20 mL), acetone (3 x 20 mL), EtOAc (3 x 20 mL), DCM (3 x 20 mL), THF (3 x 20 
mL) and diethyl ether (3 x 20 mL).  The resin was dried under vacuum overnight.  
 
General procedure for the synthesis of 3-38 
Resin 3-40 (0.5 mmol) was swollen in DCM (8 mL) for 30 min.  Dimethyldioxirane (15.7 
mL, 0.08 M) was added and the reaction mixture was stirred at room temperature for 3 h. 
Filtration of the mixture followed by solvent removal in vacuo afforded 3-38 directly. 
1-Benzyl-6,6-dimethyl-1,3,5-triazinane-2,4-dione 3-38a. Overall yield: 78%. 1H NMR: 
(DMSO-d6, 500 MHz): δ 9.67 (s, NH, 1H), 7.85 (s, NH, 1H), 7.33–7.22 (m, ArH, 5H), 4.55 
(s, ArCH2, 2H), 1.32 (s, CH3, 6H); 13C NMR (DMSO-d6, 125 MHz): δ 152.9, 152.0, 139.5, 
128.3, 126.6, 126.6, 69.2, 44.0, 26.6; HRMS (ESI) [M-H]-: calcd for C12H14N3O2- 232.1092; 
found 232.1085. 
1-(4-Methoxybenzyl)-6,6-dimethyl-1,3,5-triazinane-2,4-dione 3-38b. Overall yield: 
77%. 1H NMR: (MeOD-d4, 500 MHz): δ 7.23 (d, J = 8.8 Hz, ArH, 2H), 6.86 (d, J = 8.8 Hz, 
ArH, 2H), 4.59 (s, ArCH2, 2H), 3.77 (s, OCH3, 3H), 1.41 (s, CH3, 6H); 13C NMR (MeOD-
d4, 125 MHz): δ 160.4, 155.1, 154.6, 132.1, 129.4, 114.9, 71.1, 55.7, 45.4, 27.2; HRMS (EI) 
[M]+: calcd for C13H17N3O3 263.1270; found 263.1267. 
1-(4-Chlorobenzyl)-6,6-dimethyl-1,3,5-triazinane-2,4-dione 3-38c. Overall yield: 80%. 
1H NMR: (DMSO-d6, 300 MHz): δ 9.68 (s, NH, 1H), 7.86 (s, NH, 1H) 7.40–7.36 (m, ArH, 
2H), 7.29 (d, J = 8.5 Hz, ArCH2, 2H), 4.53 (s, ArCH2, 2H) 1.31 (s, CH3, 6H); 13C NMR 
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(DMSO-d6, 75 MHz): δ 153.2, 152.2, 139.0, 131.6, 128.9, 128.6, 69.6, 43.8, 27.0; HRMS 
(EI) [M]+: calcd for C12H14ClN3O2 267.0775; found 267.0768. 
6,6-Dimethyl-1-(3,4,5-trimethoxybenzyl)-1,3,5-triazinane-2,4-dione 3-38d. Overall 
yield: 84%. 1H NMR: (DMSO-d6, 500 MHz): δ 9.62 (s, NH, 1H), 7.82 (s, NH, 1H) 6.59 (s, 
ArH, 2H), 4.48 (s, ArCH2, 2H), 3.73 (s, OCH3, 6H), 3.63 (s, OCH3, 3H), 1.34 (s, CH3, 6H); 
13C NMR (DMSO-d6, 125 MHz): δ 152.9, 152.7, 151.9, 136.30, 135.2, 104.1, 69.1, 59.9, 
55.7, 44.21, 26.6; HRMS (EI) [M]+: calcd for C15H21N3O5+ 323.1481; found 323.1477. 
 
General procedure for the synthesis of 3-39 
Resin 3-40 (0.7 mmol) was swollen in DCM (8 mL) at -20 °C for 20 min. 
Dimethyldioxirane (25 mL, 0.08 M) was added and the resin mixture was stirred at -20 °C 
for 5 min. The resin was quickly filtered, washed with EtOAc (3 x 20 mL) and dried under 
vacuum for 4 h to obtain resin 3-43. Resin 3-43 (0.5 mmol) was then added to DMF (15 mL) 
together with diisopropylethylamine (0.44 mL, 2.5 mmol) and the corresponding amine (2.5 
mmol). The reaction mixture was stirred at 80 °C for 12 h. The resin was filtered and washed 
with DMF (3 x 20mL). The combined filtrate and washings was concentrated to dryness and 
purified with column chromatography using EtOH:DCM (1:10) with 1% glacial acetic acid 
as eluent.  It should be noted that azeotropic removal of the acetic acid additive is necessary 
to afford purified compounds 3-39.    
3-Benzyl-4,4-dimethyl-6-(butylamino)-3,4-dihydro-1,3,5-triazin-2(1H)-one 3-39a. 
Overall yield: 32%. 1H NMR: (CDCl3, 500 MHz): δ 7.31–7.26 (m, ArH, 4H), 7.22–7.19 (m, 
ArH, 1H), 4.61 (s, ArCH2, 2H), 3.17 (t, J = 6.9 Hz, NCH2CH2, 2H), 1.53–1.50 (m, 
NCH2CH2, 2H), 1.41 (s, CH3, 6H),  1.36–1.32 (m, CH2CH3, 2H), 0.86 (t, J = 6.9 Hz, 
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CH2CH3, 3H); 13C NMR (CDCl3, 75 MHz): δ 161.4, 157.6, 139.8, 128.1, 126.7, 126.5, 69.4, 
45.1, 40.4, 31.3, 26.9, 19.9, 13.6; HRMS (ESI) [M+H]+: calcd for C16H25N4O+: 289.2023; 
found 289.2013. 
3-Benzyl-6-(benzylamino)-4,4-dimethyl-3,4-dihydro-1,3,5-triazin-2(1H)-one 3-39b. 
Overall yield: 30%. 1H NMR: (DMSO-d6, 500 MHz): δ 7.34–7.26 (m, ArH, 10H), 4.53 (s, 
ArCH2N, 2H), 4.32 (s, ArCH2, 2H), 1.26 (s, CH3, 6H); 13C NMR (mixture of tautomers) 
(DMSO-d6, 125 MHz): δ 152.9, 152.0, 140.6, 139.7, 139.5, 128.2, 128.21, 128.0, 127.2, 
126.7, 126.7, 126.6, 126.3, 69.1, 44.3, 43.4, 26.6; HRMS (ESI) [M+Na]+: calcd for 
C19H22N4ONa+: 345.1686; found 345.1686. 
3-(4-Methoxybenzyl)-4,4-dimethyl-6-(butylamino)-3,4-dihydro-1,3,5-triazin-2(1H)-
one 3-39c. Overall yield: 30%. 1H NMR: (CDCl3, 500 MHz): δ 7.18 (d, J = 8.8 Hz, ArH, 
2H), 6.78 (d, J = 8.2 Hz, ArH, 2H), 4.50 (s, ArCH2, 2H), 3.24 (t, J = 6.9 Hz, NCH2CH2, 2H), 
1.48–1.44 (m, NCH2CH2, 2H), 1.41 (s, CH3, 6H), 1.31–1.25 (m, CH2CH3, 2H), 0.82 (t, J = 
7.6 Hz, CH2CH3, 3H); 13C NMR (mixture of tautomers) (CDCl3, 125 MHz): δ 158.5, 131.2, 
128.6, 128.3, 125.7, 113.7, 70.5, 55.1,  44.5, 41.1, 31.0, 26.9, 19.9, 13.7; HRMS (ESI) 
[M+Na]+: calcd for C17H26N4NaO2+: 341.1948; found 341.1945. 
6-(Benzylamino)-3-(4-methoxybenzyl)-4,4-dimethyl-3,4-dihydro-1,3,5-triazin-2(1H)-
one 3-39d. Overall yield: 31%. 1H NMR: (DMSO-d6, 500 MHz): δ 7.32–7.31 (m, ArH, 5H), 
7.21 (d, J = 8.2 Hz, ArH, 2H), 6.85 (d, J = 8.2 Hz, ArH, 2H), 4.48 (s, ArCH2N, 2H), 4.41 (s, 
ArCH2, 2H), 3.72 (s, OCH3, 3H), 1.30 (s, CH3, 6H); 13C NMR (DMSO-d6, 75 MHz): δ 
157.9, 154.8, 151.3, 138.9, 132.0, 128.3 (2 carbons), 127.2, 126.9, 113.5, 71.5, 54.9, 43.7, 




3-39e. Overall yield: 38%. 1H NMR: (DMSO-d6, 500 MHz): δ 7.35–7.28 (m, ArH, 4H), 4.51 
(s, ArCH2N, 2H), 3.08 (t, J = 6.9 Hz, NCH2CH2, 2H), 1.44–1.38 (m, NCH2CH2, 2H), 1.32- 
1.23 (m, CH2CH3 and CH3, 8H), 0.86 (t, J = 6.9 Hz, CH2CH3, 3H); 13C NMR (DMSO-d6, 75 
MHz): δ 155.9, 151.1, 139.6, 130.9, 128.7, 128.0, 71.5, 43.7, 31.0, 27.5, 19.5, 19.5, 13.6; 
HRMS (ESI) [M+H]+: calcd for C16H24ClN4O+: 323.1633; found 323.1636. 
6-(Benzylamino)-3-(4-chlorobenzyl)-4,4-dimethyl-3,4-dihydro-1,3,5-triazin-2(1H)-
one (3-39f). Overall yield: 32%. 1H NMR: (DMSO-d6, 500 MHz): δ 8.13 (s, NH, 1H), 7.36–
7.25 (m, ArH, 9H), 4.51 (s, ArCH2N, 2H), 4.29 (d, J = 6.0 Hz, ArCH2, 2H), 1.26 (s, CH3, 
6H); 13C NMR (mixture of tautomers)  (DMSO-d6, 75 MHz): δ 164.9, 161.0, 139.6, 138.9, 
130.9, 128.7, 128.3, 128.2, 128.0, 127.2, 127.2, 126.8, 126.7, 43.8, 43.4, 40.7; HRMS (ESI) 
[M+H]+: calcd for C19H22ClN4O+: 357.1477; found 357.1475. 
6-(Butylamino)-4,4-dimethyl-3-(3,4,5-trimethoxybenzyl)-3,4-dihydro-1,3,5-triazin-
2(1H)-one (3-39g). Overall yield: 38%. 1H NMR: (DMSO-d6, 500 MHz): δ 6.62 (s, ArH, 
2H), 4.49 (s, ArCH2, 2H), 3.73 (s, OCH3, 6H), 3.63 (s, OCH3, 3H), 3.12 (t, NCH2CH2, 2H, J 
= 6.3 Hz), 1.45-1.40 (m, NCH2CH2, 2H), 1.33 (s, CH3, 6H), 1.29–1.26 (m, CH2CH3, 2H), 
0.85 (t, J = 7.6 Hz, CH2CH3, 3H,); 13C NMR (DMSO-d6, 125 MHz): δ 156.3, 152.7, 145.0, 
136.2, 128.1, 125.4, 104.5, 71.3, 59.9, 55.7, 44.5, 31.0, 27.3, 19.4, 13.5; HRMS (ESI) 
[M+H]+: calcd for C19H31N4O4+: 379.2340; found 379.2345. 
6-(Benzylamino)-4,4-dimethyl-3-(3,4,5-trimethoxybenzyl)-3,4-dihydro-1,3,5-triazin-
2(1H)-one (3-39h). Overall yield: 34%. 1H NMR: (DMSO-d6, 300 MHz): δ 7.29 (s, ArH, 
5H), 6.60 (s, ArH, 2H), 4.47 (s, ArCH2N, 2H), 4.34 (s, ArCH2, 2H), 1.29 (s, CH3, 6H); 13C 
NMR (DMSO-d6, 75 MHz): δ161.1, 155.7, 152.7, 139.7, 136.3, 136.1, 128.2, 127.1, 126.7, 
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104.3, 71.9, 60.0, 55.7, 44.5, 43.4, 27.7; HRMS (ESI) [M+H]+: calcd for C22H29N4O4+ 
413.2183; found 413.2180. 
 
General procedure for the synthesis of 3-44. 
Resin 3-41 (0.5 mmol), diisopropylethylamine (0.44 mL, 2.5 mmol) and the 
corresponding amines (2.5 mmol) were added to DMF (12 mL) in a microwave vessel and 
sealed. The mixture was microwaved at 180 °C for 20 min.  The resin was filtered and 
washed with DMF (3 x 20 mL). The filtrate was concentrated to dryness and purified with 
column chromatography using acetone:hexane (1:3) with 1% glacial acetic acid as eluent. It 
should be noted that azeotropic removal of acetic acid additive was necessary to afford 
purified 3-44. 
1-Benzyl-4-(butylamino)-1,3,5-triazin-2(1H)-one 3-44a. Overall yield: 56%. 1H NMR: 
(CDCl3, 300 MHz): δ 7.77 (s, =CH, 1H), 7.23  (m, ArH, 5H), 4.87 (s, ArCH2, 2H), 3.35–
3.29 (m, NCH2, 2H), 1.49–1.41 (m, NCH2CH2, 2H), 1.29–1.22 (m, CH2CH3, 2H), 0.81 (t, J = 
7.3 Hz, CH2CH3, 3H);  13C NMR (CDCl3, 75 MHz): δ 164.8, 163.9, 157.9, 156.8, 154.5, 
153.9, 135.1, 128.8, 128.0, 49.9, 40.9, 31.67, 30.8, 19.8, 13.5; HRMS (ESI) [M+Na]+: calcd 
for C14H19N4NaO+: 281.1373; found 281.1379. 
1-Benzyl-4-(benzylamino)-1,3,5-triazin-2(1H)-one 3-44b. Overall yield: 22%. 1H NMR: 
(DMSO-d6, 500 MHz): δ 8.49 (s, =CH, 1H), 7.36–7.23 (m, ArH, 10H), 4.88 (s, ArCH2N, 
2H), 4.44 (s, ArCH2, 2H); 13C NMR (mixture of tautomers) (DMSO-d6, 125 MHz): δ 164.4, 
158.7, 153.6, 138.8, 136.8, 128.5, 128.3, 128.2, 127.7, 127.6, 127.5, 127.1, 126.9, 126.8, 
49.3, 43.5; HRMS (ESI) [M+Na]+: cald for C17H16N4NaO+ 315.1216; found 315.1225 
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4-(Butylamino)-1-(4-methoxybenzyl)-1,3,5-triazin-2(1H)-one 3-44c. Overall yield: 
49%. 1H NMR: (MeOD-d4, 500 MHz): δ 8.19 (s, =CH, 1H), 7.31–7.28 (m, ArH, 2H), 6.90–
6.89 (m, ArH, 2H), 4.88 (s, ArCH2, 2H), 3.77 (s, OCH3, 3H), 3.40–3.29 (m, NCH2, 2H), 
1.58–1.53 (m, NCH2CH2, 2H), 1.40–1.33 (m, CH2CH3, 2H), 0.94 (t, J = 7.0 Hz, CH2CH3, 
3H); 13C NMR (mixture of tautomers) (MeOD-d4, 125 MHz): δ 165.9, 161.1, 160.3, 159.0, 
157.3, 156.8, 130.6, 130.5, 129.4, 55.7, 50.8, 42.0, 32.9, 32.0, 21.0, 14.1; HRMS (ESI) 
[M+Na]+: calcd for C15H20N4NaO2+ 311.1478; found 311.1487. 
4-(Benzylamino)-1-(4-methoxybenzyl)-1,3,5-triazin-2(1H)-one 3-44d. Overall yield: 
21%. 1H NMR: (DMSO-d6, 500 MHz): δ 8.46 (s, =CH, 1H), 7.32–7.22 (m, ArH, 7H) 6.89 
(d, J = 8.2 Hz, ArH, 2H), 4.79 (s, ArCH2N, 2H), 4.42 (d, J = 6.3 Hz, ArCH2, 2H), 3.72 (s, 
OCH3, 3H); 13C NMR (mixture of tautomers) (DMSO-d6, 125 MHz): δ 164.4, 158.8, 158.5, 
153.6, 138.8, 129.3, 128.7, 128.2, 128.2, 127.1, 126.7, 113.9, 55.0, 48.8, 43.4; HRMS (ESI) 
[M+Na]+: cald for C18H18N4NaO2+ 345.1322; found 345.1333. 
4-(Butylamino)-1-(4-chlorobenzyl)-1,3,5-triazin-2(1H)-one 3-44e. Overall yield: 48%. 
1H NMR: (MeOD-d4, 300 MHz): δ 8.24 (s, =CH, 1H), 7.34 (s, ArH, 4H), 4.85 (s, ArCH2, 
2H), 3.33–3.29 (m, NCH2CH2 2H), 1.60–1.49 (m, NCH2CH2, 2H), 1.42–1.31 (m, CH2CH3, 
2H), 0.93 (t, J = 7.3 Hz, CH2CH3, 3H); 13C NMR (mixture of tautomers) (MeOD-d4, 75 
MHz): δ 166.0, 160.4, 159.1, 157.2, 136.4, 134.9, 130.5, 129.9, 50.6. 41.8, 32.8, 31.9, 21.0, 
14.0; HRMS (ESI) [M+H]+: calcd for C14H18ClN4O+ 293.1164; found 293.1167. 
4-(Benzylamino)-1-(4-chlorobenzyl)-1,3,5-triazin-2(1H)-one 3-44f. Overall yield: 35%. 
1H NMR: (CDCl3, 300 MHz): δ 8.56 (s, =CH, 1H), 8.49 (s, NH, 1H), 7.41–7.23 (m, ArH, 
9H), 4.85 (s, ArCH2N, 2H), 4.43 (s, ArCH2, 2H); 13C NMR (CDCl3, 75 MHz): δ 164.4, 
159.7, 158.7, 153.6, 153.31, 139.3, 138.7, 135.8, 135.7, 132.2, 129.7, 129.6, 128.4, 128.3, 
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128.2, 127.1, 126.9, 126.8, 48.8, 43.5; HRMS (ESI) [M+Na]+: calcd for C17H15ClN4NaO+ 
349.0827; found 349.0830. 
4-(Butylamino)-1-(3,4,5-trimethoxybenzyl)-1,3,5-triazin-2(1H)-one 3-44g. Overall 
yield: 51%. 1H NMR: (DMSO-d6, 500 MHz): δ 8.41 (s, =CH, 1H), 7.97 (s, NH, 1H), 6.70 (s, 
ArH, 2H), 4.77 (s, ArCH2N, 2H), 3.75 (s, OCH3, 6H), 3.63 (s, OCH3, 3H), 3.17 (t, , J = 6.3 
Hz, NCH2CH3, 2H), 1.47–1.44 (m, NCH2CH2, 2H), 1.29–1.26 (m, CH2CH3, 2H), 0.87 (t, J = 
7.6 Hz, CH2CH3, 3H); 13C NMR (DMSO-d6, 75 MHz): δ 164.1, 158.2, 153.8, 152.9, 137.1, 
132.5, 105.6, 59.9, 55.8, 49.4, 30.4, 19.6, 13.6; HRMS (ESI) [M+H]+: calcd for C19H27N4O4+ 
349.1870; found 349.1886. 
4-(Benzylamino)-1-(3,4,5-trimethoxybenzyl)-1,3,5-triazin-2(1H)-one 3-44h. Overall 
yield:  49%. 1H NMR: (DMSO-d6, 300 MHz): δ 8.47 (s, =CH, 1H), 7.31-7.26 (m, ArH, 5H), 
6.69 (s, ArH, 2H), 4.78 (s, ArCH2N, 2H), 4.43 (s, ArCH2, 2H), 3.74 (s, OCH3, 6H), 3.63 (s, 
OCH3, 3H); 13C NMR (DMSO-d6, 75 MHz): δ 165.4, 159.6, 154.8, 153.9, 139.9, 133.3, 
129.3, 128.1, 128.0, 127.8, 106.6, 61.0, 56.9, 50.5, 44.5; HRMS (ESI) [M+Na]+: calcd for 
C20H22N4NaO4+ 405.1533; found 405.1535. 
 
General procedure for the synthesis of 3-45 
Resin 3-42 (0.5 mmol) was swollen in DCM (8 mL) for 30 min. Dimethyldioxirane (15.7 
mL, 0.08 M) was added and the reaction mixture was stirred at room temperature for 3 h. 
Filtration of the mixture followed by solvent removal in vacuo afforded 3-45 directly. 
1-Benzyl-1,3,5-triaza-spiro[5.5]undecane-2,4-dione 3-45a. Overall yield: 70%. 1H 
NMR: (MeOD-d4, 300 MHz): δ 7.30 (m, ArH, 5H), 4.71 (s, ArCH2, 2H), 1.84–1.17 (m, 
cyclohexyl, 10H); 13C NMR (MeOD-d4, 75 MHz): δ 155.5, 154.5, 140.3, 129.5, 128.1, 
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127.9, 73.0, 45.3, 35.2, 25.3, 22.6; HRMS (EI) [M]+: calcd for C15H19O2N3: 273.1477; found 
273.1486. 
1-(4-Methoxy-benzyl)-1,3,5-triaza-spiro[5.5]undecane-2,4-dione 3-45b. Overall yield: 
75%. 1H NMR: (DMSO-d6, 300 MHz): δ 9.61 (s, NH, 1H), 7.77 (s, NH, 1H), 7.20–7.17 (m, 
ArH, 2H), 6.89–6.86 (m, ArH, 2H), 4.54 (s, ArCH2, 2H), 3.72 (s, OCH3, 3H), 1.61–1.50 (m, 
cyclohexyl, 10H); 13C NMR (DMSO-d6, 75 MHz): δ 158.3, 153.7, 152.2, 131.9, 128.3, 
114.0, 71.2, 55.3, 34.1, 24.3, 21.3; HRMS (ESI) [M+Na]+: calcd for C16H21N3NaO3+: 
326.1475; found 326.1471. 
1-(4-Chloro-benzyl)-1,3,5-triaza-spiro[5.5]undecane-2,4-dione 3-45c. Overall yield:  
79%. 1H NMR: (Acetone-d6, 300 MHz): δ 8.75 (s, NH, 1H), 7.39–7.35 (m, ArH, 4H), 4.73 
(s, ArCH2, 2H), 1.82–1.17 (m, cyclohexyl, 10H); 13C NMR (DMSO-d6, 75 MHz): δ 153.7, 
152.2, 139.2, 131.5, 128.8, 128.6, 71.4, 43.5, 34.0, 24.20, 21.3; HRMS (EI) [M]+: calcd for 
C15H18ClN3O2+: 307.1088; found 307.1097. 
1-(3,4,5-Trimethoxy-benzyl)-1,3,5-triaza-spiro[5.5]undecane-2,4-dione 3-45d. Overall 
yield:  80%. 1H NMR: (DMSO-d6, 500 MHz): δ 9.62 (s, NH, 1H), 7.79 (s, NH, 1H), 6.56 (s, 
ArH, 2H), 4.54 (s, ArCH2, 2H), 3.73 (s, OCH3, 6H), 3.63 (s, OCH3, 3H), 1.66–1.06 (m, 
cyclohexyl, 10H); 13C NMR (DMSO-d6, 125 MHz): δ 153.4, 152.7, 151.8, 136.2, 135.4, 
103.8, 70.9, 59.9, 55.8, 43.8, 33.6, 23.9, 21.0. HRMS (ESI) [M+Na]+: calcd for 
C18H25N3NaO5+: 386.1686; found 386.1674. 
 
General procedure for the synthesis of 3-47 
Resin 3-42 (0.7 mmol) was swollen in DCM (8 mL) at -20 °C for 20 min. 
Dimethyldioxirane (25 mL, 0.08 M) was added and the resin mixture was stirred at -20 °C 
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for 10 min. The resin was quickly filtered, washed with EtOAc (3 x 20 mL) and dried under 
vacuum for 4 h to obtain resin 3-46. Resin 3-46 (0.5 mmol) was then added to DMF (15 mL) 
together with DiEA (0.44 mL, 2.5 mmol) and the corresponding amine (2.5 mmol). The 
reaction mixture was stirred at 80 °C overnight. The resin was filtered and washed with DMF 
(3 x 20mL). The filtrate was concentrated to dryness and purified with column 
chromatography using EtOH:DCM (1:20) with 1% glacial acetic acid as eluent. It should be 
noted that azeotropic removal of acetic acid additive was necessary to afford the purified 3-
47.    
1-Benzyl-4-butylamino-1,3,5-triaza-spiro[5.5]undec-4-en-2-one 3-47a. Overall yield: 
29%. 1H NMR: (Acetone-d6, 300 MHz): δ 7.34–7.16 (m, ArH, 5H), 4.73 (s, ArCH2, 2H), 
3.34 (t, J = 6.7 Hz, NCH2CH2, 2H), 1.81–1.07 (m, cyclohexyl & NCH2CH2CH2CH3 , 14H), 
0.86 (t, J = 7.2 Hz, CH2CH3, 3H); 13C NMR (mixture of tautomers) (Acetone-d6, 75 MHz): δ 
143.9, 140.1, 138.9, 128.1, 127.9, 126.6, 126.3, 125.6, 72.0, 44.2, 40.6, 34.0, 30.9, 27.9, 
24.2, 21.5, 20.1, 19.6, 13.0; HRMS (ESI) [M+H]+: calcd for C19H28N4O+; 329.2336; found 
329.2329. 
1-Benzyl-4-benzylamino-1,3,5-triaza-spiro[5.5]undec-4-en-2-one 3-47b. Overall yield: 
23%. 1H NMR: (Acetone-d6, 500 MHz): δ 7.31–7.16 (m, ArH, 10H), 4.66 (s, ArCH2N, 2H), 
4.42 (s, ArCH2, 2H), 1.65–1.04 (m, cyclohexyl, 10H); 13C NMR (Acetone-d6, 75 MHz): δ 
157.1, 151.0, 141.5, 140.3, 129.2, 129.0, 128.3, 127.9, 127.8, 127.4, 74.7, 45.2, 36.0, 25.7, 
22.8; HRMS (ESI) [M+H]+: calcd for C22H27N4O+: 363.2179; found 363.2195. 
4-Butylamino-1-(4-methoxy-benzyl)-1,3,5-triaza-spiro[5.5]undec-4-en-2-one 3-47c. 
Overall yield: 18%. 1H NMR: (Acetone-d6, 300 MHz): δ 7.26 (d, J = 8.5 Hz, ArH, 2H), 6.84 
(d, J = 8.6 Hz, ArH, 2H), 4.65 (s, ArCH2, 2H), 3.74 (s, OCH3, 3H), 3.32 (t, J = 6.7 Hz, 
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NCH2CH2, 2H), 1.80–1.29 (m, cyclohexyl & CH2CH2CH3, 14H), 0.90 (t, J = 6.9 Hz; 
CH2CH3, 3H); 13C NMR (Acetone-d6, 75 MHz): δ 159.1, 132.8, 128.9, 128.8, 126.4, 114.1, 
72.8, 55.1, 44.3, 41.4, 34.9, 31.8, 25.1, 22.3, 20.4, 13.8; HRMS (ESI) [M+H]+: calcd for 
C20H31N4O2+: 359.2442; found 359.2448. 
4-Benzylamino-1-(4-methoxy-benzyl)-1,3,5-triaza-spiro[5.5]undec-4-en-2-one 3-47d. 
Overall yield: 27%. 1H NMR: (DMSO-d6, 300 MHz): δ 7.32 – 7.23 (m, ArH, 5H), 7.17 (d, J 
= 8.5 Hz, ArH, 2H), 6.84 (d, J = 8.4 Hz, ArH, 2H), 4.49 (s, ArCH2N, 2H), 4.34 (s, ArCH2, 
2H), 3.71 (s, OCH3, 3H), 1.50–1.03 (m, cyclohexyl, 10H); 13C NMR (DMSO-d6, 75 MHz): δ 
157.8, 153.4, 145.4, 139.8, 132.5, 128.2, 127.9, 127.3, 126.7, 113.4, 74.7, 54.9, 43.6, 43.0, 
35.7, 24.6, 21.8; HRMS (ESI) [M+H]+: calcd for C23H29N4O2+ 393.2285; found 393.2294. 
4-Butylamino-1-(4-chloro-benzyl)-1,3,5-triaza-spiro[5.5]undec-4-en-2-one 3-47e. 
Overall yield: 26%. 1H NMR: (DMSO-d6, 500 MHz): δ 7.32 (d, J = 8.2 Hz; ArH, 2H,), 7.25 
(d, J = 8.2 Hz, ArH, 2H), 4.54 (s, ArCH2N, 2H), 3.12 (m, NCH2CH2, 2H), 1.52–1.08 (m, 
cyclohexyl & CH2CH2CH3, 14H), 0.87 (t, J = 7.6 Hz, CH2CH3, 3H); 13C NMR (mixture of 
tautomers)  (DMSO-d6, 75 MHz): δ 154.8, 147.9, 139.6, 130.8, 128.9, 128.4, 128.0, 125.4, 
73.0, 43.1, 34.6, 30.9, 24.3, 21.7, 19.4, 13.5; HRMS (ESI) [M+H]+: calcd for C19H28ClN4O+: 
363.1946; found 363.1957. 
4-Benzylamino-1-(4-chloro-benzyl)-1,3,5-triaza-spiro[5.5]undec-4-en-2-one 3-47f. 
Overall yield: 26%. 1H NMR: (Acetone-d6, 500 MHz): δ 7.31–7.19 (m, ArH, 9H), 4.64 (s, 
ArCH2N, 2H), 4.44 (s, ArCH2, 2H), 1.62–1.07 (m, cyclohexyl, 10H); 13C NMR (Acetone-d6, 
75 MHz): δ 159.0, 152.2, 140.7, 140.4, 132.5, 129.6, 129.1, 129.0, 128.2, 127.7, 73.9, 44.9, 





47g. Overall yield: 27%. 1H NMR: (Acetone-d6, 300 MHz): δ 6.67 (s, ArH, 2H), 4.64 (s, 
ArCH2, 2H), 3.76 (s, OCH3, 6H), 3.68 (s, OCH3, 3H), 3.32 (t, J = 6.5 Hz, NCH2CH2, 2H), 
1.79 -1.12 (m, cyclohexyl & CH2CH2CH3, 14H), 0.88 (t, J = 7.3 Hz; CH2CH3, 3H); 13C 
NMR (Acetone-d6, 75 MHz): δ 159.2, 154.9, 138.6, 138.0, 106.1, 74.4, 61.1, 57.1, 45.9, 
42.0, 36.4, 33.0, 26.4, 23.6, 21.4, 14.8; HRMS (ESI) [M+H]+: calcd for C22H35N4O4+: 
419.2653; found 419.2661. 
4-Benzylamino-1-(3,4,5-trimethoxy-benzyl)-1,3,5-triaza-spiro[5.5]undec-4-en-2-one 
3-47h. Overall yield: 16%. 1H NMR: (DMSO-d6, 300 MHz): δ 7.36–7.20 (s, ArH, 5H), 6.65 
(s, ArH, 2H), 4.61 (s, ArCH2N, 2H), 4.47 (s, ArCH2, 2H), 3.73 (s, OCH3, 6H), 3.68 (s, 
OCH3, 3H), 1.69–1.29 (m, cyclohexyl, 10H); 13C NMR (DMSO-d6, 75 MHz): δ 158.8, 
157.6, 154., 140., 138., 137.2, 129.2, 128.2, 127.7, 105.5, 74.3, 60.5, 56.4, 45.2, 45.0, 36.0, 
25.7, 22.9. HRMS (ESI) [M+H]+: calcd for C25H32N4O4+: 453.2496; found 453.2496. 
 
3.8 Traceless cleavage via Liebeskind-Srogl cross coupling on solid phase 
In the previous sections, either safety catch methodology or microwave assisted cleavage 
conditions was applied on the solid supported triazine substrates to cleave the triazines, and 
in the process a new C-N bond was formed in place of the C-S bond at the point of cleavage. 
In this section a cleavage mechanism via C-C bond formation will be discussed.  
The oxidative addition of the soft organosulfur compound catalyzed by a soft transition 
metal like palladium has been well established.135 However until recently, there are limited 
studies on the application of organosulfur compounds to palladium catalyzed cross coupling 
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reaction. This is due to the lack of appropriate organometallic compound that can promote 
successful transmetalation with the metal thiolate intermediate.136  
The solution to the above problem was reported by Liebeskind and Srogl in 2000.137 Their 
protocol allows the synthesis of ketones from coupling between thioesters and boronic acids 











Scheme 3.26. Palladium catalyzed, copper(I) mediated Liebeskind-Srogl cross coupling 
CuTC = copper(I) thiophene-2-carboxylate, dba=dibenzylideneacetone, TFP=tris(2-
furyl)phosphine. 
 
Since initial publication documenting the use of thioesters and boronic acids, further 
developments on applying Liebeskind Srogl coupling conditions on heteroaromatic 
thioether138and cyclic thioamide139 substrates have also been reported in the recent years.   
The key to the success of these reactions is use of a stoichiometric amount of the copper(I) 
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Scheme 3.27. Proposed mechanism for the Liebeskind-Srogl reaction. 
CuTC = copper(I) thiophene-2-carboxylate 
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In the mechanism proposed by the pioneers140 (Scheme 3.27) CuTC aids the 
transmetalation via selective interaction between the soft sulfur and soft copper as well as 
between the carboxylate counterion and boron center. These interactions lead to the 
polarization of the Pd-S bond as well as the activation of the trivalent boronic acid towards 
transmetalation. The requirement for stoichiometric amount of CuTC can also be explained 
via the proposed mechanism, where copper(I) scavenges the released thiolate. 
Given the requirement for the formation of a ternary complex between palladium thiolate 
intermediate, CuTC and boronic acid, it can be expected that this reaction would be sensitive 
to steric effects. Application of this reaction to release sulfide tethered substrates off solid 
support could be problematic. However, Kaval et. al. in 2007 reported the use of the 
Liebeskind-Srogl cross coupling to the solid phase synthesis of pyrazinones.141 This led our 
group to explore the feasibility of employing the same protocol to our substrates. 
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Entry Compound R1 Yield (%)
1 3-48a 4-methoxyphenyl 37
2 3-48b 3-bromophenyl 32
3 3-48c (biphenyl-4-yl)vinyl 52
4 3-49a 4-methoxyphenyl 46
5 3-49b 3-bromophenyl 57
6 3-49c (biphenyl-4-yl)vinyl 48
 
 
Table 3.7. Yields of 3-48 and 3-49 on solution phase. 
 
The solution phase Liebeskind-Srogl cross coupling was performed on using triazines 3-
39 and 3-35 (Scheme 3.28) using 3 different boronic acids. The yields of the solution phase 
reactions are shown in Table 3.7. The cross coupling reaction on triazine 3-39 on solution 
phase give 3-48 with yields of 37-52%.(Table 3.7, entry 1-3) For the coupling reaction of 3-
38 the yields of 3-49  ranges from 46–57%. (Table 3.7, entry 4-6) In these reactions, the 
effect of R1 substituent on the yield of the coupling reaction is not elucidated. Having 
successfully applied the solution phase Liebeskind-Srogl coupling reaction, we moved on the 
applying the analogous conditions on the solid supported triazines 3-40 and 3-41. Using 
exact reaction condition on resin 3-41 led to only a dismal 10% yield (Table 3.8, entry 1). 
FTIR analysis of the post coupling resin shows the adsorption bands which can be attributed 
to significant amounts of residual substrate. Due the the presence of the significant amount of 
residual substrate, we suspect that the problem lies in difficulty in the cleavage of the sulfide 
hetercycle bond during the oxidative addition step of the catalytic cycle.  We proceeded to 
optimize the reaction by exploring the palladium precatalyst and the phosphine ligands used 
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CuTC (3 equiv.),
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Scheme 3.29. Optimization of solid phase Liebeskind-Srogl cross coupling. 
. 
Entry Reaction Conditions Yield (%)
1 Pd(Ph3P)4, CuTC, 4-methoxyphenyl boronic acid (1.2 equiv.) 10
2 Pd2(dba)3, CyPh2P, CuTC, 4-methoxyphenyl boronic acid (1.2 equiv.) 13
3 Pd2(dba)3, CyPh2P, CuTC, 4-methoxyphenyl boronic acid (2.2 equiv.) 25
4 Pd2(dba)3, Ph3As, CuTC, 4-methoxyphenyl boronic acid (2.2 equiv.) 19
5 Pd2(dba)3, Cy3P, CuTC, 4-methoxyphenyl boronic acid (2.2 equiv.) 26
6 Pd2(dba)3, CyPh2P, CuMethylsalicylate, 4-methoxyphenyl boronic acid (2.2 
equiv.)
10
Table 3.8. Yields of 3-44a under various reaction conditions 
 
Changing the palladium catalyst system was not enough to boost the yield. An excess of 
boronic acid (2.2 equiv.) was found to be needed as well. Additionally, an alternative 
copper(I) cofactor, copper(I) methylsalicylate, reported by Liebeskind and Srogl was used 
(Table 3.8, entry 6). This however resulted in a drop in yield. Thus the reaction condition 
listed in entry 5 (Table 3.8) was found to be the optimal condition. 
The reaction that uses Pd2(dba)3 (3 mol%), Cy3P (24 mol%), CuTC (3 equiv.), 4-
methoxylphenyl boronic acid (2.2 equiv.) (Table 3.8, entry 5) was subsequently applied to 
resin 3-40 and 3-41 (Scheme 3.30). Intriguingly, the yields obtained from the cross coupling 
of 3-40 and 3-41 on solid phase were lower than the yields of the corresponding substrates on 
solution phase (Table 3.9). Another pertinent point is the significantly lower yield of the 
coupling of (biphenyl-4-yl)vinyl boronic acid to both 3-40 and 3-41. This again is in stark 
contrast to the yields obtained via the solution phase. As both triazines 3-40 and 3-41 were 
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immobilized on the same batch of bromomethyl resin, the steric effects conferred by the 
polymer backbone are likely to be similar. Additionally, (biphenyl-4-yl)vinyl boronic acid 
has two phenyl rings which makes it larger than the other two boronic acids. Thus these 
results further support proposed steric effects on the formation of the proposed ternary 





















Pd2(dba)3 (6 mol%), Cy3P (24 mol%) 
CuTC (3 equiv.), R1B(OH)2 (2.2 equiv.)
THF, MW,135°C, 45 min
3-41 3-48
Pd2(dba)3 (6 mol%), Cy3P (24 mol%) 
CuTC (3 equiv.), R1B(OH)2 (2.2 equiv.)




Scheme 3.30. Liebeskind-Srogl cross coupling on solid phase.  
 
 
Entry Compound R1 Yield (%)
1 3-48a 4-methoxyphenyl 26%
2 3-48b 3-bromophenyl 26%
3 3-48c (biphenyl-4-yl)vinyl 8% 
4 3-49a 4-methoxyphenyl 17%
5 3-49b 3-bromophenyl 29%
6 3-49c (biphenyl-4-yl)vinyl 10%
Table 3.9. Solid-phase yields of 3-48 and 3-49  
 
3.8.2 Traceless cleavage via Liebeskind-Srogl Cross Coupling on 3-11. 
Having demonstrated the feasibility applying Liebeskind-Srogl coupling based cleavage 
on resin 3-41 and 3-40, we proceeded to apply the analogous conditions on other triazine 













Pd2(dba)3 (6 mol%), Cy3P (24 mol%) 
CuTC (3 equiv.),
4-methoxyphenyl boronic acid (2.2 equiv.)




Scheme 3.31. Liebeskind-Srogl coupling between 3-5a and 4-methoxyphenyl boronic acid 
 
Applying the optimized condition (Table 3.8, entry 5) to 3-5a gave 3-50a as the 
corresponding coupling product in 70% yield. (Scheme 3.31) Having successfully used the 
Liebeskind-Srogl coupling conditions for the synthesis of 3-5a, we proceeded to subject resin  
3-11 to the coupling conditions to generate a set of 3-50 with yields of 16-34% (Scheme 











Pd2(dba)3 (6 mol%), Cy3P (24 mol%)
CuTC (3 equiv.), R1B(OH)2 (2.2 equiv.)
THF, MW, 135 °C, 45 min
 
Scheme 3.32. Liebeskind-Srogl coupling on 3-11 to yield 3-50  
 
Entry Compound R1 Yield (%)
1 3-50a 4-methoxyphenyl 23%
2 3-50b p-Tolyl 34%
3 3-50c 4-bromophenyl 16%
Table 3.10. Yields of 3-50 from the Liebeskind-Srogl coupling on resin 3-29 
The structure of triazine analog 3-50a was confirmed using x-ray diffraction 





Figure 3.20. ORTEP diagram of 3-50a 
 
Despite the initial success of the applying the coupling reaction on substrate 3-11, 3-40 
and 3-41, attempts to cleave the bicyclic triazine 3-29 and triazine-dione 2-9 and 3-20 failed 
to afford the corresponding cleaved products and IR analysis of the post cleavage resin 
shows substantial amount of residual substrate. Since transition metal catalysed coupling 
reactions are very sensitive to the inherent electronic factors of the substrates, Liebeskind 
Srogl type cleavage on 3-9, 3-20 and 3-29 will require further experimentation with other 
coupling partners, metal pre-catalyst and the ligands. 
 
3.8.3 Experimental Section 
3.8.3.1 Solution phase synthesis of 3-48, 3-49 and 3-50 
THF (3 mL) was charged into a microwave vessel and degassed with argon for 2 min. 
Triazine substrate (3-5a/3-39/3-35, 0.25 mmol), Pd(PPh3)4 (17.3 mg, 0.015 mmol), CuTC 
(142.5 mg, 0.75 mmol) and the corresponding boronic acids (0.3 mmol) were then added into 
the microwave vessel under N2. The mixture was then subjected to microwave at 135 °C for 
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45 min. The reaction mixture was filtered through a plug of silica gel to remove palladium. 
The filtrate was concentrated to dryness and purified using column chromatography to afford 
the compounds.  
 
3.7.8.2 Solid phase synthesis of 3-48, 3-49 and 3-50 
THF (3 mL) was charged into a microwave vessel and degassed with argon for 2 min. 
Resin 3-11/3-40/3-41 (0.50 mmol), Pd2(dba)3 (13.7 mg, 0.015 mmol), PCy3 (33.6 mg, 0.12 
mmol), CuTC (0.285 g, 1.5 mmol) and the corresponding boronic acids (1.15 mmol) were 
then added into the microwave vessel under N2. The mixture was then subjected to 
microwave at 135 °C for 45 min. The reaction mixture was filtered through a plug of silica 
gel to remove palladium. The filtrate was concentrated to dryness and purified using column 
chromatography to afford the compounds.  
1-Benzyl-4-(4-methoxyphenyl)-1,3,5-triazin-2(1H)-one 3-48a. Column chromatography 
using EtOAc:hexane (1:2) afforded 3-48a as a white solid (Overall yield: 37%). 1H NMR: 
(CDCl3, 500 MHz): δ 8.40 (d, J = 8.8 Hz, ArH, 2H), 8.27 (s, NH, 1H), 7.38–7.37 (m, ArH, 
5H), 6.94 (d,  J = 8.8 Hz, ArH, 2H), 5.09 (s, ArCH2, 2H), 3.87 (s, OCH3, 3H); 13C NMR 
(CDCl3, 125 MHz): δ 172.1, 164.1, 157.9, 154.6, 134.1, 131.9, 129.2, 128.8, 128.5, 126.8, 
55.4, 51.1; HRMS (ESI) [M+Na]+: calcd for C17H15N3NaO2+ 316.1056; found 316.1066. 
1-Benzyl-4-(3-bromophenyl)-1,3,5-triazin-2(1H)-one 3-48b. Column chromatography 
using EtOAc:hexane (1:3) afforded 3-48b as a white solid (Overall yield: 32%). 1H NMR: 
(DMSO-d6, 500 MHz): δ 9.12 (s, NH, 1H), 8.42 (s, ArH, 1H), 8.31 (d, J = 7.5 Hz, ArH, 1H), 
7.84 (d, J = 8.2 Hz, ArH, 1H), 7.52 (m, ArH, 1H), 7.42–7.32 (m, ArH, 5H), 5.10 (s, ArCH2, 
2H); 13C NMR (DMSO-d6, 125 MHz): δ 170.3, 161.4, 153.4, 136.9, 135.6, 135.2, 131.2, 
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131.0, 128.5, 127.9, 127.8, 127.2, 121.9, 50.8; HRMS (ESI) [M+H]+: calcd for 
C16H13N3BrO+: 342.0237; found 342.0254. 
(E)-1-Benzyl-4-(2-(biphenyl-4-yl)vinyl)-1,3,5-triazin-2(1H)-one 3-48c. Column 
chromatography using EtOAc:DCM (1:20) afforded 3-48c as a white solid (Overall yield: 
52%). 1H NMR: (CDCl3, 500 MHz): δ 8.22 (s, =CH, 1H), 8.17 (d, J = 15.8 Hz, =CH, 1H,), 
7.68 -7.61 (m, ArH, 6H), 7.47–7.37 (m, ArH, 7H), 6.98 (d, J = 15.8 Hz, =CH, 1H), 5.08 (s, 
ArCH2, 2H); 13C NMR (CDCl3, 125 MHz): δ 172.9, 157.6, 154.4, 144.5, 143.2, 140.0, 134.0, 
133.8, 129.3, 128.9, 128.9, 128.9, 128.5, 127.8, 127.6, 127, 124., 51.2; HRMS (ESI) 
[2M+Na]+: calcd for C48H38N6NaO2+: 753.2948; found 753.2951. 
3-Benzyl-6-(4-methoxyphenyl)-4,4-dimethyl-3,4-dihydro-1,3,5-triazin-2(1H)-one 3-
49a. Column chromatography using EtOAc:hexane (1:2) afforded 3-49a as a white solid 
(Overall yield: 46%). 1H NMR: (CDCl3, 300 MHz): δ 9.60 (s, NH, 1H), 7.75 (d, J = 8.7 Hz, 
ArH, 2H), 7.31–7.17 (m, ArH, 5H), 6.65 (d, J = 8.7 Hz, ArH, 2H), 4.65 (s, ArCH2, 2H), 3.68 
(s, OCH3, 3H), 1.41 (s, CH3, 6H); 13C NMR (CDCl3, 125 MHz): δ 161.78, 154.28, 148.76, 
139.2, 128.4, 128.4, 127.0, 126.8, 125.0, 113.7, 75.2, 55.3, 45.4, 28.1; HRMS (ESI) 
[M+Na]+: calcd for C19H21N3NaO2+: 346.1526; found 346.1529. 
3-Benzyl-6-(3-bromophenyl)-4,4-dimethyl-3,4-dihydro-1,3,5-triazin-2(1H)-one 3-49b. 
Column chromatography using EtOAc:hexane (1:4) afforded 3-49b as a white solid (Overall 
yield: 57%). 1H NMR: (CDCl3, 300 MHz): δ 10.26 (s, NH, 1H), 8.09 (s, ArH, 1H), 7.83 – 
7.76 (m, ArH, 1H), 7.43 – 7.41 (m, ArH, 1H), 7.19 – 7.15 (m, ArH, 5H), 7.02 – 6.97 (m, 
ArH, 1H), 4.63 (s, ArCH2, 2H), 1.40 (s, CH3, 6H); 13C NMR (CDCl3, 75 MHz): δ 154.3, 
148.0, 139.0, 134.6, 133.8, 130.1, 129.8, 129.0, 128.4, 127.15, 126.9, 125.4, 122.6, 45.4, 




one 3-49c. Column chromatography using EtOAc:hexane (1:5) afforded 3-49c as a white 
solid (Overall yield: 48%). 1H NMR: (CDCl3, 300 MHz): δ 9.86 (s, NH, 1H), 7.51–7.19 (m, 
ArH & =CH, 15H), 6.51 (d, J = 16.6 Hz, =CH, 1H), 4.73 (s, ArCH2, 2H), 1.43 (s, CH3, 6H); 
13C NMR (CDCl3, 75 MHz): δ 154.2, 148.8, 141.8, 140.3, 138.9, 136.4, 134.1, 128.8, 
128.57, 127.8, 127.5, 127.3, 127.0, 126.9, 126.7, 121.4, 75.2, 45.4, 28.0; HRMS (ESI) 
[M+H]+: calcd for C26H26N3O+: 396.2070; found 396.2087. 
(Z)-N-(1,6-Dimethyl-4-p-tolyl-1,3,5-triazin-2(1H)-ylidene)aniline 3-50a: Flash column 
chromatography using EtOAc:hexane (2:7) afforded 3-50a as a yellow solid (34% overall 
yield). 1H NMR: (CDCl3, 500 MHz): δ 8.14 (d, J = 8.20 Hz, ArH, 2H), 7.34–7.18 (m, ArH, 
2H), 7.22-7.18 (m, ArH, 4H), 7.04 (m, ArH, 1H), 3.59 (s, NCH3, 3H), 2.51 (s, NCH3, 3H), 
2.38 (s, ArCH3, 3H).  13C NMR (CDCl3, 125 MHz): δ 167.0, 165.6, 148.9, 148.3, 142.5, 
132.9, 129.1, 128.9, 128.8, 123.4, 122.3, 33.2, 23.1, 21.5; HRMS (ESI) [M+H]+: calcd for 
C18H19N4+: 291.1604; found 291.1597. 
(Z)-N-(4-(4-Methoxyphenyl)-1,6-dimethyl-1,3,5-triazin-2(1H)-ylidene)aniline 3-50b: 
Column chromatography using EtOAc:hexane (1:2) afforded 3-50b as a yellow solid (23% 
overall yield). 1H NMR: (CDCl3, 300 MHz): δ 8.11 (d, J = 9.0 Hz, ArH, 2H), 7.26–7.10 (m, 
ArH, 2H), 7.12 (m, ArH, 2H), 6.94 (m, ArH, 1H), 6.78 (d, J = 8.7 Hz, ArH, 2H),  3.72 (s, 
OCH3, 3H), 3.46 (s, NCH3, 3H), 2.37 (s, NCH3, 3H).  13C NMR (CDCl3, 125 MHz): δ 166.8, 
165.1, 162.9, 148.9, 148.4, 131.0, 128.2, 128.1, 123.4, 122.2, 113.5, 55.2, 33.1, 23.1; HRMS 
(ESI) [M+H]+: calcd for C18H19 O1N4+: 307.1553; found 307.1540. 
 (Z)-N-(4-(4-Bromophenyl)-1,6-dimethyl-1,3,5-triazin-2(1H)-ylidene)aniline 3-50c: 
Column chromatography using EtOAc:hexane (1:2) afforded 3-50c as a yellow solid (16% 
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overall yield). 1H NMR: (CDCl3, 500 MHz): δ 8.31 (d, J = 9.0 Hz, ArH, 1H), 8.05 (d, J = 7.5 
Hz, ArH, 1H), 7.50 (m, ArH, 1H), 7.26 (m, ArH, 2H), 7.17-7.09 (m, ArH, 3H), 6.97 (m, 
ArH, 1H),  3.52 (s, NCH3, 3H), 2.43 (s, NCH3, 3H);  13C NMR (CDCl3, 125 MHz): δ 167.6, 
164.4, 148.4, 147.9, 137.7, 134.7, 132.0, 129.7, 128.3, 127.6, 123.3, 122.6, 122.3, 33.3, 23.1; 
HRMS (ESI) [M+H]+: calcd for C17H16 BrN4+: 355.0553; found 355.0542. 
 
3.9 Conclusion 
In conclusion, we have described the use of solid-supported thiouronium hydrobronide 
salt 3-10 as the primary precursor for the solid phase synthesis of 1,3,5-triazine derivatives. 
In the process, we have also demonstrated versatility of our approach by using either safety 
catch cleavage or microwave assisted cleavage of the triazine derivatives from the solid 
support. In addition, we have also reported the application of Liebeskind-Srogl coupling 
conditions for the traceless cleavage of three set of triazine derivatives. 
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Chapter 4  
Biological Evaluation of 1,3,5-Triazines Derivatives on Neuronal Nitric 
Oxide Synthase 
 
4.1   Nitric Oxide Synthase  
Nitric Oxide (NO) is an important biological messenger molecule that is involved in 
various physiological and pathological processes in the body. Processes that are regulated by 
NO include cardiovascular tone, immune responses, neuronal function, blood pressure and 
blood flow regulation.143 NO is produced by the enzyme nitric oxide synthase (NOS), of 
which there are three isoforms, namely: (i) neuronal NOS (nNOS), (ii) endothelial NOS 
(eNOS) and (iii) inducible NOS (iNOS).144 eNOS plays a role in cardiovascular actions such 
as regulation of smooth muscle relaxation and blood pressure; nNOS is responsible for 
intercellular communication of neurons; iNOS produces NO in activated macrophage cells 
which acts as a cytotoxic agent in normal immune responses.145 nNOS and eNOS are 
constitutive enzymes that are always present in cells capable of expressing NOS and are 
activated by the presence of calcium ions. iNOS differs by being calcium independent and 
appears only in response to an immunological stimulus. Once expressed, iNOS is constantly 
active. 
The main function of all forms of NOS is to utilize L-arginine as substrate and catalyze its 
oxidation to L-citrulline and using reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) as the source of electrons (Figure 4-1).146,147 In addition, a number of co-factors 
including FAD, FMN, (6R)-5,6,7,8-tetrahydro-L-biopterin (H4Bip) and iron protoporphyrin 
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Figure 4.1. NOS catalyzed oxidation of L-arginine.  
 
The schematic structure of NOS enzymes is shown in Figure 4-2. These enzymes contain 
two functional subunits, a reductase and an oxygenase domain connected by a calmodulin-
binding linker. For the synthesis of NO, a dimer is necessary, that is, in a functional complex 




Figure 4.2. Schematic presentation of NOS primary structure149 
 
Despite the importance of NO in several biological processes, an elevated concentration of 
NO has been implicated in many diseases. The mechanism of cell damage is complex, of 
which includes production of peroxynitrile (ONOO-) which is a powerful oxidant that can 
destroy biological membranes, modify proteins and lipids by nitration,150,151 induce DNA 
damage by free radicals and overactivate DNA repair enzymes which deplete energy stores 
and cause cell death. Such detrimental effects on health can lead to sepsis, inflammation, 







disease.152,153 Hence, the design of nitric oxide synthase (NOS) inhibitors as regulators of NO 
may have important therapeutic implications in the future.  
 
4.2   NOS inhibitors 
To date, a wide variety of strategies have been developed in the search for isoform-
selective NOS inhibitors. Investigations on the relationship between the quaternary structure 
of the enzyme and its catalytic activity have paved new ways for the design of potential 
inhibitors.154 The NOS inhibitors interact with the enzyme on several locations and the 
design of NOS inhibitors is based on three approaches namely: (i) substrate-based 
inhibitors,145 (ii) dimerization inhibitors145,155 and (iii) cofactor inhibitors.145 
Substrate-based inhibitors of NOS were mainly analogues of the substrate L-arginine156 such 
as is Nω-methyl-L-arginine. Such compounds compete with L-arginine at the arginine-
binding site, reducing enzymatic activity. However, substrate-based inhibitors may also 
interfere with other L-arginine-dependent biological pathways,157 making the compound less 
ideal as an inhibitor.  
Cofactor binding sites that have been targeted includes the flavin cofactor sites (FMN and 
FAD) using inhibitors such as diphenyleneiodonium that interfere with flavin function. Other 
inhibition targets include the heme prosthetic group by indazoles and imidazole compounds. 
Although some of these inhibitors display promising potency, they are unable to specifically 
distinguish between the three NOS isoforms. Moreover, these compounds could interfere 
with the activities of other enzymes that utilize similar cofactors.149 
A more promising target is the (6R)-5,6,7,8-tetrahydrobiopterin (H4Bip) - binding site in 
NOS. Since NOS are the only heme-containing enzymes that require H4Bip as cofactor for 
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enzymatic activity, it is of great interest to explore H4Bip-based analogues selective NOS 
inhibitors.  
 
4.3 Structure Activity Relationship of Cofactor H4Bip 
Although the mechanism by which H4Bip stimulates NOS is still unclear, investigations 
have shown that H4Bip is an important cofactor to NOS, markedly increasing the activity of 
NOS upon binding.158 H4Bip is known to be involved in stabilizing the quaternary structure 
of the enzyme by preventing monomerization and inactivation during the oxidation of L-















Figure 4.3. Structure of cofactor H4Bip157 
 
The potential of developing effective NOS inhibitors targeting the H4Bip binding site has 
been the subject of intense studies. Earlier studies have highlighted the importance of 
position 4 of H4Bip in inhibitory activity. Replacing the amino group with an oxo group at 
C4 showed enhanced inhibition, possibly due to better hydrogen bonding interactions with 
the heme side chain and the guanidinium moiety of Arg367 which are found in proximities at 
4- and 5- positions of H4Bip. Thus, a series of pterin-based NOS inhibitors containing the 4-
oxopterin nucleus157 was synthesized. From structure-activity relationship studies, it was 
found that the upper portion of the pterin molecule, i.e. positions 4, 5, 6 of H4Bip, are 
responsible for efficient insertion and binding of the cofactor into the pterin binding pocket 
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of NOS160 (Figure 4.4). Bulky aromatic and aliphatic substituents were found to be desirable 
at C6. The substituent at C2 was thought to influence the inhibitory potential but limited 







































Figure 4.4 Possible interaction in the H4Bip binding site160 
 
4.4   Screening of 1,3,5-triazine derivatives 
After careful comparison of the structures of 1,3,5-triazines substrate with the structure of 
H4Bip, we realized that there are structural similarities between 1,3,5-triazine substrates with 









































































Figure 4.5. Comparison of H4Bip and 1,3,5-triazine derivatives 
 
In this chapter, we are interested to investigate the potential of 1,3,5-triazine derivatives as  
selective inhibitors of nNOS. To achieve our objective, we will screen a small library of 45 
1,3,5-triazine derivatives synthesized in the previous chapters for their inhibitory activities 
against nNOS. 
 
4.5 Experimental Methods 
The inhibition activities of the test compounds were determined by the NOS assay 
described by Wong et al161. Sprague-Dawley rats, male, 200-250g were decapitated and the 
cerebellum were isolated and  suspended in 9 times of its  weight of ice-cold, pH 7.2, 20 mM 
HEPES /0.5 mM EDTA/ 1 mM DTT buffer. The tissues were then homogenized in 0.4 ml of 
a freshly prepared buffer, pH 7.2, containing HEPES (20 mM), EDTA (0.5 mM), and 
dithiotreitol (1 mM) with a Polytron (setting 6, 20 s). The homogenates were centrifuged at 
20,000 g for 20 min. NOS activity in the supernatant was measured with a radiometric assay 
using [3H]arginine as described by Bredt and Snyder.162 The supernatant (0.34ml) was mixed 
with L-[2,3,4,5-3H]arginine (Amersham, 0.3Ci, 50 pM final concentration), NADPH (2 
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mM), and CaCl2 (0.45 mM) in a final volume of 0.4 ml and incubated at 37°C for 45min. N-
Nitro-L-arginine methyl ester (L-NAME, 1 mM), a specific NOS inhibitor, was used for the 
determination of blank activity. Dowex (50WX-8, 200400 dry mesh, H+-form) resins were 
equilibrated with 0.5 M sodium phosphate buffer, pH 7.2, and packed into 2-ml columns 
which were then eluted with 4 ml of 0.1 M sodium phosphate buffer at the same pH. 
Immediately after incubation, reaction mixtures were loaded into columns which were each 
eluted with 2 ml of water. The eluant containing the reaction product, [3H]citrulline, was 
mixed with 16 ml of liquid scintillant (Ready Safe, Beckman) for radioactivity determination 
in a Beckman LS3801. 
The test compounds were prepared in DMSO and diluted to a series of concentrations. 
Preliminary screen was performed at 100 µM for each compound at 0.2% v/v DMSO. The 
final concentration of DMSO present for subsequent dose response-inhibition was fixed at 
0.2% v/v for various concentrations of compounds. 
 
Inhibitory property of the compounds was given by the expression:  
Percentage Inhibition = ([3H] compound –  [3H] blank / [3H]  Tissue control  – [3H]  blank) x 100 
where [3H] is the count of 3H as indicated by Beckman LS3801.   
 
Each concentration of test compound was evaluated in duplicates, on 2 separate occasions. 


















Entry Compound R1 R2 R3 Average Inhibition, % 
1 2-1a1 Bn CH3NH Me 15 
2 2-1a2 p-tolyl CH3NH Me 29 
3 2-1a3 Phenylethyl CH3NH Me 21.1 
4 2-1a5 Allyl CH3NH Me -15 
5 2-1a6 Ph CH3NH Me 50 
6 2-1a7 o-tolyl CH3NH Me 47 
7 2-1a8 Ph BuNH Me 28 
8 2-1b8 Allyl NH2 Me 20 
Table 4.1. Structures and inhibition values of 2-1 
 
 
The tabulated results presented in Table 4.1 shows only two compound with substructure 
2-1 exhibit mild inhibition for nNOS activity (Table 4.1, entry 5-6). Based on the results in 
table 4.1, we can conclude that having aromatic R1 substituent and R2 substituent as a 
methylamine results in increase in the inhibition of nNOS enzyme. In addition, the position 
of the methyl substituent on the aromatic ring at the R1 will also affect the inhibition of 
nNOS. Moving from the methyl substituent of the tolyl group from ortho position to para 
position will result in a decrease of nNOS inhibition from 47% to 29% (Table 4.1, entry 2 
and 6). Increasing the size of R2 substituent from methyl to butyl will result a decrease in 














Entry Compound R1 R2 R3 Average Inhibition, % 
1 3-17b Bn H Me 33 
2 3-17g Ph H Me -22 
3 3-17h Ph H Bu 0 
4 3-17i Phenol H Bu 21 
5 3-17q Allyl Piperidine - 20 
6 3-17r Allyl H Bu 23 
Table 4.2. Structures and inhibition values of 3-17 
 
The tabulated results presented in Table 4.2 show that triazinediones 3-17 do not 
significantly inhibit nNOS activity. These results indicate that triazine substrates with a free 










Entry Compound R1 R2 X Average Inhibition, %
1 2-2a Me Bn O 59 
2 2-2c Bn Bu O 46 
3 2-2h Me Hexyl O 68 
4 2-2i Me Allyl O 60 
5 2-2j Ph Ph O -2 
6 2-2k Me Ph O 20 
9 2-1d1 Me Bn HON 50 
10 2-1d2 Me Phenylethyl HON 29 
11 2-1d3 Me Ph HON 48 
12 2-1d7 Ph Ph HON 19 




The tabulated results presented in Table 4.3 shows that compounds 2-2 with R1 = Me and 
R2 = Bn, alkyl or allyl (Table 4.3, entry 1, 3 and 4) inhibit nNOS activity by more than 50%. 
Changing the either R1 or R2 to phenyl (Table 4.3, entry 5-6) is detrimental to the inhibitory 
properties of 2-2. Changing the substituent X from O to oxime leads to a 10% decrease in 
activity for R2 = Bn (Table 4.3, entry 1 and 9), however, for R2 = Ph changing X from O to 













Entry Compound R1 R2 R3 Average Inhibition, % 
1 3-38a H Me H 9 
2 3-38c Cl Me H -2 
3 3-45b OMe cyclohexyl H 24 
4 3-45c Cl cyclohexyl H 17 
5 3-45d OMe Cyclohexyl OMe 16 
Table 4.4. Structures and inhibition values of 3-38 and 3-45 
 
Results tabulated in Table 4.4 show that switching from a carbonyl to two R2 alkyl 
substituents on the triazine hetercyclic template is resulted in inhibition of only -2 to 24% 































9% inhibition  
Figure 4.6. Comparison of inhibition values of structurally similar 1,3,5-triazine derivatives 
 
Based on the results of the biological assay on the monocyclic 1,3,5-triazine analogs we 
deduced that triazinetriones 2-2 are potential candidate for further development  as inhibitors 
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of nNOS.  In addition, changing from the substituent at the 6th position from amino to 



















Entry Compound R1 R2 n % Inhibition*
1 3-28e H Bu 1 14 
2 3-28f H Me 1 27 
3 3-28g - Piperidine 1 17 
4 3-28h H Morpholine 1 19 
5 3-28a H Bu 2 5 
6 3-28b H Me 2 17 
7 3-28c - Piperidine 2 19 
8 3-28d - Morpholine 2 23 
9 3-28i H Me 3 36 
10 3-28j - Morpholine 3 27 
11 3-28k - Piperidine 3 37 
12 3-28m Me Me 1 13 
13 3-28l Me Me 2 -2 
14 3-28n Me Me 3 30 
15 3-29a - - 2 6 
16 3-29b - - 3 46 
Table 4.5 Structures and inhibition values of 3-28 and 3-29 
 
 
The nNOS inhibition assay results of 3-28 and 3-29 shows a correlation between the size 
of the B ring and the inhibition values. For smaller B ring size of five and six (n = 1-2, Table 
4.4, entry 1-8, 12 and 15) the inhibition ranges between 5% to 27%. Increasing the B ring 
size to seven (n = 3, Table 4.4, entry 9-11, 14 and 16) the inhibition values are increased to 
between 27% to 46%.  However, despite the structural similarities of 3-28 and 3-29 with 





Among the 45 triazine compounds evaluated for inhibition of nNOS, three compounds 
bearing the  triazinetriones substructure 2-2 (Figure 4.7) exhibited significant inhibition 




































Figure 4.7 Structures of compound with more than 50% inhibitions. 
 
The preliminiary results show that potential nNOS inhibitors should possess a N,N’-
disubstituted triazinetrione substructure with R1 as a small substituent like methyl or a proton 
and R2 can be alkyl, benzyl or allyl. In order to elucidate a more detailed structure activity 
relationshiip, more derivatives with different diversity on R1 and R2 should be generated for 
further biological evaluations.  
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